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BACKGROUND 
Being a major cause of death worldwide, cancer remains one of the key disease areas with the 
greatest unmet medical needs. Chemotherapy, the cornerstone of systemic treatment, damages 
DNA in cells affecting all dividing cells. Currently, drugs are being developed that target tumors 
more selectively. Much experience has been obtained with targeted antibodies, which are 
successfully used in daily clinical practice for the treatment of cancer. Among other mechanisms, 
antibodies can bind and subsequent inactivate pro-oncogenic proteins. Their successful use 
spurred interest in the development of antibody derivatives, including the variable domains of 
heavy chain only antibodies (VHHs or nanobodies; Fig. 1A). With their small size of 15 kDa, 
high stability and straightforward production1, they can be used as potential antitumor agents by 
inactivating pro-oncogenic proteins and as targeted carriers of cytotoxic payloads2. Due to their 
specific binding to tumor-associated antigens, nanobodies may also serve as imaging agents.
 In addition, antibodies and antibody derivatives can be produced so that they simultaneously 
target both tumor and host immune cells. By linking both cell types these proteins can 
stimulate the targeted host immune cells to kill the targeted tumor cells.  The use of drugs 
that stimulate host immune cells to destroy cancer cells is known as cancer immunotherapy. 
Cancer immunotherapy is currently gaining much attention and many immune system 
stimulating bispecific antibody constructs are in development. However, the first bispecific 
antibody (blinatumomab) that activates immune cells (cytotoxic T-cells) to destroy tumor cells 
has just recently been approved for the treatment of cancer. Blinatumomab is approved for the 
treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute 
lymphoblastic leukemia. Blinatumomab is a member of the novel class of BiTE antibodies that 
facilitate the linkage between tumor cells and cytotoxic T-cells. BiTE antibody constructs are 
engineered by combining two single-chain (sc)Fv domains of two different antibodies (Fig. 1B). 
One scFv domain is directed against the epsilon chain of cluster of differentiation (CD)3, a part 
of the T-cell receptor complex, and the other domain is directed against a tumor-associated 
antigen. After connecting CD3ε on T-cells with tumor-associated antigens on tumor cells, BiTE 
antibodies activate T-cells to destroy adjacent tumor cells.3 
 In addition to Blinatumomab that targets soluble tumors, other solid tumor targeting BiTE 
antibodies are in development, including AMG 110 (MT110; solitomab), AMG 211 (MEDI-565; 
MT111) and AMG 212 (BAY2010112). These BiTE antibodies target respectively anti-epithelial cell 
adhesion molecule (EpCAM), anti-carcinoembryonic antigen (CEA) and anti-prostate-specific 
membrane antigen (PSMA). Several phase I trials with these BiTE antibodies are ongoing or 
completed.4,5 
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Figure 1: Antibody derivatives used in this thesis. (A) A nanobody or VHH is the variable domain of heavy chain only 
antibodies that are produced in camelids. (B) BiTE antibody constructs are engineered by combining two scFv domains, 
derived from an anti-CD3ε antibody and an antibody targeting a tumor-associated antigen. (C) The nanobody construct 
MSB0010853 is derived from two anti-HER3 nanobodies and an anti-albumin nanobody. MSB0010853 binds HER3 at domain 
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 Many anti-cancer drugs are currently in development, including the nanobody and BITE 
antibody constructs described in this thesis. However, only a minority will eventually be approved 
for clinical use. Two of the biggest challenges are the identification of the best drug candidates 
in early phase clinical studies and the search for an optimal design of late phase clinical studies. 
Early insight in tumor uptake, biodistribution and (organ) pharmacokinetics of drug candidates 
might facilitate to address these challenges. Insight in tumor uptake might enable optimization of 
patient selection, dose finding, dose scheduling and administration (e.g. bolus versus infusion), 
while insight in biodistribution and (organ) pharmacokinetics might help to anticipate toxicity 
in highly exposed organs.
 This thesis focuses on the use molecular imaging in the process of drug development of 
nanobodies and BiTE antibodies. By labeling drug candidates with radionuclides, these drugs 
can non-invasively be traced in vivo. As a result, tumor uptake, biodistribution and (organ) 
pharmacokinetics of drug candidates can be visualized and quantified non-invasively with 
molecular imaging.6 The gained information can potentially be used to facilitate their clinical 
development. In addition, this thesis focuses on the use of near infrared fluorescent imaging 
in order to study the distribution of these drug candidates at a cellular level and to develop 
an imaging agent that could facilitate the visualization of tumor tissue in an intra-operative 
setting.7,8
The aim of this thesis is to obtain insight in the biodistribution and tumor uptake of novel tumor 
targeting antibody derivatives using molecular imaging, in order to support drug development.
OUTLINE OF THE THESIS 
The clinical success of therapeutic antibodies has raised interest in the development of other 
types of protein drugs. These proteins are currently also modified to try to improve their efficacy, 
tumor targeting, dosing frequency and toxicology profile. Examples of frequently used protein 
modifications include humanization, glycosylation, polyethylene glycol (PEG)ylation and (non)
covalent albumin binding. In order to support fast preclinical and clinical drug development of 
protein drugs, there is an increasing focus on obtaining information about their biodistribution, 
their tumor targeting potential and the presence of their targets in tumors. These properties 
can be assessed by radiolabeling these drugs and visualize them non-invasively with positron 
emission tomography (PET) imaging. However, radiolabeling and other above-mentioned 
protein modifications could unintentionally affect tumor uptake, biodistribution and other 
pharmacokinetics of protein drugs. In order to optimize the use of molecular imaging and to 
interpret the obtained data correctly, insight in protein characteristics that affect biodistribution 
and tumor uptake is essential. In chapter 2 we reviewed literature, concentrating on often-applied 
protein modifications and their effect on biodistribution and tumor uptake of these proteins. 
We searched PubMed to identify data for this review. Full articles were obtained and references 
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were checked for additional material as appropriate. The different types of proteins that were 
included in this review are antibodies, antibody fragments and non-immunoglobulin protein 
scaffolds. In this chapter we first focused on how specific protein properties including size, 
target interaction, binding to neonatal Fc receptor, and charge can affect the biodistribution of 
proteins. Subsequently, we aimed to describe how protein modification such as glycosylation, 
humanization, albumin binding, PEGylation, radioactive labeling and drug conjugation affect 
the biodistribution and tumor uptake of these drugs.
 Given the fact that optical imaging lacks ionizing radiation, optical imaging is recently gaining 
more attention.9 Furthermore, molecular imaging using optical imaging allows image-guided 
tumor resection.7 Due to their high and specific target affinity, fluorescently labeled (anti-HER2) 
nanobodies could potentially be used as a probe for optical molecular imaging of HER2 positive 
breast cancer.1 In chapter 3 we focused on the selection and evaluation of anti-HER2 nanobodies 
that are conjugated to the near infrared fluorophore IRDye 800CW. By using phage display, three 
anti-HER2 nanobodies (11A4, 18C3, 22G12) were selected. They were subsequently conjugated 
with IRDye 800CW to the C-terminal cysteine (site-specific conjugation) or to lysines (random 
conjugation). Binding affinities of these probes were tested in vitro using a HER2 positive human 
breast cancer cells line (SKBR3). To test the potential of these probes, serial optical imaging was 
performed in male nude BALB/c mice, xenografted with human breast cancer cell lines SKBR3 
or MDA-MB-231 (HER2 negative). The performance was compared with trastuzumab-800CW 
and an IRDye 800CW labeled, non-HER2 binding, control nanobody (R2). To demonstrate 
the potential of image-guided surgery, we resected a SKBR3 tumor that was subcutaneously 
xenografted in mice, under the guidance of the fluorescent signal of the most potent IRDye 
800CW labeled nanobody.
 As a third member of the HER family, HER3 activation and subsequent dimerization with 
other members of the family can initiate pro-oncogenic signaling. Blocking HER3 signaling 
could therefore potentially inhibit cancer progression. Interestingly, a mixture of two anti-HER3 
antibodies (A5 and F4) blocked ligand-induced and independent HER3 signaling, and inhibited 
tumor cell growth better than each antibody alone.10 Blocking two different HER3 epitopes, 
with a biparatopic nanobody construct (MSB0010853), is therefore an interesting option. In 
contrast to the single VHH described in chapter 3, MSB0010853 (39.5 kDa) consists of two HER3 
targeting nanobodies and an additional third that is able to bind albumin, extending its half-life 
(Fig. 1C). The aim of the study described in chapter 4 is to gain insight in the pharmacological 
behavior of MSB0010853 by labeling the nanobody construct with 89-Zirconium (89Zr). 89Zr is 
a PET isotope with a half-life of 78.4 hours, matching the potential long circulation time of 
albumin binding constructs.11 Dose- and time-dependent biodistribution and tumor uptake 
of 89Zr-MSB0010853 were evaluated in male nude BALB/c mice bearing subcutaneous human 
tumors. In addition, tumor uptake was determined in three tumor models with different HER3 
expression. Cross-reactivity of MSB0010853 for HER3 and albumin of mice origin contributed to 
a translational mouse model. 
 Similar to the HER receptor proteins, EpCAM is expressed on many tumor cells. EpCAM 
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is expressed on epithelial tumors and cancer stem cells. Therefore, it is an attractive target for 
BiTEs. An EpCAM targeting BiTE called solitomab (AMG 110) enables T-cell mediated killing of 
EpCAM positive cancer cells.12 Preliminary results of a phase I study with AMG 110 demonstrated 
that doses up to up to 48 µg/day were tolerated.4 The study also revealed signs of pharmacological 
activity. In addition to AMG 110, another BiTE antibody (AMG 211) has been developed that 
targets CEA. In the presence of T-cells, AMG 211 can trigger dose-dependent in vitro cell killing 
of CEA-expressing human colon, pancreatic, stomach, lung, breast, and prostate cancer cell 
lines.13 For solid tumors of especially the gastrointestinal tract, AMG 211 is an interesting new 
BiTE antibody construct, as it in vitro lyses explants of metastatic colorectal cancer cells of 
patients who progressed on chemotherapy.14 AMG 211 is currently tested in a phase 1 clinical 
trial in colorectal cancer patients.15 In order to support drug development of AMG 110 and AMG 
211, we preclinically studied the biodistribution and tumor uptake of radiolabeled/fluorescent 
labeled AMG 110 and AMG 211. These data can potentially be used to initiate clinical studies with 
radiolabeled BiTEs to determine their biodistribution and tumor uptake in early phase clinical 
trials.
 In Chapter 5 we studied the tumor targeting potential and tissue distribution of AMG 
110 after labeling it with 89Zr or IRDye 800CW. For ex vivo biodistribution studies, 89Zr-AMG 
110 at protein doses of 20-500 µg, was administered to nude BALB/c mice xenografted with 
EpCAM expressing HT-29 colorectal adenocarcinoma cells. Non-invasive microPET imaging 
and ex vivo biodistribution was performed up to 72 hours after 89Zr-AMG 110 injection. Ex 
vivo biodistribution of 89Zr-AMG 110 was studied up to 72 hours after injection. Non-specific 
distribution was determined using 89Zr labeled Mec14, a non-specific control BiTE targeting a 
hapten named mecoprop and human CD3ε. With flow cytometry EpCAM expression has been 
determined on the tumor cell lines that were xenografted in nude BALB/c mice, being the HT-29 
cell line, the human head and neck squamous cell cancer FaDu cell line and the EpCAM negative 
promyelocytic HL-60 cell line. Subsequently, ex vivo tumor uptake of 89Zr-AMG 110 has been 
measured and correlated with EpCAM expression. Labeling of AMG 110 with IRDye 800CW 
allowed us to determine the intratumoral distribution of AMG 110. Non-specific distribution of 
Mec14 was determined in the same by co-injecting IRDye 680RD labeled Mec14. 
 Chapter 5 proved that molecular imaging with BiTEs was feasible. Chapter 6 therefore 
describes the study in which a second BiTE antibody (AMG 211), which is in phase 1 development, 
was labeled with 89Zr or IRDye 800CW in order to study its tumor targeting property, tissue 
distribution and in vivo integrity. Dose-dependent biodistribution was determined ex vivo after 
administration of 89Zr-AMG211 in a dose range of 10-500 µg, in nude BALB/c mice xenografted 
with CEA-expressing LS174T colorectal adenocarcinoma cells. Tumor uptake and biodistribution 
of 10 μg 89Zr-AMG211 was visualized with non-invasive microPET imaging in LS174T xenografted 
mice. To check for CEA-specific tumor uptake, biodistribution and tumor uptake 89Zr-Mec14 
was also studied in the same mice models. In order to study the influence of CEA expression on 
89Zr-AMG211 tumor uptake we determined 89Zr-AMG211 tumor uptake in LS174T, CEA-positive 
human breast cancer BT474 and CEA-negative promyelocytic HL-60 cell lines. CEA expression 
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of these cell lines was determined flow cytometrically. The integrity of 89Zr-AMG211 has been 
studied in LS174T xenografted mice, at 24 h after injection. Tumor, liver and kidneys were 
lysed and subsequently analyzed, together with serum, with gel electrophoresis combined 
with autoradiography image analysis. Co-injection of IRDye 800CW labeled AMG 211 and 
IRDye 680RD labeled Mec14 in LS174T xenografted mice enabled us to study CEA dependent 
distribution of AMG 211. If PET imaging with 89Zr-AMG211 is feasible, it will be used to study the 
distribution and tumor uptake of AMG211 in cancer patients. Therefore, we tested if we could 
produce 89Zr-AMG211 according to the Good Manufacturing Practice (GMP) guidelines.
The results of all the studies presented in this thesis are summarized in chapter 7. The future 
perspectives following the studies described in this thesis are discussed in chapter 8.
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ABSTRACT 
Newly developed protein drugs that target tumor-associated antigens are often modified in order 
to increase their therapeutic effect, tumor exposure and safety profile. During the development 
of protein drugs, molecular imaging is increasingly used to provide additional information on 
their in vivo behavior. As a result, there are increasing numbers of studies that demonstrate 
the effect of protein modification on whole body distribution and tumor uptake of protein 
drugs. However, much still remains unclear about how to interpret obtained biodistribution 
data correctly. Consequently, there is a need for more insight in the correct way of interpreting 
preclinical and clinical imaging data. Summarizing the knowledge gained to date may facilitate 
this interpretation. This review therefore provides an overview of specific protein properties 
and modifications that can affect biodistribution and tumor uptake of anticancer antibodies, 
antibody fragments and non-immunoglobulin scaffolds. Protein properties that are discussed in 
this review are molecular size, target interaction, FcRn binding and charge. Protein modifications 
that are discussed are radiolabeling, fluorescent labeling drug conjugation, glycosylation, 
humanization, albumin binding and polyethylene glycolation. 
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INTRODUCTION 
Protein drugs are increasingly used in oncology. Much clinical experience has been obtained with 
monoclonal antibodies (mAbs). Due to their clinical successes, researchers additionally focus 
on the development of antibody derivatives and non-immunoglobulin (Ig) protein scaffolds. 
These protein drugs, when targeting tumor-associated antigens, are often modified to optimize 
therapeutic effects, tumor exposure and safety profile. Examples of such protein modifications 
include humanization, glycosylation, polyethylene glycol (PEG)ylation and both covalent and 
non-covalent albumin binding (Fig. 1). Currently, ~66% of Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) approved mAbs have been humanized to some extent, 
conjugated to cytotoxic drugs or conjugated to therapeutic radionuclides.1 Apart from mAbs also 
antibody fragments and non-Ig scaffolds are being modified.2,3 
Figure 1. Overview of common modifications to proteins. ABD = albumin binding domain.
 Clinical development of protein drugs is challenging. Up to 2015 more than 200 different 
anticancer mAbs have been tested in clinical trials.4 Currently, only 27 mAbs are FDA or EMA 
approved for the treatment of cancer.1 One of the biggest challenges is the identification of 
the best drug candidates in early phase clinical studies. Early insight in whole body and organ 
pharmacokinetics, as well as tumor uptake of protein drugs, might facilitate this identification. 
Influence of protein properties and protein modification on biodistribution and tumor | 23
uptake of anticancer antibodies, antibody derivatives and non-Ig scaffolds 
22 | Chapter 2
Both characteristics can non-invasively be visualized and quantified with molecular imaging.4 
In this way, real-time dynamics can be obtained on whole body biodistribution of protein drugs 
or protein drug candidates in the same animal or patient. Furthermore, a correlation between 
tumor uptake of radiolabeled antibodies, as determined by positron emission tomography (PET) 
imaging, and intratumoral target levels, as determined by enzyme-linked immunosorbent assay 
or immunohistochemistry, has been observed in cancer patients.5, 6
 Protein modification can both intentionally and unintentionally alter in vivo behavior of 
protein drugs. Therefore these modifications may hamper a sound interpretation of the obtained 
imaging data in both the preclinical and clinical setting. This review aims to give insight into 
protein characteristics that affect biodistribution and tumor uptake of tumor-targeting protein 
drugs. In this review we included antibodies, antibody derivatives and non-Ig scaffolds that 
were retrieved with the search strategy we used. Furthermore, we summarize the influence of 
common protein modifications on biodistribution and tumor uptake of these proteins. 
Search strategy 
Articles for this review were found by searches of PubMed, using the terms as mentioned in table I.
Table I. Used search terms.
Primary search terms Combined with
‘biodistribution
OR pharmacokinetics’
‘protein AND affinity AND cancer’
‘FcRn’
‘protein AND charge’
‘labeling AND proteins AND chelator’
‘site AND specific AND labeling’
‘(chelator AND conjugation) OR chelated’
‘(antibody AND drug AND conjugate) OR ADC’
‘(glycosylation OR glycosylated) AND protein AND cancer’
‘humanized AND cancer’
‘albumin AND cancer’
‘protein AND cancer AND (PEG OR PEGylation)’
´fluorescent AND protein AND imaging AND cancer`
´EPR effect´ -
Moreover, we included useful studies that were mentioned in the references of obtained articles. 
We did not focus on studies that only included small peptides such as somatostatin analogs. 
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PROPERTIES OF PROTEIN DRUGS DETERMINING BIODISTRIBUTION 
AND TUMOR UPTAKE.
Pharmacokinetics and tumor uptake can be influenced by a multitude of protein properties. 
In this review we focus on the influence of size, target interaction, the neonatal fragment 
crystallizable (Fc) receptor (FcRn) binding capacity and charge. 
Molecular size
Both the molecular weight and size of proteins may affect biodistribution. Due to the fact that 
biodistribution studies often mention protein weights rather than the hydrodynamic radius, in 
this review we focus on the impact of molecular weight of proteins on their biodistribution. 
The different proteins that will be discussed in this review differ in molecular weight, which for 
antibodies generally is ~150-160 kDa, antibody fragments ~12-110 kDa and non-Ig scaffold ~<20 
kDa (Table II).7,8 
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Intact IgG 150-160 1-3 weeks Hepatic
F(ab’)2 110 8-10 hr Hepatic
Minibody 75 5-10 hr Hepatic
Fab 50-55 12-20 hr Renal
Diabody 50 3-5 hr Renal
scFv 28 2-4 hr Renal
VHH 12-15 30-60 min Renal
Affibody 7 30-60 min Renal
F(ab’)2 = antibody of which the Fc domain is removed by pepsin digestion; Fab = antigen-binding fragment; scFv = single 
chain variable fragment; VHH = variable domain of a heavy chain of heavy-chain antibodies
It is thought that the pores in the glomerular filtration membrane are approximately 75Å and 
that proteins are generally renally filtered until a threshold of around 60-70 kDa proteins.9-12 As a 
result proteins smaller than ~60-70 kDa are more prone for fast renal clearance and are therefore 
subjected to reabsorption in the proximal tubule as compared to larger proteins. Likely due to the 
fact that proteins are flexible constructs, proteins larger than the above-mentioned threshold, 
such as a 80 kDa carcinoembryonic antigen (CEA) targeting minibody, can still be prone to 
renal clearance.13 Fast renal filtration of small proteins generally results in low accumulation and 
exposure to normal and tumor tissue. Increasing the weight of proteins to >60-70 kDa can prolong 
serum half-life and increase tissue levels, tumor levels and target exposure.14 However, high tumor 
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levels of large proteins are not only the result of antigen binding in the tumor. Due to leakiness 
of blood vessels and a poorly developed lymphatic system in tumors, macromolecular particles 
tend to penetrate easily into tumors and poorly drain back onto the blood or lymphatic system, a 
process known since the 80’s.15 This so-called enhanced permeability and retention (EPR) effect is 
size depending and thought to non-specifically increase tumor uptake of nano-sized anticancer 
drugs, including particles, vesicles, micelles, antibodies, or macromolecules.16 It is thought 
that this effect may increase the intratumoral concentration of nano-sized anticancer drugs by 
20-30%.16 This EPR effect is more pronounced in murine models with fast-growing tumors and 
immature blood vessel formation as compared to slow-growing tumors.17 In mice with slowly 
growing human tumors, which are models closer to the clinical setting, this EPR effect is less 
pronounced.17 As a result, the impact of the EPR effect on non-specific tumor accumulation is 
likely more pronounced in mice than in patients. In addition, the impact of the EPR effect on 
non-specific uptake of nano-sized anticancer drugs likely differs between individual tumors. For 
example, tumor uptake of 64Cu-labelled liposomes in 11 canine cancer patients with spontaneous 
growing tumors seemed to be EPR-mediated in 6 out of 7 carcinomas and 1 out of 4 sarcomas.18
 Due to the fact that large proteins (typically with a molecular weight of >60-70 kDa) are 
excreted relatively slow, these proteins show relatively long and high tumor exposure after a 
single admission.14 Therefore increasing molecular weight and size may result in a reduction of 
the required administration frequency. Consequently, there is a growing interest in increasing 
the molecular weight and size of small protein drug candidates, in order to reduce their excretion 
rate. Modifications that have been used include the fusion to an elastin-like peptide, gelatin-like 
protein, homo-amino acid polymer, proline-alanine-serine polymer, polyethylene glycol and to 
antibody fragments.19-23
 In conclusion, modifications that increase size can drastically increase blood, tissue and 
tumor levels. Such an increase should be taken into account when interpreting molecular 
imaging data obtained with radiolabeled modified proteins. As modifications that increase 
protein size can increase non-specific tumor uptake, it may complicate the interpretation of 
antigen-dependent tumor uptake, particularly in tumors with low antigen levels. 
Target interaction 
As proposed by Gerard Levy in 1994 and described in a mathematical model by Mager and Jusko 
in 2001, target binding can influence antibody pharmacokinetics.24,25 Relative high antigen levels, 
as compared to antibody dose, is thought to shorten the half-life of antibodies due to target 
binding. Nonlinear kinetics have been observed for antibodies targeting membrane-associated 
antigens, such as trastuzumab (targeting human epidermal growth factor receptor 2 (HER2)) 
and panitumumab (targeting epidermal growth factor receptor).26,27 Furthermore, shedding of 
membrane-associated antigens may also affect the half-life of antibodies.28 In a phase II study 
the half-life of trastuzumab in patients with low circulating levels of the extracellular domain of 
HER2 (<500 µg/L) was 9.1 days (n = 40), while in patients with high circulating levels (>500 µg/L) 
the half-life of trastuzumab decreased to 1.8 days (n = 5).28 Both groups received the same dose of 
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trastuzumab (loading dose of 250 mg, followed by a 10 weekly dose of 100 mg each). 
 In addition, the extent of target binding also depends the degree of tumor accumulation of 
protein drugs targeting tumor-associated antigen. Their target affinity can majorly affect tumor 
uptake. Both decreasing and increasing target affinity can reduce tumor uptake of these protein 
drugs.29,30 Increasing target affinity of antibodies and single chain variable fragments (scFvs) to 
extremely high levels, prevents them to detach from their targets in the tumor rim, making them 
prone for antigen internalization and catabolization, precluding them to bind targets located 
deeper in tumors.29,30   
 The impact of antigen affinity on the penetration depth of proteins may partly depend on 
the internalization rate of the targeted antigens when these antigens are expressed on the cell 
membrane of tumor cells. At dissociation rates faster than the rate of antigen internalization, 
increasing antigen affinity of antibodies may promote antibody catabolism, which prevents them 
to penetrate deeply into tumors. This has been demonstrated with anti-HER2 antibodies.29 As 
dissociation rates of the studied antibodies were not measured, the authors used the known 
dissociation rates of the scFvs of these antibodies. In contrast, at dissociation rates slower than 
the rate of antigen internalization, differences in dissociation rates may have less to no effect on 
antibody catabolism and tumor penetration.29 
 The fact that a high affinity can prevent deep tumor penetration is known as the “binding 
site barrier effect”.31 This barrier effect has been visualized in mice with four antibodies targeting 
the same HER2 epitope with different affinities (G98A, C6.5, ML39 and H3B1).29 These anti-HER2 
antibodies have target affinities of respectively 2.7 x 10-7 M, 2.3 x 10-8 M, 7.3 x 10-9 M and 5.6 x 
10-10 M, as determined by surface plasmon resonance.32 In severe combined immunodeficient 
(SCID) mice xenografted with HER2 expressing human ovarian carcinoma cells (SKOV-3), 
tumor penetration of the four antibodies negatively correlated with affinity.29 This was based on 
immunohistochemistry at 120 hr after injection. Interestingly, tumor uptake of the high-affinity 
iodine-125 (125I)-labeled H3B1 was lower than that of 125I-C6.5, with intermediate affinity. In 
contrast, no difference was observed between the tumor uptake of the two antibodies when 
radiolabeled with indium-111 (111In). However, a low affinity of 2.7 x 10-7 M did prevent high tumor 
accumulation, as observed with 111In-G98A (the lowest affinity antibody). Tumor uptake of 
111In-G98A was lower than that of the other 111In labeled higher affinity antibodies. 
 The same group also studied the effect of HER2 affinity of anti-HER2 scFvs on tumor 
uptake in SKOV-3 xenografted C.B17/Icr-scid mice.30 ScFvs were derived from a single clone 
with increasing affinities for the same HER2 epitope (3.2 x 10-7 M, 1.6 x 10-8 M, 1.0 x 10-9 M, 1.2 x 
10-10 M, and 1.5 x 10-11 M). This study also showed that a high affinity could prevent deep tumor 
penetration of proteins. As demonstrated by fluorescence microscopy, tumor penetration of the 
scFv with an affinity of 1.5 x 10-11 M was much less than of the scFv with an affinity of 3.2 x 10-7 M. 
Tumor uptake of the 125I labeled scFvs depended on both target affinity and the administered 
dose. Increasing HER2 affinity up to 1.0 x 10-9 M resulted in increased tumor uptake of the studied 
anti-HER2 scFv, which remained similar at an affinity of 1.2 x 10-10 M. However, increasing the 
affinity to 1.5 x 10-11 M resulted in a reduction of tumor accumulation. Noteworthy, this decrease in 
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tumor uptake was observed at a 1-μg dose level but not at a higher dose level of 20 μg, suggesting 
that this effect is dose-dependent. As both doses are within the range of often used tracer doses 
in preclinical imaging studies, this effect might very well be relevant for other HER2 binding 
antibody fragments or non-Ig scaffolds. Apart from tumor uptake, this study additionally 
demonstrated that a high affinity could prevent deep tumor penetration, as was observed in 
ex vivo immunohistochemistry and immunofluorescence experiments. Nephrectomized SCID 
mice bearing SKOV-3 tumors were injected with anti-HER2 scFvs with an affinity of 3.2 x 10-7 M 
or 1.5 x 10-11 M, at a 100-μg dose. The lowest affinity molecule exhibited diffuse tumor staining 
whereas the highest affinity molecule was primarily retained in the perivascular regions of the 
tumor. 
 Although not observed with the above-mentioned HER2 antibodies and scFvs, receptor 
binding of proteins could mediate transcytosis instead of catabolism, which may result in 
deeper tumor penetration. Under such circumstances, high target affinity may increase tumor 
penetrations.    
 In contrast to the above 125I labeled anti-HER2 scFvs and antibodies, HER2 affinity of 
technetium-99m (99mTc) labeled HER2 targeting designed ankyrin repeat proteins and 111In 
labeled affibodies in SKOV-3 tumors bearing mice did not affect tumor uptake.33,34 The affinities 
of these proteins range between respectively 1 x 10-8 – 1 x 10-11 and 3.8 x 10-9 M - 1.6 x 10-10 M.
 In conclusion, antigen binding can affect the pharmacokinetics of proteins, especially when 
affinities become extremely high or low. Either extremely high or extremely low affinities may 
prevent high tumor uptake, which can be dose-dependent. The effect of extremely high target 
affinity can be  less pronounced or absent at high doses. Protein modifications that decrease 
antigen affinity can, but not necessarily do, decrease target specific tumor uptake. Therefore, the 
effect of protein modifications on antigen affinity should be taken into account when interpreting 
molecular imaging data.  
FcRn binding 
Both albumin and the Fc domain of immunoglobulin G (IgG) antibodies are able to bind to the 
FcRn receptor.35,36 It is generally accepted that the FcRn receptor protects serum albumin and 
endogenous IgG antibodies from catabolism, as they strongly bind to FcRn at low endosomal 
pH (<6.5) and weakly at extracellular physiological pH (7.4).37 Upon endosomal FcRn binding, 
endogenous and exogenous IgG antibodies are transported back to the cellular surface and are 
then released at physiological pH. This process has been visualized with fluorescent microscopy 
in FcRn expressing human endothelial cells.38 Upon endocytosis, fluorescently labeled wild-type 
IgG1 was transported to the cellular surface, while, fluorescently labeled IgG1 mutant without 
detectable FcRn binding was transported to the lysosomes for degradation.38 
 The impact of FcRn dependent protection from catabolism has been demonstrated in 
mice.39 In FcRn-deficient mice, the serum half-life of IgG1 was considerably shorter (1.4 days) 
than in sex-matched FcRn wild-type animals with functional FcRn expression (9 days). The fact 
that FcRn protects IgG1 from catabolism has also been shown with molecular imaging. Yip et 
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al. radiolabeled both wild-type IgG1 and non-FcRn binding IgG1 with 111In.40 Indeed, 111In labeled 
non-FcRn binding antibody cleared much faster from plasma. In addition, a lack of FcRn binding 
promoted accumulation in the liver, spleen and intestines. These results suggest that FcRn 
binding protects antibodies from catabolism in these organs. 
 Similar findings were observed after the reduction of FcRn affinity of an anti-Lewis-Y 
antibody (hu3S193), radiolabeled with lutetium-177 (177Lu). Complete abrogation of mouse 
FcRn affinity decreased blood levels from 15.67 ± 2.47% of injected dose per gram (% ID/g) to 
1.05 ± 0.27% ID/g, as observed 48 hr after tracer injection in mice.41 This resulted in a reduced 
uptake in most organs.41 However, uptake of the non-FcRn binding 177Lu-hu3S193 I253A/H310A, 
increased in liver (from 5.99 ± 1.43% ID/g to 14.16 ± 1.28% ID/g) and spleen (from 9.32 ± 1.33% ID/g 
to 13.77 ± 2.57% ID/g) as compared with wild-type 177Lu-hu3S193.  
 In addition to the above preclinical studies, changes in FcRn affinity can also affect in 
vivo behavior in humans. Substitutions of specific amino acids located in the Fc domain of 
motavizumab (M252Y/S254T/T256E), resulted in a 10-fold increase of in vitro human FcRn 
binding at pH 6.0. It prevented high lysosomal degradation of motavizumab and increased its 
serum half-life in healthy adults from 19-34 days to 70-100 days.42 
 In conclusion, modifications that reduce or prevent the binding of antibodies to FcRn can 
increase serum clearance and increase organ uptake, which is mostly observed in the liver and 
spleen. Therefore, if molecular imaging with modified antibodies shows unexpected high uptake 
in these organs, the modification could have reduced FcRn binding.  
Charge
Protein modifications that change protein charge may affect charge-dependent interactions in 
vivo and potentially alter both tissue accumulation and pharmacokinetics. The effect of charge 
on the biodistribution of antibodies, antibody derivatives and non-Ig scaffolds is mainly studied 
by using cationizing or anionizing protein modifications. 
 Cationization of already positively charged particles induced non-specific uptake in normal 
tissue.43 This was likely due to increased interaction of the positively charged particle with negative 
cell surface charges. Similarly, cationization of antibodies by attaching hexamethylenediamine 
tends to increase the deposition of antibodies in both target (e.g. tumor) and normal tissues 
in rats and mice.44-48 As studied at 1-2 hr after injection, cationization mainly increased organ 
uptake in liver, lung and kidneys. Increased organ uptake additionally resulted in increased 
plasma clearance. Interestingly, anionization of antibodies, by diethylenetriaminepentaace-
tic acid (DTPA) conjugation and/or succinylation also increased plasma clearance in mice and 
rats.49-51 While cationization increased non-specific tissue uptake and subsequently plasma 
clearance, anionization of antibodies mainly increased whole body clearance. Anionization of 
111In labeled antibodies generally decreased their organ uptake (except for liver), as studied 1-24 
hr after injection.49-51 The fact that hepatic uptake did not decrease might be due to the fact that 
anionization may have increased the interaction of the modified antibodies with intrahepatic 
scavenger receptors.51 At high antibody doses liver uptake of 111In labeled highly succinylated 
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bovine IgG could be saturated, suggesting that the binding to these scavenger receptors can be 
saturated.51
 In contrast to antibodies, charge changing protein modifications can have a different 
effect on the biodistribution of smaller proteins. As small proteins (<60 kDa) are prone to 
renal excretion, they are exposed to charge dependent renal tubular reabsorption.52 In cancer 
patients, high renal accumulation has been observed with small size radiolabeled proteins such 
as a trastuzumab antigen-binding fragment (Fab) and an anti-HER2 affibody.53,54 This high renal 
uptake potentially hampers the visualization of tumor uptake in tumors that are located in 
close proximity of the kidneys. Modifications that affect the charge of small protein drugs can 
thus alter renal accumulation, potentially hampering the visualization of their tumor uptake. 
Attaching negatively charged glycolate molecules to both an interleukin-2 receptor targeting 
Fab and disulfide-bonded variable region fragment, generally reduced renal accumulation in 
mice.55,56 As glycolation of the disulfide-bonded variable region fragment hardly increased its 
size (a maximum of 2.8%), the observed effect was most likely due to the anionization of the 
protein.56 Renal accumulation of the non-glycolated interleukin-2 receptor targeting Fab was 
indeed triggered by positive charge interaction in the kidneys, as co-injection with positively 
charged lysine drastically reduced renal accumulation (from 196.2 ± 18.8% ID/g to 24.9 ± 2.0% 
ID/g).55 In line with this finding, co-injection of cationic amino acids also reduced renal 
accumulation of other proteins including Fab, F(ab’)2, scFv and a variable domain of a heavy 
chain of heavy-chain only antibodies (VHH).57-61 Similar to cationic proteins, anionic peptides 
are also prone for charge dependent renal accumulation. Renal uptake of e.g. negatively charged 
111In-minigastrin, 111In-bombesin and 111In-exendin could be reduced by co-injection of negatively 
charged poly-glutamic acid.62 In contrast to that observed with antibodies, the blood clearance of 
Fab fragments and disulfide-bonded variable region fragments targeting interleukin-2 receptor 
alpha did not increase upon anionization.55,56 Anionization of the disulfide-bonded variable 
region fragment had negligible impact on blood levels as measured up to 3 hr after injection in 
mice.55 In case of the Fab fragment, anionization decreased the clearance rate in mice.56 
 As discussed above, the overall charge of proteins can change due to anionizing and 
cationizing protein modifications. Likewise, protein modifications can also reduce local and 
overall charge, potentially introducing “lipophilic patches” and increasing overall lipophilicity 
of proteins. The presence of a lipophilic patch likely promoted hepatic uptake of radiolabeled 
peptides in monkeys.63 In addition, increasing the lipophilicity of anti-HER2 affibodies increased 
the uptake of these affibodies in the liver and spleen of mice at 4 hr and 24 hr after injection.34 
Moreover, protein modifications promoting hydrophobic interactions, such as increasing the 
amount of lipophilic drugs to create antibody-drug conjugates (ADCs), can make proteins 
prone to aggregation.64 Aggregation may subsequently alter the biodistribution of proteins. 
When using lipophilic drugs and drug linkers, increasing the drug to antibody ratio (DAR) can 
also promote the uptake of ADCs in sinusoidal endothelium and Kupffer cells in the liver of 
rats, increasing their clearance rate.65 The use of less lipophilic drug linkers can prevent a large 
increase in clearance rate.65 
Influence of protein properties and protein modification on biodistribution and tumor | 31
uptake of anticancer antibodies, antibody derivatives and non-Ig scaffolds 
30 | Chapter 2
 In conclusion, both anionizing and cationizing protein modifications can decrease plasma 
half-lives of antibodies. However, the underlying mechanisms differ. Anionization of antibodies 
usually increases whole body clearance, while cationization of antibodies promotes non-specific 
accumulation in normal tissue. In contrast however, anionization of smaller proteins may 
decrease clearance rate. For small sized protein drugs that are prone to renal excretion, both 
anionization and cationization can trigger accumulation in the kidneys. This accumulation 
is primarily due to an increase in charge dependent renal tubular reabsorption rather than an 
increase in renal excretion. The discussed findings may be translational to other types of protein 
drugs and may explain an unexpected biodistribution seen on imaging scans.   
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Table III. Protein properties that can affect biodistibution proteins. 
Protein properties Effect on protein pharmacokinetics / biodistribution References
Weight
High weight (>60-70 kDa)
Serum half-lifea  9, 10
Renal excretion / uptake  7, 8
Organ uptake (except kidneys)  14
Tumor uptake, including non-specific tumor uptake  14, 15
Target Interaction
Low protein dose / high 
antigen levels
Serum half-lifeb  26-28
Increasing target affinity
Tumor penetration (anti-HER2 antibodies at an affinity of <7.3 x 10-9 M)  29
Tumor uptake
(anti-HER2 125I-scFv at an affinity of <1.0 x 10-9 M)




(anti-HER2 125I-scFv at an affinity of <1.2 x 10-10 M)d
(anti-HER2 125I-antibodies at an affinity of <7.3 x 10-9 M)e
 29, 30
Tumor uptake
(anti-HER2 99mTc-designed ankyrin repeat proteins at affinities of 1 x 
10-8 - 1 x 10-11 M)
(anti-HER2 111In-affibodies at affinities of 3.8 x 10-9 - 1.6 x 10-10 M)
~ 33, 34
FcRn Binding
Lack of FcRn binding
Serum half-life  39, 40
Organ uptake (in most organs)  41
Uptake in liver, spleen and intestines  40, 41
Increasing FcRn affinity Serum half-life  42
Charge
Highly charged Renal accumulation of a renally excreted proteins/ peptides  55-62
Anionization
Serum half-life of antibodies  49-51
Serum half-life of fab fragment  55
Serum half-life of disulfide-bonded variable region ~ 56
Organ uptake of antibodies (in most organs)  49-51
Cationization
Serum half-life of antibodies  44-48
Organ uptake of antibodies  44-48
Lipophilic patches
Liver uptake  34, 63
Serum clearance  65
a Exceptions have been described 42; b Trastuzumab 100mg at 10 week interval and shed HER2 blood levels of <500 μg/L vs. 
<500 μg/L; c not observed with anti-HER2 125I-antibodies; d Observed at a dose of 1 μg but not at a dose of 20 μg; e not observed 
with anti-HER2 111In-antibodies; f Renal accumulation likely increases with the increase of overall charge of proteins that are 
prone to renal excretion 
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PROTEIN MODIFICATIONS THAT AFFECT PHARMACOKINETICS AND 
TUMOR UPTAKE OF PROTEIN DRUGS. 
Radiolabeling 
Radiolabeling of protein drugs changes their chemical structure, potentially altering their in 
vivo behavior. Below we discuss how differences in radionuclide, radiolabeling method, site of 
labeling, chelator/protein (c/p) ratio and chelator type can alter the in vivo behavior of protein 
drugs. 
Radionuclides / radiolabeling method 
 Protein drugs can be radioactively labeled with different PET and single photon emission 
computed tomography (SPECT) radionuclides. Predominant radionuclides that are currently 
used in SPECT imaging include 99mTc, iodine-123 (123I) and 111In. Often used PET radionuclides 
are carbon-11 (11C), fluorine-18 (18F), copper-64 (64Cu), gallium-68 (68Ga), zirconium-89 (89Zr) and 
iodine-124 (124I). 
 The choice for a specific radionuclide determines which information can be retrieved from 
the labeled proteins, as radionuclides can be trapped in cells after internalization of radiolabeled 
proteins in these cells. Internalization of protein drugs that are directly labeled with neutrally 
charged radiohalogens (e.g. radioactive iodine) are generally catabolized into neutrally charged 
catabolites that can pass the cell membrane.66 These radiocatabolites do not accumulate in cells 
upon internalization of radiolabeld proteins. However, indirectly radiolabeled protein drugs, 
with for example 89Zr or 111In, are often catabolized into charged radiocatabolites that remain 
trapped intracellularly.66 Consequently, indirect labeling results in higher tumor signals and is 
therefore a more sensitive approach to visualize tumor uptake.67-72 Its use additionally results in 
higher signals in normal tissue, which is for antibodies and their fragments most pronounced 
in liver, spleen and kidneys.67-72 Extremely high organ uptake may hamper the visualization of 
tumor uptake in tumors that are located in or in close proximity of these organs. As charged 
radiocatabolites remain trapped intracellularly after internalization and catabolism, their use 
could provide additional insight in catabolic sites of therapeutic proteins and delivery of toxic 
drugs by for example ADCs.6 
 One should always take into account that with molecular imaging the biodistribution 
of (radio)labels rather than the biodistribution of proteins is studied. When the radiolabel is 
attached to the protein, both are the same. However, if these labels detach or if the protein 
degrades, respectively the label or labeled protein fragment are traced in vivo. In addition, the 
attachment of radiometal labels involves the conjugation of (mainly negatively) charged chelating 
agents. The introduction of such charged chelating agents will alter protein charge and may 
hamper target and FcRn binding. As discussed earlier in this review this can potentially alter the 
biodistribution of protein drugs. Chelating agents require high selectivity and binding capacity 
for the radiometal as the human body possess an excess of biometals and biochelators, which 
concentrations in the human body are typically much higher than that of injected radiolabeled 
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proteins. Copper for example has many chelating biomolecules that may cause transchelation of 
radioactive copper to these biomolecules.73,74 Such transchelation occurs when chelators are not 
kinetically inert and may cause increased liver levels.75-77 As a result much effort has put into the 
development of kinetically inert chelators.78 Like copper, radioactive gallium may transchelate 
from chelating moieties as it is well established that gallium(III) has affinity for transferrin.79 It 
has been shown that 68Ga-apo-transferrin may accumulate in liver, spine and muscle of mice.80 
Similarly, 111In may transchelate to transferrin and accumulate in liver, spleen and bone tissue.81,82 
Of the remaining often used radionuclides, free 89Zr likely accumulates in bone tissue83-85, 
while non-labeled radioactive iodine and 99mTc may accumulate in thyroid, salivary glands and 
stomach.86, 87
 In addition to the above-mentioned differences between radionuclides, the choice for a 
specific radionuclide is often based on their availability. The radionuclides 123I, 111In, 11C, 18F, 64Cu, 89Zr 
and 124I can only be produced in centers that have a cyclotron, hampering their worldwide use. In 
contrast, 99mTc and 68Ga can be retrieved from specific generators producing these radionuclides 
on site. Furthermore, the choice for a specific radionuclide can be based on its physical half-life 
(Table IV) that most often matches the serum half-life of the protein of interest. However, one 
may prefer a longer-lived radionuclide in order to study long-term in vivo biodistribution and in 
particular tumor uptake.88 A radionuclide with a relative long half-life can additionally be used to 
study long-term stability in serum and tumor tissue.89 
Table IV. Frequently used SPECT and PET isotopes
SPECT PET
Radionuclide Half-life Radionuclide Half-life
 99mTc 6.0 hr 11C 20.4 min
123I 13.2 hr 18F 109.8 min




Type of chelator or chelating amino acid sequences
Indirect labeling can be performed using a wide range of charged chelators, chelating amino 
acid sequences, and charged radioisotopes. Therefore indirect radiolabeling might alter 
biodistribution and tumor uptake, depending on the type of chelator used. 
 Several studies have demonstrated that the use of specific chelating agents can alter the 
biodistribution of HER2 targeting affibodies (Z
HER2
). Switching between the macrocyclic 
chelators 4,7-triazacyclononane-N,N′,N″-triacetic acid (NOTA), 1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid (DOTA) and 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triaza-
cyclononane (NOGADA) did alter the biodistribution of Z
HER2:S1
, as determined 4 hr after 
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injection in mice.90, 91 Largest differences in 111In-Z
HER2:S1
 levels were observed in blood and liver. 
Blood levels were lowest for NOGADA conjugated Z
HER2:S1
 in NMRI mice, but not in BALB/C 
nu/nu mice.90,91 Hepatic accumulation of 111In-NOTA-Z
HER2:S1 






(<3.0% ID/g) in both mouse strains.90,91 It was 
suggested that this difference was due to the fact that 111In-NOTA is positively charged (+1), while 
both 111In-DOTA and 111In-NOGADA complexes are neutrally charged. Interestingly, labeling 
with another trivalent positively charged radiometal (gallium-68) resulted in less pronounced 
differences in hepatic accumulation of Z
HER2:S1
.91
 In addition to macrocyclic chelators, radiometals can be labeled to chelating amino 
acid sequences present in protein drugs. The impact of using different chelating amino acid 
sequences on the biodistribution of protein drugs has extensively been studied using 99mTc 
labeled Z
HER2:342
 in mice. At 4 hr after injection, differences in 99mTc- Z
HER2:342
 levels were mainly 
observed in liver, kidney, spleen and blood (Table V). The radioactivity of the intestines with 
content has been determined to estimate hepatobiliary excretion of radioactivity. Radiolabeled 
affibodies were administered subcutaneously or intravenously, which is expected to result in 
a similar biodistribution profile at 4 hr after injection.92 Introducing six consecutively placed 
positively charged histidines (H
6
) at the N-terminus of Z
HER2:342
 increased hepatic uptake nearly 
a 5-fold in NMRI mice.93 In addition, it resulted in an unusually high hepatic accumulation (19% 
ID/g) in SCID mice.93 Similarly, the use of positively charged lysines in the chelating sequence at 
the N-terminus of Z
HER2:342
 also resulted in high liver (7-23% ID/g), high kidney (36-127% ID/g) 
and relatively high spleen (~2.5% ID/g) uptake of mice.94,95 Replacing three of the six histidines 
in the N-terminal H
6
-tag by three hydrophobic isoleucines resulted in increased levels in 
both the liver (32 ± 4% ID/g) and spleen (38 ± 9% ID/g) and decreased renal levels (9 ± 2% 
ID/g).95 Replacing the same histidines (at the N-terminus) with negatively charged glutamic 
acids reduced uptake in liver (<1.5% ID/g) and spleen (~0.2% ID/g).95,96 The use of N-terminal 
mercaptoacetyl (ma)-glycine (G)-glycine-glycine (maGGG), a chelating sequence containing 
side chain deficient amino acids, decreased renal and hepatic accumulation to respectively 
≤8.2% ID/g and ≤0.93% ID/g.97,98 Replacing the glycines with negatively charged glutamic acids 
(E), increased renal uptake (≤8.2% ID/g for maGGG, 8.9 ± 0.8% ID/g for maGEG and 95 ± 23% 
ID/g for maEEE), while it slightly decreased hepatic uptake (0.93-0.66% ID/g for maGGG, 0.3 
± 0.1% ID/g for maGEG and 0.21 ± 0.02% ID/g for maEEE) and decreased the amount of the 
intestines with content (29.84-32% ID/g for maGGG, 8.7 ± 0.8% ID/g for maGEG and 3 ± 2% 
ID/g for maEEE).92,98 Reducing overall charge of the chelating sequence by using the neutrally 
charged mercaptoacetyl-serine (S)-serine-serine (maSSS) chelator, resulted in low uptake in the 
liver (0.47 ± 0.05% ID/g) and spleen (<0.5% ID/g), relatively low uptake in the kidneys (33 ± 2% 
ID/g) and high radioactive content in the intestines (11 ± 1% ID/g).99 
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 The above-discussed effects of amino acid-based chelators on the biodistribution 
of affibodies strongly depend on their location in affibodies (Table V). This may be due to a 
difference in charge distribution. As N-terminal amino acids form a more stable complex with 
99mTc as compared to the same sequences located at the C-terminus, this may partly explain the 
observed differences in biodistribution.95 Weakly bound 99mTc transchelates to blood proteins, 
increasing circulation time and blood levels of 99mTc as seen at 4 hr after injection (Table V).95,96 
 Switching between chelators has a less pronounced effect on the biodistribution of 
antibodies in mice. Both DOTA and DTPA conjugation of an anti-EGFR variant III antibody 
resulted in a similar biodistribution pattern, as studied with 177Lu labeling of anti-EGFR variant 
III monoclonal antibody.100 In addition, no differences in biodistribution and tumor uptake have 
been observed after conjugation of cetuximab and anti-cluster of differentiation (CD) 44v6 
antibody with similarly charged tetrafluorophenol-N-succinyldesferal or p-isothiocyanatoben-
zyl-desferrioxamine B and subsequent 89Zr labeling.101 
Site-specific labeling 
Indirect radiolabeling by attaching chelating agents to amino acid residues located in or in 
close proximity of antigen binding domains may interfere with target binding. This may affect 
antigen affinity and subsequently affect tumor accumulation. In a study with an anti-HER2 
VHH (11A4), random labeling with a fluorescent dye (IRDye CW800) reduced target affinity of 
11A4 a 1,000-fold.102 Despite the fact the impact of fluorescent labeling was studied instead of 
radiolabeling, it does demonstrate the potential effect of labeling, inlcuding indirect radioactive 
labeling. The observed reduction in affinity prevented tumor accumulation of randomly labeled 
800CW-11A4 in HER2 overexpressing xenografts. In contrast, using site-specific labeling of IRDye 
800CW to a C-terminal cysteine of 11A4, high HER2 affinity could be retained and HER2 positive 
tumors could be visualized at 4 hr after tracer injection. However, if conjugation sites are not in or 
in close proximity of antigen binding domains, no difference in biodistribution and tumor uptake 
between site-specific and random labeling is expected. For that reason, site-specific (cysteine) 
and random (lysine) labeling of an anti-HER2 VHH targeting with 111In, resulted in comparable 
biodistribution and tumor uptake.103 Nevertheless, indirect labeling is increasingly performed 
site-specifically to amino acids not located in or in close proximity of antigen binding domains 
e.g. cysteines or oligosaccharides. Given the low quantity and well-known locations of cysteines 
present in proteins, site-specific labeling of cysteines increases labeling homogeneity. This 
leads to a well-defined stoichiometry, increasing batch-to-batch reproducibility of radiolabeled 
targeted protein drugs.
 In addition to lysines and cysteines, chelators can be conjugated to oligosaccharides. 
Conjugation of DOTA to oligosaccharides of an ephrin type-B receptor 4 targeting antibody 
(hAb47) did not reduce its affinity.104 In mice, it did promote hepatic accumulation and reduce 
blood levels of copper-64 labeled hAb47. It was suggested that high hepatic uptake might 
be due to the fact that DOTA conjugation to the sugar chains could reveal galactose residues 
from the CH2 domain of antibodies.104 These could then be recognized by the intrahepatic 
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carbohydrate-recognition systems. At 48 hr after injection, conjugation of DOTA to 
oligosaccharides of hAb47 also resulted in a tumor uptake that was lower than when DOTA was 
conjugated to lysines or cysteines. Tumor uptake was respectively 9.5 ± 0.6% ID/g, 11.8 ± 2.1% 
ID/g and 18.1 ± 1.7% ID/g. 
Chelate/protein ratio
Like chelator type and the site of chelator conjugation, the number of chelators attached to 
protein drugs, expressed in chelate/protein ratios, could also alter in vivo behavior. Increasing 
the c/p ratios increases the amount of radioactivity that can be labeled to a specific amount 
of protein drug (specific activity). It reduces the amount of radioactively labeled protein drug 
that is needed to inject in order to provide good quality PET or SPECT scans. This is especially 
of importance in preclinical animal studies, as often small amounts of radioactively labeled 
protein drugs are injected into small animals. However, increasing c/p ratio can also increase the 
chance that randomly labeled radiolabels attach in or in close proximity of the antigen binding 
domains of protein drugs, potentially reducing target affinity and tumor uptake. In addition, 
increasing c/p ratio can increase charge differences as compared to parental proteins, potentially 
affecting the biodistribution of protein drugs. In order to determine the optimal c/p ratio, both 
specific activity and the potential effect on biodistribution and tumor uptake should be taken 
into account. 
 In Table VI we summarized the effect of c/p ratio on the level of antibodies and a F(ab’)2 
fragment in blood, liver, kidney, spleen and tumor. A c/p ratio as low as 5.5 altered the 
biodistribution of DTPA-conjugated, mesothelin targeting, MORAb-009 in mice.105 Increasing 
the c/p ratio of DTPA-MORAb-009 from 2.4 to 5.5 resulted in higher 111In-MORAb-009 levels in the 
liver and spleen, and decreased tumor uptake. DTPA conjugation also altered the biodistribution 
of a 111In labeled antibody targeting human serum albumin (HSA), in mice.49 Although exact 
values were not given, increasing c/p ratio from 2 to 3.2 to 11.2 to 16 gradually increased hepatic 
uptake at 24 hr after injection, while uptake in other organs remained unchanged. Contradictory, 
increasing the c/p ratio from 3.2 to 5.6 decreased uptake in all studied organs, except for the 
liver in which levels did not change. As aggregates were removed prior to administration, ex vivo 
aggregation did not cause the increase in hepatic uptake. The largest increase in hepatic uptake 
was observed between the c/p ratios of 5.6 and 11.2. This increase in c/p ratio also resulted in the 
largest difference in isoelectric point (respectively 6.5 and 5.9), suggesting that the increase in 
hepatic uptake is influenced by a difference in overall charge.
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Table VI. Effect of increasing chelation ratio on biodistribution and tumor uptake.
Chelator
(increase in c/p ratio)
Time after injection Blood Liver Kidney Spleen Tumor
Antibodies
DTPA (2.4 to 5.5)105
1 day −  −  −
2 days −  − − 
5 days − − −  
MAG3 (2.9 to 9.5)110 40 hr     
BAT (4.3 to 8.3)109 72 hr   − − 
DOTA (5 to 20)108 48 hr   −  
DOTA (7 to 12)107
24 hr (c/p ratio of 7) and
48 hr (c/p ratio of 12)
  N.D. N.D. N.D.
MAG3 (9.5 to 12.8)110 40 hr     
F(ab’)2 DOTA (3 to 5)
106 24 hr     
Red arrow = decrease in protein drug levels; blue arrow = increase in protein drug levels; horizontal black line = no significant 
change in protein drug levels; BAT = 6-(p-bromoacetamidobenzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8,11- tetraacetic 
acid; N.D. = not determined
 Similar to DTPA conjugation, DOTA conjugation can also alter the biodistribution of protein 
drugs. Increasing the c/p ratio (from 3 to 5) of a 177Lu labeled F(ab’)2 targeting a L1 cell adhesion 
molecule, decreased its accumulation in the kidneys (from ~35% ID/g to ~5% ID/g) and tumor 
(from ~15% ID/g to <5% ID/g), while it increased accumulation in the liver (from ~10% ID/g 
to ~35% ID/g) and spleen (from ~5% ID/g to ~10% ID/g).106 The labeling of DOTA to the full 
antibody, targeting the same target, also affected its biodistribution. However, the lowest tested 
c/p ratio was 7. Increasing the c/p ratio from 7 to 12 to 15 gradually increased both clearance 
rate and hepatic uptake.107 In addition to these two studies, DOTA conjugation also altered the 
biodistribution of a 111In labeled sjögren syndrome type B antigen targeting antibody (DAB4) and 
its 111In labeled isotypic control in mice.108 Increasing the c/p ratio from 5 to 20 of 111In-DAB4 and 
its 111In labeled isotypic control promoted the uptake in liver and spleen. Tumor uptake was only 
affected by c/p ratio for 111In-DAB4 in target positive tumors, suggesting that this is due to the 
observed decrease in antigen affinity.
 Increasing the c/p ratio of a BAT chelated lymphoma targeting antibody, had a similar effect 
on the biodistribution as above described DOTA or DTPA chelated antibodies.109 The tested 
c/p ratios were 2.1, 4.3, 8.7, and 11.4. Finding the optimal ratio was triggered by the fact that 
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copper-67 was used as an electron-emitting therapeutic radioisotope, which is contaminated 
with non-radioactive copper. At 72 hr after injection, tumor uptake significantly decreased at c/p 
ratios >4.3 and liver levels increase gradually increased with increasing c/p ratios. The increase 
in c/p ration did not affect antibody uptake in other organs. It did affect clearance, which at c/p 
ratios of 2.1, 4.3, 8.7, and 11.4 were respectively 4.0, 5.5, 2.6 and 2.8 days.
 The fact that increasing c/p ratios result in higher hepatic uptake of radiolabeled protein 
drugs, suggests that increasing the c/p ratio promotes hepatic excretion. Indeed, increasing the 
c/p ratio (from 7 to 10) of a MaGGG conjugated antibody E48 not only increased hepatic uptake at 
24 hr after injection, it also increased the radioactive content (estimation of hepatic excretion) in 
the ileum and colon of mice.110 At the same time blood levels decreased. Increasing the c/p ratio 
from 2.9 to 9.5 and from 9.5 to 12 also decreased blood levels at 40 hr after injection. This decrease 
in blood levels additionally resulted in lower organ uptake. Despite the promotion of hepatic 
excretion, the increase in c/p ratio reduced the uptake of rhenium-168 labeled MaGGG-E48 in 
the well-perfused liver, as observed 40 hr after injection. 
 The above-mentioned studies have been performed in mice, in which high c/p ratios are often 
used to obtain high-quality scans. However, lower c/p ratios are generally used in non-human 
primate and clinical studies.111,112 Such differences can hamper extrapolation of preclinical results 
to the clinical setting.   
Conclusion 
By radiolabeling antibodies, antibody fragments and non-Ig scaffolds, these can be traced in 
vivo. However, radiolabeling can also alter their biodistribution and tumor uptake. Such an 
impact may hamper a sound interpretation of imaging data, as the data is often used to predict 
the biodistribution of non-labeled protein drug candidates or protein drugs. When interpreting 
imaging data, one should consider the fact that biodistribution depends on the radiolabeling 
method, type and site of chelator conjugation and c/p ratio. Generally, indirect labeling results 
in higher organ and tumor uptake as compared to direct labeling, as it results in a more efficient 
intracellular accumulation of radiocatabolites over time. Furthermore, the use of cationic 
chelating amino acid sequences generally increases hepatic and renal accumulation, as seen with 
affibodies. Increasing hydrophilicity of these amino acid sequences tends to increase the uptake 
of affibodies in the spleen and liver. These findings may be translational to other small-sized 
proteins. In contrast to affibodies, switching between chelators has a less pronounced effect on 
antibodies. However, increasing the c/p ratio can decrease antibody levels in blood and tumor 
and promote accumulation in spleen and liver. Finally, site-specific labeling can prevent a 
reduction in tumor uptake of protein drugs that is caused by chelation to sites in or in close 
proximity of antigen binding domains.
 
Fluorescent labeling
Similar to radioactive labeling of antibodies, antibody derivatives and non-Ig scaffolds, these 
proteins can be labeled with non-ionizing fluorescent dyes to enable optical imaging. This 
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emerging imaging modality can support researchers to study normal tissue and tumor 
distribution of these proteins, which could complement the PET/SPECT imaging modalities. 
Moreover, optical imaging may enable real-time tumor visualization in an intra-operative setting 
or visualization of tumor margins in excised tissues.113,114 Furthermore, reactive oxygen species 
generating fluorescent dyes can be used to load tumor targeting proteins.115 Such labeled proteins 
possess antitumor activity.115
 Several near-infrared (NIR) fluorescent dyes have been used to label proteins. An often used 
NIR dye is IRDye 800CW, as it can be produced under good manufacturing practice conditions, 
allowing a fast translation of fluorescent labeled proteins to clinical studies. NIR fluorescent 
dyes often have a hydrophobic core with negatively charged groups. Labeling could therefore 
affect local charge and hydrophobicity of proteins upon conjugation, which may subsequently 
alter their biodistribution. Furthermore, labeling may induce protein aggregation and albumin 
binding.116,117 A comparison between the distribution of dual-labeled (89Zr and IRDye 800CW) 
anti-CA19.9 antibody (5B1) with 89Zr labeled 5B1 demonstrated that conjugation of IRDye 
800CW can increase liver uptake and reduced levels in blood and in other organs, at 120 hr after 
injection.118 The decrease in splenic uptake was most pronounced, which decreased from 19.8% 
ID/g to 5.7% ID/g. An uptake of 19.8% ID/g is relatively high for antibodies. According to the 
authors, the observed decrease in splenic uptake might be the result of a reduced formation of 
aggregates. Unfortunately, the formation of aggregates was not studied after tacer production or 
post injection. Therefore, the amount of aggregation at the time of injection is unknown. 
 Although optical imaging holds great promise as a stratagy to visualize tumor tissue both 
in vivo and ex vivo, it is challanging to get sufficient high signals from tumor tissue. In order to 
overcome this challenge, the administered dose of fluorescent labeled proteins can be increased. 
However, the use of high dose fluorescent labeled proteins should be evaluated for safety 
pharmacology and toxicology. A safety pharmacology study has been performed with therapeutic 
doses of IRDye 800CW labeled cetuximab in cynomolgus macaques.119 Cetuximab-800CW was 
well tolerated and all significant treatment effects were due to cetuximab and not to the IRDye 
800CW. The only exception was a slightly higher and more persistent prolongation of the corrected 
QT interval after injection of cetuximab-800CW, as compared to non-conjugated cetuximab. 
This resulted in cardiac monitoring of patients that were injected with cetuximab-800CW, in a 
terminated clinical phase 1 study (NCT01987375). 
Dye/protein ratio
Instead of increasing the total dose in order to obtain sufficient high signals from tumor tissue, 
one could increase the dye/protein ratio (d/p ratio). However, fluorophores can have the 
tendency to self-aggregate and to quench each other when placed in near proximity to each 
other.120 Therefore, increasing the d/p ratio may result in quenching of fluorescent signal and 
may increase the tendency of labeled proteins to aggregate. Aggregation has been observed 
with panitumumab conjugated with a NIR fluorescent cyanine dye (FNIR-G-765) at a d/p 
ratio of 5 and with an anti-mesothelin antibody that was conjugated with IRDye 800CW at a 
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d/p ratio of 4.111,116 For both constructs a d/p ratio of 2 did not result in visible precipitation of 
labeled antibodies. Aggregation can be observed directly after conjugation, however, it may also 
occur in vivo. Incubation of an IRDye 800CW labeled anti-EpCAM antibody in human serum 
promoted aggregation of the labeled antibody.117 This antibody was labeled with a d/p ratio of 2.6 
± 0.9. Aggregation increased from ~10% at start of incubation to ~25% at 96 hr of incubation. 
Interestingly, incubation in human serum also triggered albumin binding, which was maximal 
after 24 hr of incubation (~10%) and remained stable up to 96 hr of incubation. 
 As compared with 125I labeled 8C2, an antibody targeting an unspecified target, IRDye 800CW 
labeled 8C2 showed higher liver exposure, shorter serum half-life and lower organ exposure in all 
other studied organs.121  The d/p ratio of 8C2-800CW was 1.2-1.4. It should be noted that the serum 
half-life of 8C2-800CW was determined by using enzyme-linked immunosorbent assay, while 
the serum half-life of 125I-8C2 was determined by using gamma counting. In mice, increasing 
the d/p ratio from 2 to 5 also increased hepatic accumulation and decreased tumor uptake of 
IRDye 800CW labeled cetuximab and panitumumab.122 After quantification of ex vivo fluorescent 
images at 24 hr after injection, increasing the d/p ratio seemed to increase liver-to-tumor ratio 
of cetuximab-800CW with a factor 5.6 and decrease tumor-to-background ratio a factor 3.4. 
Similar results were observed with panitumumab-800CW. Increasing the d/p ratio increased 
liver-to-tumor ratio a factor 5.6 and decreased tumor-to-background ratio a factor 3.5. D/p 
dependent tumor-to-background ratio was not observed with FNIR-774-panitumumab and 
FNIR-774-cetuximab. In contrast, liver-to-tumor ratios increased a factor 1.4-1.6 after increasing 
d/p ratio from 2 to 5. These results suggest that FNIR-774 labeling has less impact on tumor 
and hepatic accumulation of cetuximab and panitumumab as compared to labeling with IRDye 
800CW. 
 Another approach to study the effect of d/p ratio on the biodistribution of proteins is by 
dual labeling these proteins with both fluorescent dyes and radionuclides. This approach has 
been used to study the effect of d/p ratio of IRDye 800CW labeled cetuximab and bevacizumab 
in mice.123 Both antibodies were first conjugated with desferal using a c/p ratio of 0.5 and 
subsequently with IRDye 800CW using d/p ratios of 0-2, whereafter the constructs were labeled 
with 89Zr. Fluorescent labeling with a d/p ratio of 1 promoted liver uptake and decreased blood 
levels of cetuximab at 72 hr after injection. Increasing the d/p ratio to 2, significantly increased 
liver uptake and reduced blood levels of both antibodies at 24 and 72 hr after injection. In line, 
Oliveira et al. also observed extremely high liver uptake of cetuximab-800CW (~80% ID/g) using 
a d/p ratio of 1.4.124 Similar preclinical findings were reported in another biodistribution study with 
MN-14 (anti-CEA), girentuximab and cetuximab dual labeled with 111In and IRDye 800CW.125 All 
antibodies were conjugated with DTPA using c/p ratios ranging 1.9-4.1 and with d/p ratios of 0-3. 
Increasing d/p ratios gradually increase liver uptake in mice, which was significantly increased 
for all antibodies at a d/p ratio of 3. The same d/p ratio significantly decreased tumor uptake of 
111In-MN-14-800CW and 111In-cetuximab-800CW, but not 111In-girentuximab-800CW. Although 
IRDye 800CW conjugation of cetuximab by using a d/p ratio of 1-2 increased liver uptake and 
decreased blood levels in mice, the half-life of therapeutically dosed cetuximab-800CW in 
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cynomolgus macaques (2.5 days) is comparable with that of non-labeled cetuximab when using 
a d/p ratio of 1.8.119 Similarly, conjugation of IgG with Cy5 or Cy3, using a c/p ratio of 1-2, did not 
affect serum half-life in macaques.126 The macaques were co-injected with 50 mg/kg Cy5 labeled 
IgG and 50 mg/kg Cy3 labeled IgG, resulting in a total protein dose of 100 mg/kg labeled IgG.
Site-specific labeling 
As discussed in the chapter concerning radiolabeling, labels that are conjugated to proteins 
may interfere with their antigen binding. In order to prevent such interference, labeling can 
be performed site-specifically at locations distant from antigen binding domains. Additional 
advantages of site-specific labeling have been discussed in the section concerning radiolabeling. 
Site-specific labeling may need modification of protein structures prior to the conjugation of 
fluorescent dyes. In the case of VHHs for example, a C-terminal cysteine can be introduced. 
Such a cysteine is able to react with thiol-reactive NIR fluorescent dyes. As discussed earlier, 
random labeling of an anti-HER2 VHH (11A4) with IRDye CW800 reduced target affinity of 
11A4 a 1,000-fold.102 This decrease in affinity resulted in a drastic decrease in tumor uptake. In 
contrast to site-specifically labeled 11A4-800CW, tumor uptake of randomly labeled 11A4-800CW 
was not visible at 4 hr after injection. Similar findings have been published with IRDye 680RD 
labeled anti-HER2 VHH (2Rs15d) in mice.127 Compared to site-specific labeled 2Rs15d-680RD, 
random labeling decreased tumor uptake and, except for the kidneys, increased the levels in 
blood and normal organs, at 24 hr after injection. Like for 11A4, site-specific labeling of 2Rs15d 
was performed by using cysteine as a conjugation partner of the NIR fluorescent dye. Although 
the use of cysteine tagging of VHHs may prevent affinity loss after labeling, potentially resuling 
in higher tumor uptake, cysteine tagging of VHHs currently results in a significant reduction 
of production yields.103 This may hamper large-scale production, which is necessary for clinical 
application. Furthermore, cysteines can form intermolecular disulfide bridges and reduction of 
disulfide bridges may reduce crucial intramolecular disulfide bridges.
 In contrast to site specific labeling of VHHs, site-specific labeling of huA33, an A33 targeting 
antibody, with 89Zr and Dye 680 may have less impact on the distribution.128 No difference in 
immunoreactivity was found between random or site-specific labeling of 89Zr-huA33-800CW. 
Although the authors concluded that in vivo behavior of both constructs is comparable, data 
about organ-specific biodistribution and serum half-life is missing. 
Zwitterionic NIR fluorescent dyes
NIR fluorescent dyes often are negatively charged. Conjugation of these charged dyes to proteins 
may therefore alter the biodistribution of proteins. In order to prevent a change in total protein 
charge, zwitterionic NIR fluorescent dyes have been developed (e.g. ZW800-1, FNIR-Z-759 and 
FNIR-G-765). These dyes have a nett charge of +1, which is the same nett charge of the terminal 
amine of lysines they replace. As a result, conjugation of a zwitterionic NIR fluorescent dye to 
lysines does not change overall protein charge. The labeling with such a zwitterionic dye may 
therefore have less impact on the charge-dependent biodistribution of proteins as compared 
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to for example anionic fluorescent dyes.129 Labeling of a secondary antibody, used to stain for 
α-methylacyl-CoA racemase or HER2, with ZW800-1 resulted in less non-specific cell binding 
as compared to the same antibody that was labeled with IRDye 800CW or Cy5.5. Non-specific 
binding increased when d/p ratio increased from 1.2 to 2.5. The same study showed that labeling 
a cyclic peptide consisting of Arg-Gly-Asp-D-Tyr-Lys with ZW800-1 resulted in tumor uptake 
with lower background signal than was observed when was conjugated with IRDye 800CW or 
Cy5.5. Although total protein charge is not altered after conjugation with zwitterionic dyes, 
small structural changes in NIR fluorescent dyes can alter whole body distribution of antibodies. 
This has been observed with panitumumab labeled with the zwitterionic dyes FNIR-Z-759 or 
FNIR-G-765.116 Both dyes have a total charge of +1 but different positively charged groups. At the 
sites were FNIR-Z-759 has trimethyl ammonium groups, FNIR-G-765 has guanidine groups. The 
most pronounced difference was observed in liver accumulation. Hepatic uptake was highest for 
panitumumab-FNIR-G-765, as was visible on fluorescent images of injected mice.
Conclusion 
Labeling of proteins with fluorescent dyes can cause aggregation of fluorescently labeled proteins, 
which is most pronounced at high d/p ratios. Visible precipitation has been observed at d/p 
ratios of 4-5. In addition, increasing d/p ratio can alter de biodistribution of proteins. Already 
at a d/p ratio of 2 fluorescent labeling could affect the biodistribution and pharmacokinetics of 
proteins. However, the impact seems to be depending on the NIR fluorescent dye and protein. 
Furthermore, the effect of fluorescent labeling on the half-life of the protein may additionally 
depend on the protein dose or species in which the pharmacokinetic study is performed.     
Drug conjugation  
In order to increase the selectivity of cytotoxic drugs, they can be attached to tumor targeting 
proteins. Due to the clinical successes and their high potential, an increasing amount of ADCs 
are in development. In 2000 the first ADC (gemtuzumab ozogamicin) gained FDA approval 
and due to extensive research over 60 ADCs are in clinical development.130 These successes led 
to the interest in the conjugation of cytotoxic drugs to tumor-targeting antibody fragments 
and non-Ig scaffolds.131-133 However, drug conjugation can change overall or local charge/
lipophilicity and destabilize proteins, e.g. by affecting their intraprotein charge and lipophilic 
interactions or intraprotein disulfide bonds. This may consequently alter the biodistribution 
and pharmacokinetics of proteins. Most experience with drug conjugation has been obtained 
with ADCs.134-136 Currently, three ADCs are FDA and EMA approved, brentuximab vedotin, 
trastuzumab emtansine and inotuzumab ozogamicin, while gemtuzumab ozogamicin is FDA 
approved and is under consideration at the EMA.137-140 In addition, over 40 different ADCs are 
evaluated in the clinical setting.141 Drugs that have been conjugated to antibodies target tubulin 
(e.g. maytansinoids and auristatin), DNA (e.g. calicheamicin), or RNA (e.g. amanitin).142 
 Each time an antibody is loaded with a cytotoxic drug, the biodistribution and tumor 
uptake potentially changes. Due to the increasing amounts of available linkers, cytotoxic drugs 
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and protein sites that can be used to attach cytotoxic drugs to antibodies, the impact of drug 
conjugation on the distribution of antibodies is potentially different for each new ADC. The 
impact of drug conjugation is likely higher when antibodies are loaded with relatively high 
amounts of cytotoxic drugs. High DARs might be beneficial for situations in which tumors 
marginally express antigens. Current techniques allow the loading of antibodies with drugs using 
DARs as high as 20, without compromising in antigen affinity and with increased tumor toxicity 
in mice.143 However, such high DARs may change biodistribution in patients and may increase 
the uptake in normal organs, potentially increasing toxicity. 
 These drugs can be conjugated to multiple sites of antibodies. Lysines are often used as 
conjugation sites for cytotoxic compounds. However, monoclonal antibodies contain ~90 
accessible lysines.144 Therefore this strategy results in highly heterogeneous ADCs. When aiming 
at a drug to antibody ratio of 2-4, 1 x 106 different species are statistically possible. This results 
in a highly heterogeneous mixture of ADCs. The different structures will likely possess different 
efficacies, toxicities and pharmacokinetics, as has been demonstrated with a monomethyl 
auristatin E labeled anti-CD30 antibody (cAC10).145 In vitro efficacy and pharmacokinetics in 
SCID mice were compared between ADCs with a DAR of 2, 4 or 8. Efficacy directly correlated 
with DAR (8 > 4 > 2), while the ADC with a DAR of 8 cleared a 3-fold faster than with a DAR of 4 
and a 5-fold faster than with a DAR of 2.   
 Heterogeneity can be reduced by targeting cysteines instead. Reducing the four available 
disulfide bindings in antibodies, an antibody to drug ratio of 2-4 drug will statistically result in 
~15 different species.144 Although the disulfide bridges in antibodies covalently interconnect the 
heavy chains and connect heavy chains with the light chains, reducing these disulfide bindings 
does not affect the chemical structure of antibodies. This is due to the many non-covalent 
interactions that primarily determine the chemical structure of antibodies.145,146 Similar to 
cysteine conjugation, other conjugation methods can be used to reduce heterogeneity as well. 
These include chemo-enzymatic loading of cytotoxic drugs and the conjugation of cytotoxic 
drugs to glycans and incorporated cysteines or unusual amino acids.142,147 
 To study in vivo behavior of ADCs, they can be radiolabeled and traced in vivo using 
molecular imaging. However, radiolabeling might decrease the stability of ADCs. To circumvent 
potential problems with stability of the radiolabeled ADC, its naked antibody counterpart can 
be radiolabeled instead and used to provide insight in its biodistribution. In order to predict 
the in vivo behavior of an anti-mesothelin ADC (DMOT4039A), its 89Zr labeled naked antibody 
counterpart (MMOT0530A) has been studied in cancer patients.6 This study revealed normal 
antibody distribution of 89Zr-MMOT0530A and heterogeneous uptake between tumor lesions. 
Tumor uptake differed a 2.4-fold within patients and a 5.3-fold between patients. Tumor 
uptake of radiolabeled naked antibody counterparts of ADCs can have predictive value. It has 
been demonstrated for trastuzumab emtansine (T-DM1) in the ZEPHIR study.148 By combining 
pretreatment 89Zr-trastuzumab PET/computed tomography imaging with early [18F]2-fluoro-2-
deoxy-D-glucose PET/computed tomography imaging, patients that benefit from T-DM1 could 
be distinguished from patients that did not benefit from T-DM1 treatment. This combination 
2Influence of protein properties and protein modification on biodistribution and tumor | 45
uptake of anticancer antibodies, antibody derivatives and non-Ig scaffolds 
44 | Chapter 2
resulted in positive and negative predictive values of 100%.
 However, antibody-drug conjugates can have a different biodistribution pattern as their 
naked counterparts. It has been observed in rats with an antibody targeting six-transmembrane 
epithelial antigen of prostate 1, conjugated with monomethyl auristatin. Hepatic uptake of the 111In 
labeled ADC was 2-fold higher than the 111In labeled parental antibody at 120 hr after injection.149 
Drug conjugation only marginally increased spleen uptake of the parental antibody. The observed 
increased uptake in these organs did not affect whole blood levels. A more pronounced effect was 
observed after conjugation of a humanized anti–Lewis Y antibody (hu3S193) with calicheamicin 
in cancer patients.150 As determined after 111In labeling, drug conjugation increased both clearance 
and hepatic uptake (4.5-fold, at 24 hr after injection), while it decreased maximum tumor uptake 
(nearly 20-fold).150
 The impact of drug conjugation on the pharmacokinetics of antibodies could depend on 
the site of drug conjugation. This has been demonstrated with the conjugation of maytansine 
to lysines on trastuzumab (T-DM1, DAR = 3.4) and to three other enzymatically created sites in 
trastuzumab.151 By enzymatically converting cysteines into aldehydes in specific inserted amino 
acid sequences (CXPXR, where X is usually serine, threonine, alanine, or glycine), maytansine 
could site-specifically be conjugated to trastuzumab through Hydrazino-iso-Pictet-Spengler 
ligation. Maytansine was conjugated to trastuzumab in either the light chain, the CH1 domain, 
or at the heavy chain C-terminus. This resulted in ADCs with DARs of ~2. The site at which 
maytansine was conjugated did impact the half-life of the ADCs. Conjugation of maytansine 
at the C-terminus resulted in the ADC with the longest half-life in BALB/c mice, being 7.8 ± 
0.5 days. The ADC half-lives were shorter when maytansine was conjugated to incorporated 
aldehydes in the light chain (5.2 ± 0.2 days), the CH1 domain (5.7 ± 0.3 days) or to lysines (T-DM1, 
6 ± 0.3 days).  
 In addition to the enzymatic introduction of aldehydes, aldehydes can be created in an 
oxidizing environment. Such an environment can affect the pharmacokinetics of ADCs. One 
of the strategies to site-specifically conjugate cytotoxic drugs to antibodies is by oxidizing 
carbohydrate residues in the native glycans at the Fc-domain of IgG antibodies, in order to 
create aldehydes. These aldehydes can then be targeted with activated cytotoxic drugs. However, 
over-oxidation could oxidize methionine residues that are located in close proximity of the FcRn 
binding site of antibodies, which can negatively affect FcRn binding and subsequently serum 
half-life.152 Oxidation was also used in the process to site-specifically conjugate monomethyl 
auristatin E and D to modified trastuzumab.147 Zhou et al. post-translationally introduced 
sialic acid into native N297 glycans of trastuzumab. Subsequently, mild oxidizing conditions 
were used to form aldehyde-functionalized trastuzumab. In addition, these conditions partially 
oxidized methionine residues close to the FcRn binding region, roughly 40% of Met-252 and 
<10% of Met-428 was oxidized, resulting in a ~15% reduction of FcRn binding. Such oxidation 
and reduced FcRn is not likely to majorly affect half-life. Partial oxidation of (∼40%) of Met-252 
on trastuzumab reduced its FcRn binding by ~25%, which only had a minimal effect on half-life 
in human FcRn transgenic mouse.152 However, a higher degree of oxidation (80%) of Met-252 
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in trastuzumab has been shown to negatively affect both FcRn binding (by ~60%) and serum 
half-life (by ~80%).152  
 Drug conjugation does not always alter the biodistribution of antibodies. It has been 
demonstrated in preclinical biodistribution studies with an N-methyl-N-[4-mercapto-4-meth-
yl-1-oxopentyl]-L-alanine ester of maytansinol that was conjugated to lysines of an anti-CanAg 
antibody (DAR 3.5-4.0), toxic tubulysin analog TUB-OMOM conjugated to lysines of trastuzumab 
(DARs of 2 and 4) and auristatin conjugated to p-Acetylphenylalanine (an unnatural amino acid) 
that was site-specifically incorporated into the heavy chains of an anti-HER2 IgG1 antibody (DAR 
~2.0).153-155 The pharmacokinetics of these radiolabeled ADCs were comparable with that of the 
radiolabeled parental antibodies in non-tumor bearing mice or rats. Due to the use of non-tumor 
bearing mice or rats, it is not known if drug conjugation altered tumor uptake of these antibodies. 
 Similar to tumor targeting antibodies, both tumor targeting antibody fragments and non-Ig 
scaffolds can be conjugated with cytotoxic drugs.156,157 Protein backbones that have been used to 
target anticancer drugs include diabodies, Fab fragments and designed ankyrin repeat proteins.157 
The effect of drug conjugation has been described for an anti-CD30 diabody that was engineered 
with two cysteine mutations for site-specific drug conjugation.158 The diabody was conjugated 
with monomethyl auristatin E or F (DAR ~4), which negatively altered the clearance rate of the 
diabody by roughly a 5-fold. The reason for the observed decrease in diabody clearance is unclear. 
As the increase in size was small, from ~38kDa to 47kDa, the increase in size is not likely the 
reason. Remarkably the major route of clearance changed from renal to hepatobiliary excretion. 
The reason for the change in clearance route was not studied and is therefore unknown. However, 
the fact that the lipophilicity of the diabodies increases upon conjugation with both drugs may 
have caused the change in clearance route. As the β half-lives between the diabody and the 
diabody-drug conjugate were similar, the difference in clearance rate might be due to a difference 
in distribution and distribution rate. Unfortunately, no biodistribution study was performed that 
could give an answer to that question. Interestingly, drug conjugation of an anti-CD30 an IgG1 
antibody (DAR ~4) in the same mouse models did not significantly alter the clearance of the 
antibody.  
 In conclusion, drug conjugation can increase hepatic uptake, clearance from circulation and 
decrease tumor uptake of antibodies and decrease the clearance of diabodies. Such an impact 
should be taken into account when interpreting imaging data that is obtained with radiolabeled 
ADCs or diabody drug conjugates. 
Glycosylation 
When protein drugs are produced in eukaryotic cell systems, they typically undergo the process 
of glycosylation.159 Glycosylation of protein drugs can affect their conformation, solubility, 
stability, in vivo activity and immunogenicity.160,161 In addition, glycosylation may also alter the 
biodistribution and tumor uptake of protein drugs. 
 Glycosylation is a complex post-translational modification by which glycans are enzymatically 
attached to side chains of asparagine (N-glycosylation), serine or threonine (O-glycosylation) of 
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protein drugs.159 This process strongly depends on the expression system of the protein drug. In 
yeasts, glycans contain many mannose sugars, plants consistently add α1,3-fucose and β1,3-xylose 
sugars and although Escherichia coli bacteria are not capable of adding glycans to proteins, a 
glycosylation machinery can be incorporated in their DNA.162-164 Mammalian cells can add a variety 
of glycans to proteins, often resulting in highly heterogeneous glycosylated proteins.165 Switching 
expression system can therefore change the glycosylation status. Subsequently, it can alter the 
biodistribution of protein drugs as has been demonstrated with a 124I labeled anti-HER2 diabody 
(C6.5db) in mice.166 Production of C6.5db in yeasts (Pichia pastoris) resulted in the addition of 
branched mannose glycans, while production in Escherichia coli resulted in non-glycosylated 
C6.5db. In mice, mannose glycosylated 124I-C6.5db cleared faster from the blood as compared 
to non-glycosylated 124I-C6.5db, resulting in ~2-fold lower tumor uptake at 24 hr after injection. 
The observed increase in clearance of glycosylated 124I-C6.5db may be due to the recognition of 
mannose sugars by mannose receptors on intrahepatic cells present in mice and humans.167,168 
Contradictory, at 2 hr after injection hepatic uptake of mannose glycosylated 124I-C6.5db was 
lower than was observed with non-glycosylated 124I-C6.5db. It was suggested that this was due 
to mannose receptor-mediated hepatic clearance that likely occurred within 2 hr after tracer 
injection. In contrast to C6.5db, glycosylation without mannose but with fucose, hexose, 
N-acetylhexosamine and sialic acid-containing glycans, moderately increased circulation time 
of a bispecific single-chain diabodies (scDb) targeting CEA and CD3.169 Except for renal uptake, 
glycosylation had a minor effect on the biodistribution of this scDb labeled with iodine-131 (131I).14 
Glycosylation did decrease renal uptake from ~25% ID/g to ~5% ID/g at 2 hr after injection. 
 In order to increase the antibody-dependent cellular cytotoxicity of therapeutic antibodies, 
glycosylated antibodies can be defucosylated.170 By removing fucose from the glycans of RG7116, 
a HER3 targeting mAb, its antibody-dependent cellular cytotoxicity improved.171 A study 
with 89Zr-RG7116 in mice demonstrated a normal antibody biodistribution profile, except for 
extremely high splenic uptake of >50% ID/g for all dose groups tested.172 Its 111In labeled naturally 
glycosylated IgG control showed much lower splenic uptake in mice. The fact that splenic uptake 
of 89Zr-RG7116 in SCID mice was higher than 111In-IgG might be due to the glycosylation status of 
RG7116. Glycoengineering of RG7116 increased the affinity to Fc-gamma receptor IIIA. As SCID 
mice express a murine homolog of this receptor on monocytes and macrophages, both present 
in the spleen, glycoengineering of RG7116 might have enhanced splenic uptake 89Zr-RG7116. 
Although a high splenic uptake could be due to the glycosylation status of RG7116, high splenic 
uptake (>80% ID/g) was also observed with non-glycoengineered 111In labeled anti-mesothelin 
antibody and 89Zr-pertuzumab at respectively 24 hr and 7 days after tracer injection in mice.173,174 
High splenic uptake might be mouse strain-specific instead, as in the above three studies only SCID 
mice were used. Indeed splenic uptake of 89Zr-pertuzumab was much lower in athymic nu/nu mice 
(2.7 ± 1.7% ID/g). In addition, extremely high splenic uptake of 89Zr-RG7116 was not observed in 
patients.175 Four days after injection, the concentration of 89Zr-RG7116 in the spleen, quantified as 
maximum standardized uptake value, was lower than its concentration in the blood pool. 
 In conclusion, unexpected organ and tumor uptake might be the result of the glycosylation 
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status of proteins. Most relevant organs in which protein uptake can be affected by glycosylation 
status are the kidneys, liver and spleen. Both defucosylation and glycosylation, especially 
mannosylation, can change the biodistribution of proteins. As the glycosylation status depends 
on the expression systems, its effect on biodistribution might be relevant in the search for an 
optimal system.
Humanization 
Protein drugs can elicit anti-drug antibodies (ADAs) in patients. Formation of ADA-drug 
complexes can subsequently increase drug clearance via the liver or spleen.176 Humanization 
of targeted proteins reduces the chance of being recognized by the human body as ‘foreign’ 
and potentially reduces the chance of ADA production. As a result, humanization may affect 
the biodistribution of protein drugs. Although humanization may reduce the chance of ADA 
production in humans and in cynomolgus monkeys, both humanized and fully human antibodies 
can still induce ADA production.177 This may partly be due to factors other than humanization, 
e.g. related to clinical use, product formulation and patient characteristics. These factors may 
be responsible for the variability in ADA production after administration of drugs and drug 
candidates.178 By linking variable domains of murine antibodies to human constant regions, 
murine antibodies can be humanized.179 To further enlarge the human content of antibodies, 
mouse complementarity-determining residues (CDRs) can be grafted into human antibodies.180 
Current technology additionally allows the production of fully human antibodies.181,182 Despite 
being fully human, these antibodies can still elicit ADAs.183 In addition to the humanization of 
antibodies, VHHs can be humanized as well.184 Given a high homology with the heavy chain 
variable domain of human antibodies, humanization of VHHs is rather straightforward. 
 Similar to antibodies, other human proteins have been used to develop drug candidates, 
including anticalins and adnectins. Although these drug candidates have been derived from 
human proteins, they still can elucidate an immune response. For example, an anticalin 
(PRS-050) targeting vascular endothelial growth factor A, derived from human lipocalins, seems 
to be non-immunogenic in cancer patients, while a vascular endothelial growth factor receptor 
2 targeting adnectin (CT-322) still provoked ADA production in 31 out of 38 (82%) cancer 
patients.185,186 
 Humanization does affect the half-life of antibodies in humans (Fig. 2). Generally, half-lives 
of antibodies in humans correlate with the degree of humanization, in the order of “fully-ro
dent” < chimeric < CDR-grafted human < “fully human”.187 In line, humanization can decrease 
the clearance rate in non-human primates. Humanization, using a CDR-grafting method, 
of an anti-tumor necrosis factor-alpha murine antibody increased its half-life to 40-90 hr (a 
2-3 fold increase) in cynomolgus monkeys.188 In contrast, humanization of antibodies can 
increase clearance rate in mice. This has been observed with an astatine-211 labeled humanized 
antibody (Rebmab200) and murine antibody (MX35) targeting sodium-dependent phosphate 
transporter.189 At 24 hr after tracer injection in tumor-bearing mice, slightly lower blood levels 
were observed for astatine-211 labeled Rebmab200 as compared to astatine-211 labeled MX35 
2Influence of protein properties and protein modification on biodistribution and tumor | 49
uptake of anticancer antibodies, antibody derivatives and non-Ig scaffolds 
48 | Chapter 2
(respectively ~15% ID/g and ~20% ID/g). No differences were observed in organ and tumor 
uptake. In contrast to the astatine-211 labeled antibodies, no differences in both blood levels 
and tissue levels were observed between when both antibodies were labeled with 125I instead of 
astatine-211. 
Figure 2. Effect of IgG humanization on imaging characteristics. Based on references 187 and 189.
 In rare cases, humanization of antibodies can introduce off-target binding to e.g. 
complement component 3 as observed with a humanized anti-fibroblast growth factor receptor 
4 antibody in mice.190 This humanized antibody cleared faster than its native chimeric antibody, 
due to complement component 3 binding of the humanized antibody in plasma. It resulted in 
reduced target specific liver accumulation, which decreased from ~80% ID/g to 35% ID/g. This 
interaction was only present in mice and absent in cynomolgus monkey and human plasma, 
suggesting that complement component 3 binding and the observed decrease in half-life are 
species specific.
 Humanization of an anti-CEA VHH (NbCEA5) marginally decreased antigen affinity.191 The 
effect of humanization has been studied in mice by labeling both the humanized and parental 
form of the VHH with 99mTc. Humanization did majorely effect clearance rate and uptake in lung, 
muscle, liver and tumor at 1 hr after injection. 
 In conclusion, humanization of antibodies generally increases their half-life in humans 
an can increase half-life in cynomolgus monkeys, while it can decrease the half-life in mice. 
Furthermore, humanization can introduce off-target interaction. Understanding these potential 
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effects of humanization may help to interpret imaging data and pharmacokinetic of protein drug 
candidates or protein drugs. The effect of humanization on the in vivo behavior of proteins has 
not extensively been studied for proteins other than antibodies.
Albumin binding 
Albumin, the most abundant protein in human and murine plasma, displays an extraordinary 
ligand-binding capacity. The large size of albumin (67 kDa) prevents fast renal filtration and 
its FcRn affinity further enhances circulation time. As a result, albumin has a serum half-life of 
~19 days in humans.192 Because of its long half-life, albumin can perfectly serve as a carrier in 
order to extend the half-life and thus target exposure of targeted proteins. Half-life extension can 
be achieved by conjugating targeted protein drugs to albumin or by introducing high-affinity 
domains that bind to albumin in vivo. With the introduction of these high–affinity domains, 
often anti-albumin affibodies or VHHs, the size of proteins also increases. As mentioned earlier 
in this review, an increase may also affect biodistribution of proteins. However, due to the fact 
that anti-albumin affibodies and VHHs are small in size, the effect of increasing the protein size 
by introducing anti-albumin domains is not discussed in this paragraph. Human serum albumin 
(HSA) conjugation and subsequent biodistribution studies have been performed with affibodies 
targeting EGFR (177Lu-DO3A-HSA-Z
EGFR:1907
) and HER2 (111In-DOTA-HSA-ZHER2:342) in mice.
193,194 At 
4 hr after injection blood levels were respectively 19.07 ± 1.05% ID/g and 20.11 ± 3.5% ID/g, which 
are much higher compared to radiolabeled affibodies that do not bind albumin in vivo, typically 
<2.4% ID/g (Table V). High blood levels of both HSA conjugated affibodies resulted in high 
uptake in normal organs, especially in the liver. High hepatic uptake has been observed with 
177Lu-DO3A-HSA-Z
EGFR:1907
 (54.93 ± 4.05% ID/g) and 111In-DOTA-HSA-ZHER2:342 (15.56 ± 1.84% ID/g). 
 Conjugation of a CEA targeting scFv (T84.66) to albumin resulted in a comparable 
biodistribution pattern in mice.195 Although exact values were not given, blood levels of 111In labeled 
albumin-bound T84.66 were much higher than that of 111In labeled T84.66 diabody, respectively 
~25% ID/g and ~5% ID/g at 4 hr after injection. Hepatic uptake of 111In-albumin-T84.66 increased 
in time, plateauing between 18 and 72 hr after injection (~11-12% ID/g). Similarly, tumor uptake 
increased in time with a maximum uptake of 125I-albumin-T84.66 at 18 hr after injection (22.7 ± 
6.0% ID/g). In contrast, maximum tumor uptake of 125I-T84.66 was observed 0.5 hr after injection 
in the same tumor model (4.9% ID/g).196 
 In addition to the conjugation of protein drugs to albumin, introducing albumin affinity 
can also extend their half-life. For that reason, a bivalent anti-EGFR VHH has been conjugated 
to an albumin binding VHH (αEGFR-αEGFR-αalb).197 Biodistribution studies in mice revealed 
that blood levels of 177Lu-αEGFR-αEGFR-αalb were higher than 177Lu-αEGFR-αEGFR. At 6 hr after 
injection these levels were respectively 21.2 ± 2.5% ID/g and 0.06 ± 0.02% ID/g. At 24 hr after 
injection, in vivo albumin binding additionally increased tumor uptake (from 3.2 ± 0.6% ID/g to 
35.2 ± 7.5% ID/g) and organ uptake. The increase in organ uptake was most pronounced in highly 
perfused lungs, heart, liver, spleen, kidneys and skin.
 Similarly, conjugation of an albumin binding VHH (Hle2) to a non-targeted VHH (Irr3) 
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increased the half-life of Irr3 in cynomolgus monkeys.198 Introducing albumin binding capacity 
increased the half-life from 0.080 days (Irr3) to 4.9 days (Hle2-Irr3), which was estimated to be 
in the same range of serum albumin in cynomolgus monkeys. The half-life of serum albumin in 
cynomolgus monkeys was estimated to be ~5.2 days, as was based on a weight of 2.4 kg and the 
formula: albumin half-life (days) = 3.75 * body weight (kg)0.368.199
 The above studies have been performed in mice. Given the fact that albumin and HSA half-life 
in mice (respectively ~1.5 days and ~5.2 days) differ from that in humans (~19 days), translating 
these results to a clinical setting is difficult.192,198,200,201 Due to the difference in albumin half-life, 
the effect of albumin binding on the clearance of protein drugs might be more pronounced 
in humans than in mice. This may also count for biodistribution and tumor uptake, as these 
parameters are affected by the clearance of protein drugs. However, despite the long half-life of 
albumin in humans, the half-lives of drugs and drug conjugates that are conjugated to albumin 
generally do not exceed 5 days in humans.202 
 In conclusion, albumin binding can increase protein levels in blood, organs and tumors. The 
largest increase can be expected in the liver. The effect of albumin binding on the biodistribution 
of protein drugs may well be more pronounced in humans than in mice, as albumin is excreted 
less efficiently in humans. These findings may facilitate the interpretation of imaging data 
obtained with albumin binding proteins.
PEGylation 
Although small protein drugs hold great promise as anticancer agents, they are cleared fast and 
therefore provide relatively low target exposure. In order to increase circulation time and tumor 
exposure, drugs can be PEGylated. PEGylation successfully increased the half-life of antibodies, 
antibody fragments and non-Ig scaffolds.14,185,203-206 In addition, PEGylation can increase solubility, 
decrease antigenicity and decrease proteolysis.207,208 To date, PEGylation has been used in the FDA 
and EMA approved cancer drugs, including PEGylated doxorubicin liposomes, PEGfilgrastim, 
PEGasparaginase, PEGintron and pegaptanib. 
 The effect of PEGylation on circulation time depends on different PEG characteristics, 
including chain length and shape. For example, increasing chain length increased the half-life 
of a Fab targeting an unspecified antigen, as studied in cynomolgus monkeys.209 PEGylation 
with 25 kDa PEG chain resulted in a plasma elimination half-life of 147.3 hr, while PEGylation 
with a PEG length of 40 kDa resulted in a plasma half-life of 188.9 hr.209 Increasing chain length 
can additionally decrease target affinity, potentially preventing high antigen-specific tumor 
uptake.210,211 However, a reduction in target affinity does not necessarily decrease tumor uptake of 
PEGylated proteins.212 
 Like chain length, the shape of PEG chains can influence the effect of PEGylation on 
circulation time of PEGylated proteins. Despite the fact that total PEG length was similar, the 
use of branched PEG chains (2 x 20 or 4 x 10 kDa) increased the serum half-life of tumor necrosis 
factor-alpha targeting VHH more than PEGylation with linear PEG chains (1 x 40 kDa), as studied 
in mice, rats and cynomolgus monkeys.213 
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 PEGylation generally promotes uptake in well-perfused organs, except for the kidneys 
and liver.14,204,206 PEGylation can enlarge protein size, decreasing renal excretion. At 2 hr after 
injection of a 125I labeled anti-CEA/CD3 scDb in mice, renal levels of 125I-scDb were higher than of 
131I-PEG-scDb.14 However, PEGylation increased renal uptake of this scDb at later time points (24, 
48 and 96 hr after injection), which is likely due to the increase in blood levels and the strong 
perfusion of the kidneys. At all time points studied (2-96 hr after injection), PEGylation did 
increase uptake of this scDb in the well-perfused liver. In contrast, PEGylation reduced hepatic 
uptake of an anti-EGFR antibody (C225/cetuximab).206 PEGylation of 111In-C225 with antibody:PEG 
ratios of 1:10 and 1:30 decreased liver uptake in mice with respectively 38% and 45%.206 This might 
be due to the fact that PEG chains potentially mask sites that could be recognized by scavenger 
receptors in the liver. 
 Like in well-perfused organs, PEGylation can also increase tumor uptake of protein drugs. 
This might be the result of both an increased circulation time, resulting in increased exposure to 
intratumoral antigens, and the EPR effect in tumor tissue. In mice, tumor uptake of a bispecific 
anti-CEA/CD3 scDb increased upon PEGylation. Tumor uptake of 125I-PEG-scDb increased in both 
CEA positive and negative tumors as compared to 131I-scDb.14 The fact that 125I-PEG-scDb uptake 
was also higher in CEA negative tumors is likely due to an increase in circulation time and due to 
the EPR effect. In contrast, PEGylation can also decrease tumor uptake as has been observed with 
the humanized A33 antibody, targeting the A33 antigen in colon cancer.205 Although PEGylation 
did not affect half-life or decrease target binding by more than 50%, it negatively affected tumor 
uptake in mice. Ex vivo staining of these tumors for human IgG, demonstrated that PEGylation 
of A33 antibodies reduced the speed of tumor penetration. This suggests that a decrease in tumor 
penetration also prevented high tumor uptake. 
 Although PEGylation generally increases the half-life of proteins, some studies show 
that PEGylation decreases the half-life of proteins. Conjugation of 124I-Fab targeting murine 
tumor-associated glycoprotein-72 with negatively charged branched maleimide-PEG (2887 Da) 
or neutrally charged maleimide-PEG (4229 Da) decreased its half-life in mice.214 Interestingly, 
PEGylation using larger negatively charged maleimide-PEG (4473 Da) increased its half-life. 
PEGylation of a 111In labeled cetuximab also decreased the level of radioactivity in serum of 
mice.215 It was suggested this is due to the detachment of 111In-PEG from cetuximab.215 Remarkably, 
a similar study from the same group demonstrated that PEGylation of cetuximab increased blood 
levels in mice at 48 hr after injection.206 In both studies DTPA conjugation and subsequent 111In 
labeling was performed similarly, at the end of the PEG chain. 
 As reviewed by Verhoef and Anchordoquy, several mechanisms have been suggested 
that could cause the PEG dependent increase in serum clearance.216 PEGylation can e.g. 
increase protein adsorption.217 The binding to proteins that interact with receptors on cells of 
mononuclear phagocyte system may promote the clearance of PEGylated proteins by these 
cells.216 In addition, the innate immune system may recognize PEG, as this system is known 
to recognize pathogen-specific repeating structures. Furthermore, human may develop PEG 
specific antibodies after repeated exposure to PEG as has been shown in a clinical study with 
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PEGasparaginase.218 The results of that same study also indicate that 25% of the study population 
had pre-existing PEG recognizing antibodies prior to the study. According to the authors this 
could be the result of repeated exposure to PEG in cosmetic products that were likely used by the 
patients. 
 In conclusion, when interpreting molecular imaging data with radiolabeled PEGylated 
proteins, one should take into account that PEGylation generally decreases clearance rate, 
increasing protein drug levels in blood, tumor and most organs. Both renal and hepatic uptake 
can either increase or decrease upon PEGylation. For renal uptake, this can be time-dependent. 
The use of branched PEG chains has a more pronounced effect on biodistribution than the use of 
linear PEG chains. Although counterintuitive, several studies have demonstrated that PEGylation 
may increase serum clearance. Furthermore, PEGylation may reduce target affinity and tumor 
penetration resulting in a decrease in tumor uptake. 
 
CONCLUSIONS AND FUTURE PROSPECTS 
To date tumor targeting antibodies, antibody derivatives and non-Ig scaffolds have been modified 
to enhance their therapeutic effect, tumor exposure and safety profile. Molecular imaging 
and biodistribution studies have shown that protein modifications, including radiolabeling 
of protein drugs, can intentionally and unintentionally alter their biodistribution and tumor 
uptake. Protein modifications often alter the levels of tumor targeting antibodies, antibody 
derivatives and non-Ig scaffolds in blood, liver, spleen, kidneys and tumor. The impact of protein 
modifications on the in vivo behavior of these proteins depend on the type of protein and should 
therefore be determined for each type of protein drug separately. 
 Currently, the distribution and tumor uptake of clinically studied protein drugs is increasingly 
being assessed using molecular imaging. For example, there are currently 24 known recruiting 
and active non-recruiting clinical trials in which the biodistribution and tumor uptake of 89Zr 
labeled antibodies is studied (www.clinicaltrials.gov). These clinical studies are often based on 
preclinical imaging studies. Given dissimilarities, the impact of protein modifications on in vivo 
behavior of protein drugs can be species or strain specific. For example labeling, humanization 
and albumin binding, as discussed in this review, can affect the biodistribution of protein drugs 
differently in preclinical mouse models as compared to non-human primates and humans (Table 
VII). As the majority of studies included in this review were performed in the preclinical setting 
in mice, further research is warranted to determine to what extent the described effects can be 
extrapolated to the clinical setting. Further research may additionally clarify which preclinical 
models best approach the clinical setting and which preclinical models should be avoided to 
study biodistribution and tumor uptake of protein drugs.
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 Ideally, the effect of protein modifications (including radiolabeling and fluorescent labeling) 
on the biodistribution of tumor targeting antibodies, antibody derivatives and non-Ig scaffolds 
is known before molecular imaging is implemented in clinical trials. This benefits a scientifically 
sound interpretation of the data. Such interpretation of the data can be difficult, raising the need 
for a comprehensive overview of specific protein properties and modifications that can affect 
biodistribution and tumor uptake of protein drugs. This review may facilitate in addressing this 
need by providing such an overview. In order to further increase the knowledge about the effects 
protein modifications have on the biodistribution and tumor uptake of proteins, molecular 
imaging can be implemented in more clinical trials. Generally, the implementation of molecular 
imaging in clinical trials can be further optimized. Especially for nuclear imaging it is critical 
to take into account the need for standardized scanning methods and the costs of molecular 
imaging.219,220 Furthermore, a good collaboration between academia and industry will expand the 
incorporation of molecular imaging in clinical trials. 
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ABSTRACT
Molecular optical imaging using monoclonal antibodies is slow with low tumour to background 
ratio. We used anti-HER2 VHHs conjugated to IRDye 800CW to investigate their potential as 
probes for rapid optical molecular imaging of HER2-positive tumours by the determination of 
tumour accumulation and tumour to background levels. 
Methods: Three anti-HER2 VHHs (11A4, 18C3, 22G12) were selected with phage display and 
produced in Escherichia coli. Binding affinities of these probes to SKBR3 cells were determined 
before and after site-specific conjugation to IRDye 800CW. To determine the potential of VHH-IR 
as imaging probes, serial optical imaging studies were carried out using human SKBR3 and 
human MDA-MB-231 xenograft breast cancer models. Performance of the anti-HER2 VHH-IR 
was compared to that of trastuzumab-IR and a non-HER2-specific VHH-IR. Image-guided 
surgery was performed during which SKBR3 tumour was removed under the guidance of the 
VHH-IR signal.
Results: Site-specific conjugation of IRDye 800CW to three anti-HER2 VHHs preserved high 
affinity binding with the following dissociation constants (KD): 11A4 1.9±0.03, 18C3 14.3±1.8 and 
22G12 3.2±0.5 nM. Based upon different criteria such as binding, production yield and tumour 
accumulation, 11A4 was selected for further studies. Comparison of 11A4-IR with trastuzumab-IR 
showed ~20 times faster tumour accumulation of the anti-HER2 VHH, with a much higher 
contrast between tumour and background tissue (11A4-IR 2.5±0.3, trastuzumab-IR 1.4±0.4, 4 h 
post-injection). 11A4-IR was demonstrated to be a useful tool in image-guided surgery.
Conclusion: VHH-IR led to a much faster tumour accumulation with high tumour to background 
ratios as compared to trastuzumab-IR allowing same-day imaging for clinical investigation as 
well as image-guided surgery.
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INTRODUCTION
Breast cancer is the most frequent cancer in the European female population and 18–25 % of 
all these cases have the HER2 gene amplified, resulting in HER2 receptor overexpression. Since 
HER2 is expressed only at very low levels in normal epithelial cells1, it is considered a clinically 
relevant tumour marker. The human HER2 receptor is a 185 kDa transmembrane protein that, 
together with HER1 (epidermal growth factor receptor, EGFR), HER3 and HER4, belongs to the 
ErbB family of receptor tyrosine kinases (RTK). It is an auto-activated receptor, which is present 
on the cell membrane in an extended open conformation, enabling the continuous formation of 
homo- and heterodimers with other family members. As a result, signalling in tumours expressing 
HER2 is enhanced causing more aggressive disease, with greater likelihood of reoccurrence.2,3
 Assessment of HER2 expression is common practice for accurate diagnosis and subsequent 
selection of the treatment protocol for breast cancer patients. At the moment, there are two ex 
vivo tests to assess HER2 expression levels, e.g. immunohistochemistry (IHC) and fluorescence 
in situ hybridization (FISH). Both methods require a biopsy of the primary tumour, which does 
not necessarily reflect the HER2 status of the entire tumour or in metastatic lesions, due to intra- 
and intertumoral heterogeneity of HER2 expression.4-7 Conversely, non-invasive molecular 
imaging with positron emission tomography (PET) imaging of HER2 can give information on 
HER2 expression levels of the entire tumour, its heterogeneity and also provide spatio-temporal 
information of the tumour within the breast at various stages of tumour progression.8 Furthermore, 
molecular imaging can provide instant information on the response to applied treatment, e.g. 
trastuzumab, and possible reoccurrence of the tumour during follow-up.9-11 Moreover, molecular 
imaging using optical imaging modalities allows for imageguided surgery, which can be of great 
help for the surgeon performing more radical tumour resections, but also for the detection of 
metastatic lesions in locoregional lymph nodes. Molecular imaging using a targeted tracer is 
usually performed with radioactive isotopes using single photon emission computed tomography 
(SPECT), PET or Cerenkov luminescence imaging (CLI).12,13 More recently, optical imaging using 
non-radioactive fluorescent tracers is gaining more attention, because of recent advances in the 
technology (e.g. multispectral fluorescence imaging) and tracer development employed14  and 
because it is more patient-friendly, lacks ionizing radiation and is costeffective.
 Advances in molecular imaging relate to novel improvements in technology simultaneously 
with the development of targeted probes which improve both specificity and sensitivity of 
imaging. This is usually done using antibodies or antibody fragments conjugated to fluorophores 
or isotopes. One of the disadvantages of antibodies is their long half-life in the bloodstream, 
which results in high background levels right after systemic administration and, consequently, 
in low tumour to background (T/B) ratios. Moreover, conventional antibodies have a rather slow 
diffusion into the solid tumour, which may even prevent them from reaching and binding to 
the entire tumour mass.10,11,15 For these reasons more interest is now expressed in smaller tracers 
such as affibodies, designed ankyrin repeat proteins (DARPins) and variable domain of the heavy 
chain of heavy-chain only antibodies that are found in animals from the Camelidae, indicated as 
Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly | 75
conjugated to IRDye 800CW for image-guided surgery 
74 | Chapter 3
VHH or nanobody.
 VHHs are the smallest, naturally occurring, functional antigen-binding fragments of only 
15 kDa. We have recently demonstrated that VHHs can be conjugated to near-infrared (NIR) 
fluorescent dyes and function as optical molecular imaging tracers.16 Due to their small size, 
VHHs distribute and diffuse efficiently throughout solid tumours, and due to their high binding 
specificity and affinity (KD<10 nM) to their target antigens, high tumour uptake of VHHs has 
been observed. Importantly, their half-life in the bloodstream is significantly shorter (1.5 h) than 
full-length antibodies (21 days for IgG1), allowing rapid clearance of the unbound fraction by the 
kidneys, leading to the visualization of tumours shortly after their administration.16–18 Moreover, 
VHHs are stable and easily produced in large quantities using industrial grade and qualified 
bacteria, yeast or mammalian cells.
 In this study we focused on selection and evaluation of anti-HER2 VHHs conjugated to the 
NIR fluorophore IRDye 800CW (IR) as a probe for optical molecular imaging of breast cancer. 
Llama glamas were immunized with HER2-expressing MCF7 or BT474 cells and HER2-binding 
VHHs were selected by phage display. We demonstrate the specific and high affinity binding of 
these VHHs to HER2 in vitro. In vivo, visualization of human tumour xenografts was observed 
already 4 h after probe injection. This was found to be 20 times faster than the delineation of the 
tumours with the monoclonal antibody trastuzumab. Moreover, better contrast was obtained 
with the VHHs, which resulted in clear delineation and real-time imaging of the xenografts 
during image-guided surgery. The obtained results highlight the potential of anti-HER2 VHHs 
as probes for optical molecular imaging of breast cancer and in particular image-guided surgery.
MATERIALS AND METHODS
Cell lines
The human breast cancer cell lines SKBR3, BT474 and MDA-MB-231 were obtained from the 
American Type Culture Collection (ATCC) and maintained in DMEM (Gibco) with 7.5 % (v/v) 
fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. 
These cells were tested and authenticated by the provider.
Ethics statement
The animal experiments were approved by the Animal Ethics Committee Board of Utrecht 
University (DEC#2010.III.03.038) and of the University Medical Center Groningen (DEC#6326A).
Immunization of llamas and construction of VHH libraries
To induce a humoral immune response directed towards the cell surface proteins of human 
breast cancer cells, llamas were immunized with approximately 108 intact human MCF7 or BT474 
cells. Each animal received four (BT474) or seven (MCF7) doses of subcutaneously administered 
cells. Preimmune and immune sera were collected and tested by enzyme-linked immunosorbent 
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assay (ELISA) using HER2 ectodomain (ECD).19 Four days after the last immunization, blood 
was collected, and peripheral blood lymphocytes (PBLs) were purified by density gradient 
centrifugation on Ficoll-Paque™ PLUS gradients (GE Healthcare). Total RNA was extracted from 
these tissues and transcribed into cDNA using reverse transcription polymerase chain reaction 
(RTPCR, Life Technologies). Purified cDNA was then used as a template for creation of immune 
libraries, as described earlier.19
Phage display selection of anti-HER2 VHH fragments
To select VHHs binding human HER2 receptor, several phage display selections were performed. 
In our first approach, phages were panned on live BT474 cells in solution, followed by a second 
round on HER2 ECD biotinylated with EZ-Link® NHS-Biotin (Thermo Scientific, Rockford, IL, 
USA). Dynabeads® M-270 Streptavidin (Invitrogen Dynal AS, Oslo, Norway) were incubated with 
phages and biotinylated HER2 ECD for 1 h at room temperature, and after ten washes with 0.05 
% Tween 20 in phosphatebuffered saline (PBS) and twice in PBS, bound phages were eluted with 
trypsin and used to infect Escherichia coli TG1. In the second approach, anti-HER2 phages were 
selected on recombinant purified HER2 ECD captured on a MaxiSorp plate (Nunc, Rochester, 
NY, USA). Coated wells were blocked with 4 % milk powder in PBS for 1 h at room temperature. 
Phages preblocked with 4 % milk powder for 30 min at room temperature were panned for 
binding to immobilized HER2 ECD. After extensive washing with PBS/0.05 % Tween 20, phages 
were eluted with trypsin (Sigma-Aldrich). In the second round, phages were panned for binding 
to subdomain 1 of HER2 ECD immobilized to the MaxiSorp plate. The coding sequences of the 
obtained VHHs binding to the HER2 ECD were identified by performing sequence analysis.
Production of VHHs and conjugation of the NIR fluorophore IRDye 800CW
Anti-HER2 VHHs genes were re-cloned into expression vector pQVQ72, which enables 
site-directed conjugation of IRDye CW800 (IR). Production of VHHs was induced with 0.1 mM 
isopropyl thiogalactoside (IPTG), when DH5α bacteria reached log phase. VHHs were purified 
from periplasmic fractions using HiTrap protein A HP columns (GE Healthcare). VHHs were 
treated with 20 mM Tris(2carboxyethyl)phosphine (TCEP) in 50 mM Tris–HCl pH 8.5 for 15 
min at room temperature, dialysed with 0.4 mM ethylenediaminetetraacetic acid (EDTA) in PBS 
and incubated with a threefold molar excess of IRDye 800CW maleimide O/N at 4 °C. After 
conjugation, free IR was removed using sequentially two Zeba Spin Desalting columns (Thermo 
Fisher Scientific, Perbio Science Nederland B.V., Etten-Leur, The Netherlands). The degree of IR 
conjugation was determined as described before.16 IR-conjugated proteins were analysed by 15 
% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and gel permeation 
chromatography in a Waters Alliance system (Waters, Milford, MA, USA) on a Superdex 75 
10/300 GL column (GE Healthcare Europe GmbH, Munich, Germany).
Determination of apparent affinity of VHHs on HER2 ECD and SKBR3 cells
MaxiSorp plates (Nunc, Rochester, NY, USA) were coated overnight at 4 °C with polyclonal 
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rabbit anti-human IgG antibody at dilution 1/500 (DakoCytomation, Glostrup, Denmark). After 
washing with PBS, the plate was incubated with 1 mg/ml of recombinant purified HER2 ECD in 
PBS for 2 h at room temperature and then blocked with 4 % milk powder in PBS for 1 h at room 
temperature. VHHs were added at decreasing concentrations and incubated for 2 h at room 
temperature on a shaker. After washing with PBS, the VHHs were detected with rabbit anti-VHH 
for 1 h at room temperature and donkey anti-rabbit horseradish peroxidase (HRP) for 1 h at room 
temperature. To develop the reaction o-phenylenediamine (OPD) was added, and the reaction 
was stopped by 1 M H2SO4 solution. For apparent affinity determination on SKBR3 cells, 2×10
4 
cells/well were seeded 1 day in advance. Cells were incubated at 4 °C for 1.5 h with a dilution series 
of VHHs in binding buffer (DMEM without phenol red, supplemented with 25 mM HEPES and 
1 % bovine serum albumin, pH 7.2). After several washes cells were fixed with 4 % formaldehyde 
(FA) for 30 min at room temperature and the fixative was blocked by 10 min incubation with 100 
mM glycine in PBS. The detection of bound VHHs was performed as described above. In the case 
of IRDye 800CW conjugated VHHs, binding was determined directly after washing steps using 
the Odyssey scanner.
Immunofluorescence
SKBR3, BT474 or MDA-MB-231 cells were grown on coverslips for 2 days. Cells were washed 
with CO2-independent medium and incubated for 1.5 h at 4 °C with a 100 nM solution of VHH. 
Unbound VHHs were removed and cells were fixed with 4 % FA. Bound VHH was detected with 
rabbit anti-VHH, followed by goat anti-rabbit Alexa 488 (Invitrogen, Breda, The Netherlands), 
and cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, Roche, Almere, The 
Netherlands). Images were acquired using wide field fluorescence microscopy.
In vivo studies
A detailed description of the in vivo studies can be found in supplementary information. In 
short, male nude BALBc mice (BALB/cOlaHSD-foxnu) were obtained from Harlan (Horst, 
The Netherlands). A subcutaneous tumour was induced by inoculating 5×106 of SKBR3 or 
MDA-MB-231 cells in Matrigel (BD Biosciences) at the right shoulder. Mice were anaesthetized 
with isoflurane and intravenously injected with either VHH-IR or trastuzumab-IR. In vivo 
fluorescence images were obtained with IVIS Spectrum (Caliper Life Sciences, Hopkinton, MA, 
USA) and the data were analysed using Living Image 3.2 software (Caliper Life Sciences). Regions 
of interest (ROI) were drawn around the tumour and in normal tissues (in the abdominal area 
in such a way that the signal derived from the kidneys or liver did not overlap the ROI). Values of 
average fluorescence radiance (photons/s/cm2/sr) of these ROIs were used to calculate the T/B 
ratio. Biodistribution studies were performed as described in more detail in the supplementary 
information section following the procedure described by Oliveira et al.16 The location of 
fluorescently labelled VHH was visualized with the realtime intraoperative fluorescence imaging 
system (T3 platform, SurgOptix, Groningen, The Netherlands). Images were generated using 
a 673 nm continuous wave (CW) laser diode (BWF2-673-0, 300 mW, B&W Tek, Newark, DE, 
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USA) for fluorochrome excitation. The collected image was divided into three channels: visible 
light towards the colour camera (670 DCXXR, Chroma, Rockingham, VT, USA) and NIR light to 
the intrinsic and fluorescence channels. A band pass filter 716±20 nm (BrightLine HC 716/40, 
Semrock, Rochester, NY, USA) was used in the fluorescence channel and a laser clean-up filter 
was employed at the intrinsic channel (Laser Clean-up 676/10 Chroma, USA). The optical 
hardware is mounted on a modified arm and can extend over the operating table to gain a vertical 
or lateral view into the field of view. Images and videos were obtained during surgery in which 
HER2-positive tumours were removed under the guidance of the camera system.
Statistical analysis
Student’s t test with Mann–Whitney correction to evaluate the significance of differences 
between two groups and analysis of variance (ANOVA) to evaluate differences among four groups 
were performed using Prism 5. A p value≤0.05 was considered significant.
RESULTS
Affinity selection and characterization of anti-HER2 VHHs
To obtain anti-HER2 VHHs, llamas were immunized with either the human breast cancer 
cell line MCF7 (expresses a low amount of HER2) or BT474 (overexpresses HER2 due to gene 
amplification).20 The development of the immune response against HER2 was confirmed by the 
presence of anti-HER2 heavy-chain only antibodies in serum, as evaluated on the HER2 ECD in 
an ELISA setup (Fig. 1A).
 Two approaches were taken to select for VHHs that bind with high affinities to the human 
HER2 receptor. In our first approach, phages from the MCF7 immune library were panned on live 
BT474 cells in solution, followed by panning on biotinylated HER2 ECD in solution. In the second 
approach, phages from BT474 immune libraries were first selected on captured recombinant 
purified HER2 ECD, followed by panning on subdomain 1 of the HER2 ECD. Together with 11A4, 
which was selected in the first approach, two other VHHs were selected for further research, 
namely 18C3, obtained from the second approach, round one, and 22G12, obtained in the second 
round of the second approach. These three VHHs, i.e. 11A4, 18C3 and 22G12, bind specifically to 
HER2, as confirmed by ELISA assays on ECDs of different ErbB receptors and immunofluorescence 
studies on live cells (Fig. 1B, C). The highest affinity was obtained for 11A4, which was even below 
1 nM (Supplemental Fig. 1). All VHHs showed a clear membrane staining of both SKBR3 and 
BT474 cell lines while no labelling of the HER2-negative MDA-MB-231 cells was observed (Fig. 
1C). Despite the high similarity in the amino acid sequence of the ECDs of HER1, HER2, HER3 and 
HER4, all three VHHs bound exclusively to the ECD of HER2, confirming their high specificity 
(Fig. 1D).
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Figure. 1 Llamas’ heavy chain immune response against HER2. (A) Immunization of Llama glama with HER2 overexpressing 
BT474 cells induces anti-HER2 humoral immune response. The reactivity of pre-immune (day 0) and immune (days 28 and 
43) sera towards HER2 ECD was determined in ELISA on HER2 ECD. Results are plotted in duplicate±SEM. (B) Binding of 
three selected VHHs, 11A4, 18C3 and 22G12, was tested in dose response using immobilized HER2 ECD in ELISA. Bound VHHs 
were detected with an anti-VHH polyclonal antibody and a secondary anti-rabbit antibody coupled to HRP. The amount 
of bound HRP was developed using OPD and absorption at 490 nm. Absorbance (490 nm) is shown in triplicate±SEM. 
(C) HER2positive (SKBR3 and BT474) or HER2-negative (MDA-MB-231) cells were incubated with the VHHs at 100 nM 
concentration and imaged using confocal microscopy (scale bar=20 μm). (D) Selected anti-HER2 VHHs bind specifically to 
HER2 ECD. VHHs were incubated with ECDs of HER1–4. Triplicate data are expressed±SEM. (E) Binding of anti-HER2 VHHs 
to SKBR3 cells. Bound VHHs were detected through a primary antibody followed by an HRP-conjugated secondary antibody. 
Absorbance (490 nm) is shown in triplicate±SEM with increasing concentrations of the purified VHH.
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 As the HER2 ECD may not mimic the receptor in its natural environment, we determined 
the apparent binding affinities of the selected VHHs to HER2 present on the surface of SKBR3 
cells. Very high apparent affinities were obtained for VHH 11A4 and 18C3 (less than 1 nM) (Fig. 
1E, Supplemental Fig. 1). The differences in affinities of the VHHs in binding were to HER2 
ECD and to cells, indicating that binding of the VHHs is sensitive to HER2 ECD conformation. 
Moreover, the Bmax of 22G12 was considerably lower than the Bmax of 11A4 and 18C3, which may 
reflect differences in epitope access (Supplemental Fig. 1). In conclusion, the employed selection 
strategy resulted in obtaining three VHHs that bind specifically and with high affinity to the ECD 
of the human HER2 in its natural surroundings.
Characterization of anti-HER2 VHHs conjugated to IRDye 800CW
The three HER2-specific VHHs were subsequently evaluated for their potential use as 
probes for optical molecular imaging. In these experiments, the VHH R2, which recognizes 
copper-containing azo-dye RR6, was used as negative control.16 VHHs were randomly conjugated 
to the NHS-IRDye 800CW (IRr) by coupling to the primary amines of the VHHs, i.e. N-terminal 
amino acid and lysine residues. Upon the IRr conjugation, a strong affinity drop was observed for 
all VHHs, especially for 11A4, which showed a 1,000-fold reduction (Fig. 2, Supplemental Fig. 1). 
This particular case was most likely due to the presence of a lysine residue in the complementarity 
determining region 3 (CDR3). The effect on the binding of the other two VHHs may reflect 
steric hindrance of the fluorophore during epitope binding. In order to avoid any effect of the 
fluorophore on the VHH binding capacity, all VHHs were provided with a C-terminal cysteine, 
which was used to couple the VHH to maleimide IRDye 800CW (IR). The obtained IR-conjugated 
VHHs are referred to as VHH-IR. The apparent affinity of the directionally coupled VHH-IR was 
higher than that of the randomly conjugated VHHs: 11A4-IR 1.9±0.3 nM, 18C3IR 14.3±1.8 nM and 
22G12-IR 3.2±0.5 nM (Fig. 2A, B) and marginally affected when compared to the non-conjugated 
VHHs (Fig. 1A, 2B, Supplemental Fig. 1). All standard quality controls (SDS-PAGE and gel 
permeation chromatography) were within acceptable parameters (Supplemental Fig. 2-4). All 
VHH-IR preparations contained less than 5.5 % of free IRDye 800CW.
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Figure. 2 High affinity of VHH can be preserved by site-directed conjugation of IRDye 800CW. (A) Reduced affinity after 
random labelling. SKBR3 cells were incubated with various concentrations of randomly labelled 11A4-IRr, 18C3-IRr and 
22G12-IRr. Bound VHHs were directly detected with an Odyssey scanner. Fluorescence intensity at 800 nm is shown in 
triplicate±SEM with increasing concentrations of the purified VHH. (B) High affinity binding of site-directionally labelled 
VHHs. SKBR3 cells were incubated with various concentrations of site-directly labelled 11A4-IR, 18C3-IR, 22G12-IR and the 
negative control R2-IR. Bound VHHs were directly detected with an Odyssey scanner. Fluorescence intensity at 800 nm is 
shown in triplicate±SEM with increasing concentrations of the purified VHH. (C) Specific binding of fluorescent VHHs to 
HER2. Site-directly labelled VHHs were incubated with HER2-positive SKBR3 cells and HER2-negative MDA-MB-231 cells. 
Bound VHHs were directly detected with an Odyssey scanner. Fluorescence intensity at 800 nm is shown in triplicate±SEM
HER2-targeted in vivo optical molecular imaging
To determine the potential of the IR-labelled anti-HER2 VHHs as probes for molecular optical 
imaging, mice bearing human tumour SKBR3 xenografts were injected with either 11A4-IR, 
18C3-IR or 22G12-IR and imaged at different time points after injection (Fig. 3). Already 1 h 
post-injection (p.i.) a clear accumulation of IR fluorescence was found at the tumour site in the 
cases of 11A4-IR and 22G12-IR. Surprisingly, no IR fluorescence was detected at the tumour area 
in mice injected with 18C3-IR (Fig. 3A). As expected, no IR fluorescence was detected in the 
case of the negative control VHH R2-IR. Optimal imaging (i.e. the highest tumour uptake of 
the probe combined with the best contrast) was obtained at 4 h p.i., when the IR fluorescence 
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of both 11A4-IR and 22G12-IR perfectly overlapped with the tumour area (Fig. 3B, red arrows). 
In all animals, immediately after injection of the IR-conjugated VHH, kidneys became clearly 
delineated (Fig. 3A, B, green arrows). The accumulation of IR fluorescence in the kidneys was 
expected due to the low molecular weight of VHH (15 kDa).
Figure. 3 In vivo optical molecular imaging. (A) Imaging of mice 1 h p.i. Male nude BALBc mice bearing SKBR3 human 
tumour xenografts at their shoulder were intravenously injected with 25 μg of site-directly labelled HER2-specific 11A4-IR, 
18C3-IR or 22G12-IR and negative control VHH R2-IR and imaged under anaesthesia at 1 h p.i. Tumours are indicated with red 
arrow and kidneys with green arrow. (B) Images of mice at 4 h p.i. (C) Average fluorescence radiance of tumours imaged by 
11A4-IR (n=6), 18C3-IR (n=6), 22G12-IR (n=6) and R2-IR (n=4). For all images obtained ROI were drawn around the tumour 
areas and the corresponding values of fluorescence radiance (p/s/cm2/sr) were plotted±SEM. (D) The T/B ratio of tumours 
imaged with 11A4-IR (n= 6), 18C3-IR (n=6), 22G12-IR (n=6) and R2-IR (n=4). For all of the images obtained ROI were drawn 
around the tumour areas and for normal tissue in the abdominal area and the corresponding values of fluorescence radiance 
(p/s/cm2/sr) were used to calculate T/B ratios.
 Fluorescence intensity was maximal shortly after injection and gradually decreased as 
a result of clearance of the unbound VHHs (Fig. 3C). The T/B ratios of 11A4-IR and 22G12-IR 
increased over time, reaching after 24 h p.i. ratios of 2.0±0.4 and 1.6±0.7, respectively. The T/B 
ratios of approximately 1.0 in the case of 18C3-IR remained constant over time, suggesting no 
specific accumulation of the probe at the tumour site. The same result was obtained for the 
negative control R2-IR, which is in agreement with the in vitro results (Fig. 2B), as well as our 
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previous study.16 Already 4 h p.i., the T/B ratio in animals injected with 11A4IR was significantly 
higher than the T/B ratio in animals injected with control R2-IR (p=0.03). Based on both the 
in vitro data and optical molecular imaging data, 11A4-IR was selected as the most promising 
imaging agent among the tested VHHs. Further in vivo studies and biodistribution studies were 
carried out with this VHH-IR. 
 The initial dose of 25 μg of IR-labelled VHH was determined based on previous studies.16 
However, an increase to 50 μg turned out to be beneficial, as indicated by the higher T/B ratio 
obtained 4 h p.i.: 1.9±0.8 in the case of 25 μg compared to 2.9±1.2 of 50 μg (p=0.03) (Fig. 4A). 
Further increase of the dose to 75 μg did not result in increased T/B ratios (T/B 2.4±1.0). On the 
basis of these results, 50 μg was considered as the optimal dose.
 As a confirmation of our expectations, the affinity loss due to the random conjugation of 
the IR (Fig. 4B, Supplemental Fig. 1) would render 11A4-IRr unsuitable for optical molecular 
imaging. Accordingly, T/B ratios of the randomly conjugated 11A4 remained approximately 1 
and no tumour delineation was observed (Fig. 4C). This clearly proved the advantage of the 
site-directed conjugation procedure for this particular VHH.
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Figure. 4 High affinity of the probe is essential for successful imaging. (A) Optimization of probe concentration. Male nude 
BALBc mice bearing SKBR3 human tumour xenografts at their shoulder were intravenously injected with 25, 50 or 75 μg 
of 11A4-IR and imaged under anaesthesia at indicated points p.i. (B) T/B ratios of randomly and/or site-directly labelled 
11A4-IR; mice were injected with 50 μg of randomly (11A4-IRr) or site-directionally labelled VHH (11A4-IR) and imaged at 
indicated time intervals. ROI were drawn around the tumour and in normal tissue (the abdomen), and the corresponding 
values of fluorescence radiance were used to calculate T/B ratios. The T/B ratio±SEM is shown (n=6). (C) Images of mice 
were taken 1 h p.i. and 4 h p.i. Tumours are indicated with red arrows and kidneys with green arrows; the yellow arrow shows 
the bladder signal
Comparison of HER2 targeting by 11A4-IR and trastuzumab-IR in HER2-positive and 
HER2-negative xenografts models
The performance of 11A4-IR as an optical imaging probe was compared to that of the 
conventional antibody trastuzumab. Trastuzumab was randomly conjugated to IRDye 800CW 
and employed as previously described.15 HER2 binding specificity of both probes was evaluated 
in vivo using mice xenografted with either SKBR3 or MDA-MB-231 cells. Histochemical staining 
of the xenografts with an anti-HER2 antibody clearly evidenced the overexpression of HER2 in 
the SKBR3 xenograft and its absence in the MDA-MB-231 xenograft (Supplemental Fig. 5). The 
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SKBR3 xenografts were rapidly delineated with the 11A4-IR probe; at 4 h p.i. the xenografts were 
clearly visible (Fig. 5A). Remarkably, trastuzumab-IR reached a similar image and T/B ratio 72 
h p.i. (Fig. 5B), which is a difference of approximately 20x. Importantly, target specificity was 
also demonstrated in vivo. A clear difference in tumour accumulation between HER2-positive 
(SKBR3) and HER2-negative (MDA-MB-231) xenografts were observed for VHH-IR as 4 h p.i. 
the negative tumour was completely devoid of fluorescence from 11A4-IR. With trastuzumab-IR, 
even 72 h p.i. fluorescence was still present in the negative tumour (Fig. 5A).
 To determine the uptake of different probes in the tumour and in the main organs 
quantitatively, we analysed the fluorescence signals in SKBR3 tumours and several organs ex vivo 
according to a recently described method.21 This method was specifically designed to determine 
the fluorescent signal quantitatively allowing determination of percentage of injected dose per 
gram tissue (%ID/g) of optical probes. Animals were sacrificed at the time points at which the 
best T/B ratios for 11A4-IR and trastuzumab-IR were obtained, which is 4 h p.i. for the VHH 
and 72 h p.i. for the mAb (Fig. 5A, B). The R2-IR VHH was included in this experiment as a 
negative control. The data clearly show that the biodistribution of the VHHs and trastuzumab 
differ significantly and are in agreement with previous studies (Fig. 5C, Supplemental Fig. 6).15,16 
In the case of mice injected with VHH-IR (both 11A4-IR and R2-IR), a high percentage of injected 
dose was detected in kidneys, while in the case of mice injected with trastuzumab-IR the largest 
percentage %ID/g was found in the liver (Fig. 5C). Interestingly, 4 h p.i. only very low levels of 
VHH-IR were present in the blood. In contrast, at 72 h p.i. trastuzumab-IR was still detected 
in the blood pool (2.7 %ID/g) and in highly perfused organs, such as spleen and lungs, while 
VHH-IR levels were low in these organs. Importantly, tumour uptake of injected probes differed 
significantly: 1.8 %±0.5 ID/g of 11A4-IR was found at the tumour site 4 h p.i. and 13 %± 3.5 ID/g of 
trastuzumab-IR 72 h p.i. As expected from the imaging data the negative control, R2-IR, did not 
accumulate at the tumour. The amount of R2-IR probe found at the tumour was similar to the 
amount present in the skin or lungs (∼0.3 %ID/g). The quantification of the IR-conjugated probes 
in the tumours and organs was used to determine the tumour to organ tissue ratios. Interestingly, 
in almost all cases the tumour to organ ratios were higher for 11A4IR (except for bladder). A 
tumour to blood ratio of 11A4IR was calculated to be ∼82, whereas for trastuzumab-IR it was 
hardly 4.5, indicating that even though 11A4-IR accumulates at the tumour to a lower extent 
than trastuzumab-IR, a much better contrast was obtained. In conclusion, 11A4-IR outperformed 
trastuzumab-IR in respect to overall T/B ratios and time at which clear imaging of tumours was 
possible.
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Figure. 5 Comparison of optical imaging using site-directly labelled 11A4-IR and randomly labelled trastuzumab-IR. (A) 
Tumour imaging. Representative pictures of male nude BALBc mice bearing HER2-positive SKBR3 human tumour xenografts 
(upper panel) and HER2-negative MDA-MB-231 human tumour xenografts (lower panel) at shoulders intravenously injected 
with 50 μg of site-directly labelled 11A4-IR or 100 μg randomly labelled trastuzumab-IR, imaged under anaesthesia at 
different time points p.i. (B) T/B ratio. T/B ratios were determined as described in the legend to Fig. 4, for both 11A4 and 
trastuzumab in HER2-positive (SKBR3) and HER2-negative (MDA-MB-231) tumours. (C) Biodistribution study. At 4 h p.i. 
mice injected intravenously with 11A4-IR and R2-IR, and at 72 h p.i. mice injected with trastuzumab-IR were sacrificed and 
their tumours and organs were collected for quantification of IR-conjugated proteins. Values are presented as percentage of 
injected dose per gram tissue/ tumour±SEM (n=5 for trastuzumab-IR and R2-IR group, n=7 for 11A4-IR group (left panel). 
From the values obtained for tumours and organs or tissues, ratios of tumour to organs were calculated and plotted±SEM 
(n=5 for trastuzumab-IR and R2-IR group, n=7 for 11A4-IR group (right panel).
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Image-guided surgery
With the results described above, the 11A4-IR probe seemed to be suitable for complementary 
approaches, where good contrast between tumour and background tissues is essential, such as in 
surgical resection of an HER2-positive xenograft from a mouse, when guided by the fluorescence 
of the probe specifically accumulated at the tumour. Assisted by a clinical NIR multispectral 
fluorescence camera system, 11A4-IR probe accumulation in the tumour guided the surgical 
removal of an HER2-positive xenograft.15 Both tumour and kidney were clearly visible through 
the skin, as depicted by the fluorescence and overlaid images (Fig. 6), as well as in the animation. 
The SKBR3 tumour was removed under the guidance of the real-time fluorescent images obtained 
by the camera system. In conclusion, contrast provided by the 11A4-IR probe was sufficient to 
allow the successful removal of the tumour by fluorescence image-guided surgery. 
Figure. 6 NIR fluorescence image-guided surgery. Representative intraoperative images of SKBR3 tumour removal after 
intravenous injection of 50 μg 11A4-IR 4 h p.i. Red arrows show the tumour and green arrows show the kidneys
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DISCUSSION
Optical molecular imaging is an important and rapidly developing technology, which in due 
time could have a great impact on clinical management of various cancer patients with solid 
tumours. In this study, we preclinically evaluated three fluorescent VHHs as potential molecular 
optical imaging probes suitable for clinical translation. Important criteria for optical probes are 
rapid accumulation into the tumour resulting in high T/B ratio. This enables a clear visualization 
and delineation of the tumour. High contrast depends on two parameters: specific binding 
leading to accumulation of the probe in the tumour next to clearance of the unbound probe from 
surrounding tissues and bloodstream, which decreases the background levels. Both parameters 
depend heavily on the molecular weight of the probe: a small probe of 15 kDa is expected to 
penetrate the tumour more rapidly than aconventional antibody with a molecular weight of 150 
kDa. At the same time, clearance from the body of such small probes by the kidneys will be fast 
(molecular weight of VHH is below the glomerular filtration threshold of 60 kDa), leading to 
short circulation and thus targeting times.
 Therefore, probes like VHHs require high affinities in order to accumulate sufficiently 
into the tumour.22 Despite the small size of the VHH, these antibody fragments bind with high 
affinities to their target proteins.16,23 Selections performed in this study were specifically aimed 
at high affinity binders to HER2. The final lead compound 11A4 showed a binding affinity for 
HER2 on SKBR3 cells of <2 nM. This VHH highlighted the tumour already 1 hr p.i. VHH 18C3-IR, 
which has a significantly lower affinity (13 nM), as compared to 11A4-IR and 22G12-IR, did not 
accumulate at the tumour at all. This observation may entirely depend on the low affinity of 
18C3-IR, which is in good agreement with predictions made on the basis of the Schmidt and 
Wittrup model.22
 A serious problem with the small size VHH is the possible effect of the conjugation of 
the ∼1 kDa fluorophore on binding affinity. Random conjugation, which involves fluorophore 
attachment to the primary amine groups, was reported previously by Oliveira et al. not to 
have a detrimental effect on the affinity of anti-EGFR VHH.16 However, there is a real chance 
of inactivation of VHHs displaying lysine residues in the CDR, which are involved in binding 
to the antigen, after conjugation to the fluorophore. The affinity of the anti-HER2 VHH 11A4 
was strongly affected by the conjugation to NHSIR, resulting in the inability to image the 
tumour (Fig. 4). To avoid affinity loss, site-directed conjugation using a maleimide group on 
the fluorophore reacting with a thiol group from an additional C-terminal cysteine was used. 
VHHs that were conjugated to maleimide IRDye 800CW showed a minor effect on the binding 
affinity. Nevertheless, the affinities of maleimide IR-labelled VHHs tested in vitro on SKBR3 cells 
remained in the low nanomolar range. The efficiency of the coupling of maleimide to thiol was 
reproducibly 50–70 %, depending on the VHH. This is in agreement with studies from Mume et 
al. and Lee et al. who reported conjugation efficiency between 60 and 80 %.24,25
 To the best of our knowledge, this is the first study in which a direct comparison is made 
between an antiHER2 VHH-IR and the conventional anti-HER2 antibody, trastuzumab-IR. 
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As could be expected due to the difference in molecular size, and based on our previous 
study16, trastuzumab-IR required more time to accumulate at the tumour site. 11A4-IR allows 
clear visualization of the tumour already 4 h p.i., obtaining a similar T/B ratio as found with 
trastuzumab-IR after 72 h. 11A4-IR accumulated only in HER2-positive tumours, whereas 
trastuzumab-IR was also found in HER2-negative tumours. This non-specific accumulation 
can be explained by an enhanced permeability and retention effect (EPR) described earlier for 
conventional antibodies.26 The biodistribution study was performed at the time point at which 
the highest T/B ratios were obtained based upon fluorescence images. The amount of 11A4-IR in 
the HER2-positive tumours 4 h p.i. was sixfold higher than the amount of the negative control 
VHH R2-IR. Similar ratios between target receptor-specific and non-specific VHH-IR were 
observed by Oliveira et al.16. The amount of trastuzumab-IR 72 h p.i. was in agreement with 
the data reported in previous studies.27 The %ID/g of 11A4-IR at the tumour was significantly 
lower than in the case of trastuzumab-IR. Vaneycken et al. reported slightly higher %ID/g at the 
tumour of the 99mTc-VHH, with values ranging from 0.78 to 4.44 %ID/g. This difference may be a 
result of different VHH, tumour xenograft model used (SKOV-3 instead of SKBR3), conjugation 
chemistry and time p.i. (1.5 h instead of 4 h).23 Biodistribution studies showed that the tumour 
to blood ratios are much better for 11A4-IR, which is in agreement with the T/B ratios obtained 
from the fluorescence images. For imaging, the contrast between tumour and healthy tissue 
is more important than the absolute amount of probe that reaches the tumour. We therefore 
conclude that in imaging at early time points (< 5 h) the VHH-based probes outperform the 
conventional antibody-based ones. The application of this novel optical probe for molecular 
imaging was clearly demonstrated in image-guided surgery. For this technology, especially 
the rapid accumulation into the tumour and high T/B ratios are important. Using VHH as the 
imaging tool, the probe would be administered intravenously to the patient a few hours prior to 
initiating surgery. This would ameliorate some of the aspects of using antibody injections 3 days 
prior to surgery from a logistical standpoint.
 In contrast to the antibody-based probe, the anti-HER2 VHH was present to a high degree 
in the kidneys obviously due to its renal clearance. This may be of concern when the VHH is used 
for radioactive imaging modalities such as SPECT or PET. It has been suggested that retention 
of the probe in the kidneys is enhanced by the presence of a positively charged HIS tag.28 In this 
study, VHHs were used devoid of the HIS tag; nevertheless, biodistribution of 11A4-IR revealed 
that ∼120 %ID/g was present in the kidney. As described by Gainkam et al., renal retention of 
anti-HER2 VHH, 99mTc-7C12, was reduced by 45 % upon co-injection of the probe with gelofusine 
and lysine, while the tumour uptake was increased.29 It would be interesting to determine whether 
co-injection of 11A4-IR with gelofusine and/or lysine would result in lower renal retention and 
higher tumour uptake leading to even higher T/B ratios. High accumulation of probe in the 
kidneys may not be critical when imaging is not focused on kidneys or tissues in their proximity.
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CONCLUSION
In conclusion, three high affinity anti-HER2 VHHs were selected from a phage display library 
and coupled to maleimide IRDye 800CW. They were evaluated in vitro and in vivo and proved 
to be a valuable tool for the optical molecular imaging of HER2-positive breast cancer. When 
successfully translated into the clinic by executing animal toxicity studies according to US Food 
and Drug Administration/European Medicines Agency guidelines, followed by a phase I-III 
study according to good clinical practice guidelines for each specific oncological indication, 
this could render more precise and specific identification and classification of HER2-positive 
tumours non-invasively, allow assessment of response to HER2 therapies in a patient-friendly and 
patient-tailored manner, and assist surgeons performing more radical tumour resections with 
improved cosmesis, thereby improving the management and welfare of breast cancer patients.
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SUPPLEMENTARY INFORMATION 
The goal of the first part of this experiment was to determine the lead compound from the 3 
tested VHH-IR, namely 11A4-IR, 18C3-IR or 22G12-IR. 25µg of tested VHH-IR was injected via 
the penile vein into mice inoculated with SKBR3 cells (for 11A4-IR, 18C3-IR and 22G12-IR n=6, 
for R2-IR n=4, dose was based on previous study16). Animals were then imaged immediately after 
injection, 15 min p.i., 30 min p.i., 1 h p.i., 2 h p.i., 4 h p.i. and 24 h p.i. Based on in vivo and in vitro 
data 11A4-IR was chosen as a lead compound. This VHH exclusively was then further evaluated 
in vivo.
 To compare in vivo performance of 11A4 conjugated with IRDye800CW site-specifically 
(11A4-IR) with 11A4 conjugated to the dye randomly (11A4-IRr), mice bearing SKBR3 tumors 
were injected intravenously with 25 µg 11A4-IRr (n=6) and imaged as described above. Results 
obtained for these animals were compared with results obtained in part one of the in vivo study 
for animals injected with 25 µg 11A4-IR.
  In the second part of in vivo study the optimal dose of lead compound was determined. 
Mice bearing SKBR3 tumors were injected via penile vein with 25µg (n=6), 50µg (n=6) or 75µg 
(n=5) of 11A4-IR and imaged at the same time points p.i. as in first part of in vivo study. 
The goal of the third part was to compare performance of 11A4-IR as an optical imaging probe 
with trastuzumab-IR both in HER2 positive and HER2 negative tumor models. For this purpose 
mice inoculated with either HER2 positive cells (SKBR3) or HER2 negative cells (MDA-MB-231) 
were injected via penile vein with either 50 µg of 11A4-IR (n=6, based on results from second part 
of this in vivo study) or 100 µg trastuzumab-IR (n=6, dose of monoclonal antibody was based on 
previous study15). Animals were imaged immediately after injection, 15 min p.i., 30 min p.i., 1 h 
p.i., 2 h p.i., 3 h p.i., 4 h p.i., 5 h p.i., 24 h p.i., 48 h p.i. and 72 h p.i. 
 Biodistribution study was performed as described earlier.16,21 Briefly, mice bearing SKBR3 
tumors were injected via penile vein with 50µg 11A4-IR (n=7), 50 µg R2-IR (n=5) or 100 µg 
trastuzumab-IR (n=5). Mice were sacrificed by heart puncture under anaesthesia. Animals 
injected with VHH-IR were sacrificed 4 h p.i., whereas animals injected  with trastuzumab-IR 72 
h p.i.. Organs were then collected; their weight was determined and they were snap frozen until 
further analysis.  
 To determine fluorescence signals quantitatively according to the method of Oliveira et 
al.21, organs/tissues and tumors were lysed with a Tissue Lyser II system  (Qiagen, Venlo, The 
Netherlands) using pre-cooled Eppendorf holders, 5-mm stainless steel beads, and RIPA buffer (50 
mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS) supplemented with 
a complete EDTA-free mini tablet protease inhibitor cocktail (Roche Applied Science, Penzberg, 
Germany). For detection of the fluorescence present in the lysates, a series of 1:2 step dilutions of 
homogenates were prepared in 96-well plates using RIPA buffer to determine the range in which 
fluorescence signal is linearly dependent on IR-probe concentration. As a reference, a dilution 
series of the injected probe was prepared in the same way. The intensity of the IR fluorescence 
was detected by an Odyssey scanner at 800 nm. Using GraphPad Prism 5 programme (GraphPad 
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Software Inc., La Jolla, California, USA), the concentration of IR probes detected in homogenates 
of organs/tissues or tumors was extrapolated from the calibration curves made with the reference 
probe. Knowing the concentration of IR probe in the homogenate as well as the homogenates’ 
volume and weight of collected organs and tumors prior to homogenization the percentage of 
injected dose per gram of tissue (%ID/g) were calculated.
 To prove the imaging potential of VHH-IR in an intraoperative setting mice bearing SKBR3 
tumors (n=2) were injected intravenously with 50 µg of 11A4-IR. 4h p.i. the fluorescent signal of 
the probe was used to guide the tumor resection. Organs of these mice were then removed and 
included in the biodistribution study.  
Supplemental figure 1. Apparent affinities of anti-HER2 VHHs (A) and IR-conjugated anti-HER2 VHHs (B). HER2-ECD 
or attached SKBR3 were incubated with increasing concentrations of indicated anti-HER2 VHHs. Affinity (KD) and maximal 
binding (Bmax) was determined as described in Materials & methods.
Supplemental figure 2. SDS-PAGE of IR-conjugated proteins. Samples of purified IR-conjugated proteins were size 
separated by SDS-PAGE and imaged using an Odyssey: green corresponds to the IR signal, and in red the molecular weight 
marker. For each protein 2 bands were found, of which the high molecular weight protein corresponds with the expected 
size of the IR conjugated VHHs (13 kDa). The second band with a lower molecular weight protein was due to the loss of the 
epitope tag during the production procedure (except for 11A4-IRr). As this modification did not affect the binding properties 
of the probe, we decided to continue with these proteins. 
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Supplemental figure 3. Gel Permeation Chromatography of IR-conjugated proteins. Samples of site-specifically labeled 
11A4-IR, 18C3-IR, 22G12-IR and R2-IR, and randomly labeled 11A4-IRr were analyzed by gel permeation chromatography, 
absorbance was recorded at 280nm (protein) and 774nm (IR) wavelength. Overlap of retention times was observed of peaks 
detected at 280nm and 774nm, which confirms the conjugation of IR to the protein. 
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Supplemental figure 4. IR/Protein ratios of IR-conjugated proteins. Quantitative assessment of the peaks shown in B, IR/
Protein ratios have been determined as described in Materials and Methods.
Supplemental figure 5. Immunohistochemical staining of HER2 receptor in MDA-MB-231 and SKBR3 tumor sections. 
Xenografts were removed from mice, fixed and processes for immunohistochemistry as described in materials and methods. 
Note the absence of staining in the HER2 negative xenografts consisting of MDA-MB-231 cells and the clear staining of 
SKBR3 cells.
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Supplemental figure 6. Biodistribution study of IR-conjugated proteins. Top table shows percentage of injected dose per 
gram of organ or tumor ± SEM (%ID/g) (n=5 for trastuzumab-IR and R2-IR group, n=7 for 11A4-IR group), and table below 
shows tumor to organ ratios (n=5 for trastuzumab-IR and R2-IR group, n=7 for 11A4-IR group).
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ABSTRACT
The human epidermal growth factor receptor 3 (HER3) is an interesting target for antitumor 
therapy. For optimal HER3 signaling inhibition, a biparatopic Nanobody construct (MSB0010853) 
was developed that binds 2 different HER3 epitopes. In addition, MSB0010853 contains a third 
epitope that binds albumin to extend its circulation time. MSB0010853 is cross-reactive with 
HER3 and albumin of mouse origin. We aimed to gain insight into MSB0010853 biodistribution 
and tumor uptake by radiolabeling the Nanobody construct with 89Zr. 
Methods: MSB0010853 was radiolabeled with 89Zr. Dose- and time-dependent tumor uptake 
was studied in nude BALB/c mice bearing a subcutaneous HER3 overexpressing H441 non–small 
cell lung cancer xenograft. Dose-dependent biodistribution of 89Zr-MSB0010853 was assessed ex 
vivo at 24 h after intravenous injection. Protein doses of 5, 10, 25, 100, and 1,000 µg were used. 
Time-dependent biodistribution of MSB0010853 was analyzed ex vivo at 3, 6, 24, and 96 h after 
intravenous administration of 25 µg of 89Zr-MSB0010853. PET imaging and biodistribution were 
performed 24 h after administration of 25 µg of 89Zr-MSB0010853 to mice bearing human H441, 
FaDu (high HER3 expression), or Calu-1 (no HER3 expression) tumor xenografts. 
Results: Radiolabeling of MSB0010853 with 89Zr was performed with a radiochemical purity 
of greater than 95%. Ex vivo biodistribution showed protein dose– and time-dependent 
distribution of 89Zr-MSB0010853 in all organs. Uptake of 89Zr-MSB0010853 in H441 tumors 
was only time-dependent. Tumor could be visualized up to at least 96 h after injection. The 
highest mean SUV of 0.6 ± 0.2 was observed at 24 h after injection of 25 µg of 89Zr-MSB0010853. 
89Zr-MSB0010853 tumor uptake correlated with HER3 expression and was highest in H441 (6.2 ± 
1.1 percentage injected dose per gram [%ID/g]) and lowest in Calu-1 (2.3 ± 0.3 %ID/g) xenografts. 
Conclusion: 89Zr-MSB0010853 organ distribution and tumor uptake in mice are time-dependent, 
and tumor uptake correlates with HER3 expression. In contrast to tumor uptake except for kidney 
uptake, organ distribution of 89Zr-MSB0010853 is protein dose–dependent for the tested doses. 
89Zr-MSB0010853 PET imaging gives insight into the in vivo behavior of MSB0010853.
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INTRODUCTION
Members of the human epidermal growth factor receptor (HER) family, consisting of epidermal 
growth factor receptor (EGFR), HER2, HER3, and HER4, play a key role in tumor growth, 
differentiation, survival, metastasis, and angiogenesis.1 Incorrect signaling of EGFR and HER2 
underlies the pathogenesis of a variety of cancers. Therefore, these prooncogenic receptors are 
targets of several therapies used for cancer treatment. Unfortunately, many patients do not 
respond to these drugs or experience tumor progression after an initial response.
 Unlike other members of the family, HER3 has reduced kinase activity but can form 
highly activated heterodimers with EGFR and HER2. HER3 overexpression is associated with 
resistance against EGFR- and HER2-targeted therapy.2 In preclinical models, a combination of 
HER3-targeting antibodies with cetuximab, erlotinib, pertuzumab, trastuzumab, or lapatinib 
plus trastuzumab resulted in increased antitumor activity.3–8 Several clinical trials evaluate this 
approach as well.9
 Interestingly, a mixture of 2 anti-HER3 antibodies (A5 and F4) blocked ligand-induced and 
independent HER3 signaling and inhibited tumor cell growth better than each antibody alone.10 
Blocking 2 different HER3 epitopes, with a biparatopic Nanobody construct (MSB0010853; 
Ablynx), is therefore an interesting option.
 With their small size (15 kDa), high stability, and straightforward production, monovalent 
Nanobodies are ideal building blocks to develop biparatopic constructs.11 Nanobodies show rapid 
tumor penetration and fast renal clearance.12 MSB0010853 (39.5 kDa) consists of 2 HER3-targeting 
Nanobodies and an additional third that is able to bind albumin, extending its half-life (Fig. 1A, 
B). MSB0010853 binds HER3 at domain 1 and at a second unknown domain. All 3 Nanobodies 
target human and mouse antigen.
      A  B









A                                     B
Figure 1. Composition of MSB0010853 (molecular weight, 39.5 kDa). (A) Nanobody is the variable domain of a heavy chain–
only antibody. (B) MSB0010853 contains 3 Nanobodies that are linked together. The individual Nanobodies bind 2 different 
epitopes of HER3 and albumin. MSB0010853 binds HER3 at domain 1 and at a second unknown domain (defined as x).
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 Currently, little information on the pharmacologic behavior of MSB0010853 is available. 
Molecular imaging can provide additional insight in biodistribution and tumor accumulation. 
Molecular imaging is currently used in drug development of monoclonal antibodies13 and might 
facilitate decision making in future early clinical trials with MSB0010853. We radiolabeled 
MSB0010853 with 89Zr, because the long half-life of 89Zr (78.4 h) allows us to follow MSB0010853 
in vivo and determine tumor uptake up to several days after injection.
 The purpose of this study was to assess 89Zr-MSB0010853 biodistribution and in vivo imaging 
in different HER3-expressing human tumor–bearing mouse models.
MATERIALS AND METHODS 
Cell lines
We used the non–small cell lung cancer cell line H441 (HER3-positive), head and neck squamous 
cell cancer cell line FaDu (HER3-positive), and non–small cell lung cancer cell line Calu-1 
(HER3-negative), obtained from American Type Culture Collection.14 FaDu and H441 cells were 
cultured in Dulbecco modified Eagle medium (Invi-trogen), supplemented with 10% fetal calf 
serum (Bodinco BV) and 2mM L-glutamine (Invitrogen). Calu-1 was cultured in RPMI 1640 
(Invitrogen) supplemented with 10% fetal calf serum and 2 mM L-glutamine. All cells were 
grown at 37°C in a fully humidified atmosphere containing 5% CO2.
Synthesis and quality control of conjugated and radiolabeled 89Zr-MSB0010853 
MSB0010853 was formulated (10.24 mg/mL) in a buffer containing 20 nM L-histidine (Merck), 
8% (w/v) sucrose (Calbiochem), and 0.01% (w/v) polysorbate 20 (Merck), pH 6.5. MSB0010853 
was purified with water for injections (B. Braun), using a Vivaspin-2 10-kDa filter (GE 
Healthcare). MSB0010853 was reacted with a 4-fold molar excess of N-succinyldesferrioxam-
ine-B-tetrafluorphenol-Fe (N-sucDf-TFP-Fe; ABX) as described previously.15 We used a different 
size-exclusion column (Superdex 75 10/300 GL column; GE Healthcare). Quality control was 
performed as described earlier.16 Because Fe3+ (in N-sucDf-TFP-Fe) absorbs light at 430 nm, we 
used size-exclusion high-performance liquid chromatography to determine the conjugation 
efficiency. Chelated MSB0010853 was stored in the original formulation buffer at -20°C and 
radiolabeled with 89Zr (PerkinElmer) on the day of the experiments, as described previously.15 
Radiochemical yields equaled the radiochemical purity after radiolabeling because purification 
was not necessary.
 The binding of 89Zr-MSB0010853 to human serum albumin (HSA [Sanquin]) was assessed 
in a competitive radioimmunoassay. Nunc-Immuno BreakApart enzyme-linked immunosorbent 
assay wells were incubated overnight at 4°C with 100 µL HSA solution (30 µg/mL in bicarbonate 
buffer: 15 mM sodium carbonate [Merck], 35 mM sodium bicarbonate [Merck], pH 9.6), blocked 
with 1% skimmed milk powder (Fluka) in phosphate-buffered saline (PBS; 140 mmol/L NaCl, 
9 mmol/L Na2HPO4, 1.3 mmol/L NaH2PO4; UMCG) at room temperature, and washed with 
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0.1% polysorbate 20 (Sigma-Aldrich) in PBS. 89Zr-MSB0010853 (final concentration, 200 nM) 
was mixed with varying final concentrations of unlabeled MSB0010853 (2 nM to 2 µM). Dilution 
series were prepared using 1% skimmed milk powder and 0.1% polysorbate 20 in PBS. The wells 
were incubated with the solutions for 2 h. Hereafter, the wells were washed twice with 0.05% 
polysorbate 20 in PBS. Radioactivity was measured by a well-type LKB-1282-Compu-γ-system 
(LKB Wallac) and set to 100% for wells without nonlabeled MSB0010853. HSA affinity of 
89Zr-MSB0010853 was compared with unlabeled MSB0010853 by dividing the concentration 
of 89Zr-MSB0010853 (200 nM) by the concentration of MSB0010853 needed to block 50% of 
89Zr-MSB0010853 binding to HSA.
 Internalization experiments were started by harvesting 106 H441 cells with Accutase 
(Millipore) and suspending in 1% bovine serum albumin in PBS. Cells were incubated for 1 h 
on ice with 50 ng of 89Zr-MSB0010853 with or without 4 µg of HSA. The excess of non-bound 
89Zr-MSB0010853 was removed and culture medium (4°C) added. Radioactivity was counted 
in a well-type γ-counter (LKB 1282 [CompuGamma]; membrane-bound activity at time zero 
[T0]). Hereafter, cells were incubated at 37°C or on ice for 1, 2, or 4 h, and medium was removed. 
Internalized (cell pellet) and membrane-bound 89Zr-MSB0010853 (medium) were separated after 
10-min incubation in 4 M urea buffer supplemented with 0.2 M glycine (pH 2). The internalized 
amount of radioactivity was calculated as a fraction of initial membrane-bound radioactivity at 
T0.
In vitro HER3 binding of 89Zr-MSB0010853
The immunoreactivity of 89Zr-MSB0010853 to HER3 was assessed with H441 cells in the 
cell-binding assay.17 Two series of H441 cell dilutions (50 x 106 cells/mL and 6.6 x 106 cells/mL) 
were incubated with 89Zr-MSB0010853 (20 ng/mL) for 2 h at 4 °C while being shaken. To 1 of 
the cell series, a more than 3,000-fold molar excess of MSB0010853 was added to correct for 
nonspecific binding. After 2 h of incubation, cells were washed twice with PBS containing 
1% bovine serum albumin to reduce nonspecific tube binding. Cell-bound radioactivity was 
measured with a well-type γ-counter. Data obtained with 50 x 106 cells/mL (n = 4) were used to 
demonstrate that a more than 3,000-fold excess of nonlabeled MSB0010853 could block HER3 
binding of 89Zr-MSB0010853 (20 ng/mL).
Animal studies
The institutional animal care and use committee of the University of Groningen approved 
all animal experiments. Animal studies were performed in male nude BALB/c mice (BALB/
cOlaHsd-Foxn1nu [Harlan]; 5–7 wk old at arrival). Animals were allowed to feed ad libitum, 
and experiments were performed under isoflurane inhalation anesthesia (induction, 5%; 
maintenance, 2%).
 Tumor cells were harvested by trypsinization and diluted in PBS. Mice were injected 
subcutaneously in the flank with 4 x 106 H441, 5 x 106 FaDu, or 5 x 106 Calu-1 cells in 0.1 mL of PBS. 
Tumor growth was followed with caliper measurements. Tracer injection was performed 4–7 wk 
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(H441), 3–5 wk (FaDu), or 19 wk (Calu-1) after tumor cell inoculation, when tumors were around 
100–200 mm3.
Protein dose escalation biodistribution study
Dose-dependent tumor uptake of 89Zr-MSB0010853 was assessed in H441 tumor–bearing mice. 
Five dose groups of 5 µg (n = 5), 10 µg (n = 4), 25 µg (n = 5), 100 µg (n = 4), and 1,000 µg 
(n = 5) were included. 89Zr-MSB0010853 was administered intravenously via penile injection, 
using a fixed volume of 150 µl. Four standards (5, 10, 15 and 20 µl) of the injected protein dose 
were stored to calculate the injected dose accurately. For the 5 µg,-, 10 µg and 25 µg doses, no 
unlabeled  MSB0010853  was  mixed  with 89Zr-MSB0010853. For the 100-µg protein dose, 75 µg 
of unlabeled MSB0010853 were mixed with 25 µg of 89Zr-MSB0010853. To reach 1,000 µg, 10 µg 
of 89Zr-MSB0010853 were supplemented with 990 µg of unlabeled MSB0010853. One batch of 
N-sucDf-TFP–chelated MSB0010853 was used for radiolabeling. The specific activity of injected 
89Zr-MSB0010853 varied between 1 and 200 MBq/mg, as a fixed amount of radioactivity (1 MBq) 
was administered. For ex vivo biodistribution, animals were sacrificed 24 h after injection. 
Subsequently, organs and tissues were excised and weighed. Samples and standards were counted 
for radioactivity in a well-type γ-counter. Ex vivo tissue activity is expressed as percentage injected 
protein dose per gram of tissue (%ID/g).
PET acquisition
Two mice were placed (one on top of the other) in a Focus 220 rodent scanner (CTI Siemens), 
with the tumor in the field of view. Mice were kept warm on heating mats. Acquisition times 
differed between 10 min (24-h time point) and 75 min (96-h time point). A transmission scan of 
515 s was obtained using a 57Co point source to correct for tissue attenuation. 
Time-dependent biodistribution and small-animal imaging of 89Zr-MSB0010853
Time-dependent  biodistribution  of  89Zr-MSB0010853 (25 µg, 1–5 MBq = 40–200 MBq/mg) 
was  evaluated  in  H441  tumor–bearing mice at 3, 6, 24, or 96 h after injection (n = 4–6). 
One batch of N-sucDf-TFP–chelated MSB0010853 was radiolabeled with 89Zr for each time point 
separately. Small-animal PET images were obtained 24, 48, 72, and 96 h after injection of 25 
µg of 89Zr-MSB0010853 (5 MBq = 200 MBq/mg, n = 5). PET data were reconstructed using a 
2-dimensional  ordered-subset expectation maximization reconstruction algorithm with Fourier 
rebinning, 4 iterations and 16 subsets. Images were quantified using Amide’s medical image data 
examiner software (version 1.0.4; Stanford University). Regions of interest were drawn for tumors 
at 50% of maximum intensity, and images were quantified using Amide’s medical image data 
examiner software. The data are presented as the SUVmean or SUVmax. 
Small-animal PET imaging and biodistribution in different tumor models
Mice bearing FaDu, H441, or Calu-1 tumors were scanned 24 h after injection of 25 µg of 
89Zr-MSB0010853 (1 MBq = 40 MBq/mg; n = 3–5/group). After scanning, mice were sacrificed for 
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ex vivo bio-distribution analysis.
Statistical analysis
Data are presented as mean ± SD. Statistical analysis between 2 non-parametric groups was 
performed using the Mann–Whitney U test (Prism 5; GraphPad). P values of 0.05 or less were 
considered significant.
RESULTS
89Zr-MSB0010853 production and quality control
On average, 1 mol of N-sucDf-TFP-Fe was conjugated to 1 mol of MSB0010853. After MSB0010853 
was labeled with 89Zr, the radiochemical purity and radiochemical yields were greater than 
95%. Size-exclusion high-performance liquid chromatography analyses did not show any 
fragmentation or aggregation of the 89Zr labeled MSB0010853 (Supplemental Fig. 1). The relative 
affinity to HSA of 89Zr-MSB0010853 compared with unlabeled MSB0010853 was 67% ± 9%. A 
small amount of 89Zr-MSB0010853 was internalized within 4 h of incubation, 5.5% ± 11.3% in the 
absence of HSA and 12.2% ± 9.6% in the presence of HSA (Supplemental Fig. 2).
In vitro HER3 binding of 89Zr-MSB0010853
The immunoreactive fraction of 89Zr-MSB0010853 against HER3 on H441 cells was 0.68 ± 0.11 (Fig. 
2A). HER3-specific binding of 89Zr-MSB0010853 could be blocked with an excess of unlabeled 
MSB0010853 (Fig. 2B).
Figure 2. In vitro HER3 binding of 89Zr-MSB0010853. (A) Reciprocal plot of 89Zr-MSB0010853 binding to H441 cells 
to determine immunoreactivity. (B) In vitro blocking of 89Zr-MSB0010853 HER3 binding on H441 tumor cells. Data are 
presented as mean ± SD (n = 4).
A B
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Protein dose escalation biodistribution study
Protein dose escalation biodistribution studies in H441-xenografted mice showed comparable 
tumor uptake of 89Zr-MSB0010853 in all tested dose groups, ranging between 4.3 and 5.7 %ID/g 
(Fig. 3A). Tumor-to-blood and tumor-to-muscle ratios, however, decreased from, respectively, 
8.0 ± 6.8 to 0.6 ± 0.2 and 17.8 ± 3.9 to 4.8 ± 2.5, when the protein dose was increased from 5 to 100 
µg (Figs. 3B and 3C). Both tumor-to-blood and tumor-to-muscle ratios did not further decrease 
by increasing the protein dose to 1,000 µg. Renal uptake was protein dose–independent, ranging 
between 14.3 and 15.4 %ID/g. Blood levels of 89Zr-MSB0010853 correlated with the administered 
dose, which was lowest in the 5-µg dose group (0.8 ± 0.4 %ID/g) and 15-fold higher in the 
1,000-µg protein dose group (12.1 ± 1.1 %ID/g). In most organs, uptake increased with increasing 
protein doses (up to 25–100 µg). Liver uptake negatively correlated with the administered dose, 
which was highest in the 5-µg protein dose group (15.4 ± 0.9 %ID/g) and a 2.8-fold lower in the 
1,000-µg protein dose group (5.5 ± 1.8 %ID/g). Because 25 µg of 89Zr-MSB0010853 resulted in 
relatively high tumor uptake and low blood levels, further animal studies were performed using 
this protein dose.
Figure 3. Protein dose–dependent ex vivo biodistribution of 89Zr-MSB0010853 in mice bearing H441 tumors injected with 5, 
10, 25, 100, or 1,000 μg at 24 h after tracer injection, expressed as %ID/g (A), tumor-to-blood ratios (B), and tumor-to-muscle 
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Time-dependent biodistribution and small-animal PET imaging of 89Zr-MSB0010853
Up to 24 h after injection, tumor uptake of 89Zr-MSB0010853 increased in time (to 6.2 ± 1.1 
%ID/g), which decreased subsequently (Fig. 4A). 89Zr-MSB0010853 rapidly cleared from the 
bloodstream, resulting in tumor-to-blood ratios increasing in time up to 33.1 ± 7.9 at 96 h after 
tracer injection (Fig. 4B). In addition, tumor-to-muscle ratios increased up to 96 h after injection 
to 13.4 ± 5.3 (Fig. 4C). Although 89Zr-MSB0010853 showed minimal internalization in H441 cells 
in vitro (Supplemental Fig. 2), H441 tumors were still clearly visible up to 96 h after injection (Fig. 
5). The highest SUVmean (0.6 ± 0.2) was observed 24 h after injection, decreasing subsequently 
(Fig. 5B).
Figure 4. Time-dependent ex vivo biodistribution of 89Zr-MSB0010853 in mice bearing H441 xenografts injected with 25 
μg of 89Zr-MSB0010853 at 3, 6, 24, and 96 h after tracer injection, expressed as %ID/g (A), tumor-to-blood ratios (B), and 
tumor-to-muscle ratios (C). Data are presented as mean ± SD (n = 4–6). pi = after injection.
A
B C
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Figure 5. (A) Representative coronal PET images of mice bearing H441 xenografts injected with 25 μg of 89Zr-MSB0010853 
obtained at 24, 48, 72, and 96 h after tracer injection. (B) Small-animal PET data quantification was performed for tumor 
uptake at 24, 48, 72, and 96 h after tracer injection in all mice. Data are presented as mean ± SD (n = 5).
Small-animal PET imaging and biodistribution in different tumor models
Tumor uptake of 89Zr-MSB0010853 could be visualized 24 h after injection in HER3-expressing 
H441 and FaDu xenografts. Less tumor uptake was observed in HER3-negative Calu-1 xenografts 
(Fig. 6A). Because Calu-1 cells do not express HER3, tumor uptake of 89Zr-MSB0010853 in Calu-1 
tumors is nonspecific. Ex vivo biodistribution data confirmed this observation. Tumor uptake 
in the HER3-negative Calu-1 model was 2.3 ± 0.3 %ID/g, which was 2.4-fold lower than in 
HER3-positive H441 (6.2 ± 1.1 %ID/g; P = 0.04) and 2.2-fold lower than in FaDu (5.1 ± 0.4 %ID/g; 
P = 0.04) xenografts (Fig. 6B).
Figure 6. Representative coronal PET images of mice bearing H441, FaDu, or Calu-1 xenografts 24 h after injection of 25 
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DISCUSSION 
To our knowledge, this is the first report describing dose- and time-dependent biodistribution 
of a biparatopic anti-HER3 Nanobody construct in mice. With small-animal PET imaging, 
biodistribution and tumor uptake of 89Zr-MSB0010853 were visualized up to at least 96 h after 
injection. This study illustrated that PET imaging with 89Zr-MSB0010853 provides noninvasive 
information on MSB0010853 biodistribution and tumor uptake. 
 We demonstrated that tissue distribution of 89Zr-MSB0010853 in mice is dose-dependent. 
At 24 h after injection, 89Zr-MSB0010853 blood levels in the 1,000-µg dose group were 15-fold 
higher than in the 5-µg dose group. This increase might be due to saturation of hepatic uptake of 
89Zr-MSB0010853, because hepatic uptake inversely correlated with blood levels. Increasing the 
protein dose of an albumin-binding anti-hepatocyte growth factor Nanobody construct18 and an 
albumin-binding anti-HER2 Affibody construct19 did not affect liver uptake. Therefore, saturation 
of 89Zr-MSB0010853 liver uptake was not due to in vivo albumin binding. Because MSB0010853 
is cross-reactive with mouse HER3 and HER3 is expressed on hepatocytes and bile duct cells in 
the liver, saturation is more likely due to intrahepatic HER3 binding.20 In line with our results, 
saturation of HER3-dependent liver uptake was also observed in mice injected with 99mTc-labeled 






















, 4–6 h after injection. This was likely 
due to the fast clearance of these small anti-HER3 Affibody molecules, without albumin-binding 
capacity that extends half-life. 
 Apart from the liver, saturation of 89Zr-MSB0010853 was also observed in other organs 
that express HER3, such as the lung, stomach, small intestines, colon, and skin.18 Uptake 
of 89Zr-MSB0010853 in these organs increased with increasing protein doses up to 25–100 µg. 
This might well be due to increased delivery of the tracer to these tissues, given the increased 
tracer blood levels. At higher protein doses, blood levels continued to increase whereas uptake 
indicating saturation of HER3-dependent organ uptake. We additionally observed saturation of 
HER3-specific tumor uptake. This can best be perceived from Figures 3B and 3C. Increasing the 
protein dose resulted in a decreased tumor-to-blood and tumor-to-muscle ratio. If tumor uptake 
of 89Zr-MSB0010853 was solely due to nonspecific uptake, the drastic 15-fold increase in blood in 
these HER3-expressing organs did not, levels would promote tumor uptake.












However, it is comparable with the renal uptake of 177Lu-aEGFR-aEGFR-aAlb, a similar-sized 
EGFR binding Nanobody construct with albumin-binding capacity.23 Additionally, blood 
radioactivity levels of 177Lu-aEGFR-aEGFR-aAlb and 89Zr-MSB0010853 were also comparable 
(~10 %ID/g) at 24 h after injection in mice. Injected protein doses were similar for both tracers 
(100 µg), demonstrating a similar effect of albumin binding on half-life extension of both 
Nanobody constructs. The half-life of murine serum albumin in mice is 1.1–1.6 d, much shorter 
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than the half-life of 15–19 d for HSA in humans.24–27 Therefore, we expect a slower clearance of 
89Zr-MSB0010853 in humans than in mice, allowing a longer 89Zr-MSB0010853 accumulation 
time in tumors of patients, likely resulting in higher tumor accumulation in patients than in 
mice.
 PET imaging is increasingly used in the development of targeting agents.13 It could provide 
useful information about the pharmacologic behavior and tumor-targeting properties of these 
agents, facilitating patient selection and the management of clinical dose-finding studies.13,28 
PET imaging in patients will likely give us additional information on MSB0010853 in vivo 
behavior and tumor targeting. The presence of target does not mean that targeted drugs are 
able to accumulate in target-positive tumors.29 This may be due to many factors such as tumor 
perfusion, presence of stroma, tumor interstitial fluid pressure, and anatomic location of the 
tumor.29 Although the level of tumor accumulation is currently missing in many early-phase 
clinical trials, it is obtainable by including PET imaging in these studies. 
 Preclinical and clinical PET imaging has also been used in the development of RG7116 
and patritumab, 2 intact anti-HER3 antibodies. Pre-clinical biodistribution studies in mice 
showed HER3-specific tumor uptake of both radiolabeled antibodies.14,30 Compared with 
89Zr-MSB0010853, maximum 89Zr-RG7116 tumor uptake at 6 d after injection was higher, with 
19.0, 13.9, and 7.6 %ID/g in H441, FaDu, and Calu-1 xenografts. This could be due to a high 
amount of nonspecific 89Zr-RG7116 tumor uptake, because uptake of control 111In-IgG in these 
tumors was, respectively, 16.5, 9.1 and 8.3 %ID/g.14 Because 89Zr-RG7116 is not cross-reactive for 
mouse HER3, it lacks specific organ binding. Therefore, tumor-to-organ ratios were higher than 
observed with 89Zr-MSB0010853. However, tumor-to-blood ratios were comparable. Preliminary 
results with 64Cu-labeled patritumab and 89Zr-RG7116 in patients show that biodistribution 
and tumor uptake of HER3-targeting agents can noninvasively be visualized with whole-body 
PET imaging.31,32 Differences in species (humans vs. mice) and the expected longer circulation 
time of 89Zr-MSB0010853 in humans preclude quantitative comparison with our preclinical 
89Zr-MSB0010853 findings.
CONCLUSION
Biodistribution of 89Zr-MSB0010853 is protein dose– and time-dependent and can be studied 
noninvasively using PET imaging. In addition, tumor uptake of 89Zr-MSB0010853 correlated with 
HER3 expression. As demonstrated in our study, PET imaging gives noninvasive insight into the 
in vivo behavior of MSB0010853. In early-phase clinical trials, 89Zr-MSB0010853 can potentially 
be used to study biodistribution and tumor uptake of MSB0010853 in cancer patients to facilitate 
clinical development.
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SUPPLEMENTARY INFORMATION 
Supplemental figure 1. A typical HPLC chromatogram of 89Zr-MSB0010853. At 280 nm 89Zr-MSB0010853 could be detected 
with a retention time of approximately 18 min, corresponding with co-registered radioactive signal. The small peak at ~25 
min represents the solvent of 89Zr-MSB0010853.
Supplemental figure 2. Internalization of 89Zr-MSB0010853 in H441 cells with and without the presence of HSA. Data is 
presented as mean ± SD.
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ABSTRACT
AMG 110, a bispecific T cell engager (BiTE) antibody construct, induces T cell–mediated cancer 
cell death by cross-linking epithelial cell adhesion molecule (EpCAM) on tumor cells with a 
cluster of differentiation 3 ε (CD3ε) on T cells. We labeled AMG 110 with 89Zr or near-infrared 
fluorescent dye (IRDye) 800CW to study its tumor targeting and tissue distribution. 
Methods: Biodistribution and tumor uptake of 89Zr-AMG 110 was studied up to 6 d after 
intravenous administration to nude BALB/c mice bearing high EpCAM-expressing HT-29 
colorectal cancer xenografts. Tumor uptake of 89Zr-AMG 110 was compared with uptake in head 
and neck squamous cell cancer FaDu (intermediate EpCAM) and promyelocytic leukemia HL60 
(EpCAM-negative) xenografts. Intratumoral distribution in HT-29 tumors was studied using 
800CW-AMG 110. 
Results: Tumor uptake of 89Zr-AMG 110 can be clearly visualized using small-animal PET imaging 
up to 72 h after injection. The highest tumor uptake of 89Zr-AMG 110 at the 40-μg dose level was 
observed at 6 and 24 h (respectively, 5.35 ± 0.22 and 5.30 ± 0.20 percentage injected dose per gram; 
n = 3 and 4). Tumor uptake of 89Zr-AMG 110 was EpCAM-specific and correlated with EpCAM 
expression. 800CW-AMG 110 accumulated at the tumor cell surface in viable EpCAM-expressing 
tumor tissue. 
Conclusion: PET and fluorescent imaging provided real-time information about AMG 110 
distribution and tumor uptake in vivo. Our data support using 89Zr and IRDye 800CW to evaluate 
tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical 
and clinical settings.
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INTRODUCTION 
Cancer remains a major cause of death worldwide and one of the key disease areas with the 
greatest unmet medical needs. Therefore, new treatment strategies are eagerly awaited. The use 
of T cells, especially cytotoxic T cells, in the battle against cancer has shown promising results 
using several approaches.1 However, most of these strategies are sensitive to inhibitory or escape 
mechanisms, such as major histocompatibility complex class I downregulation or induction of T 
cell tolerance, which can limit antitumor efficacy.2,3
 Bispecific T cell engager (BiTE) antibody constructs are created to circumvent such inhibitory 
or escape mechanisms. They comprise 2 single-chain variable antibody fragments (scFv) that are 
covalently linked by a peptide linker and bind cluster of differentiation 3 ɛ (CD3ɛ) as well as a 
surface target antigen on cancer cells.4 The activation of T cells by BiTE antibody constructs is 
independent of matching major histocompatibility complex class I or costimulatory molecules.5,6 
Furthermore, BiTE antibody constructs engage a polyclonal population of T cells, including CD4+ 
and mainly CD8+ T cells.7 Binding of tumor cells and T cells by BiTE antibody constructs results 
in the formation of a cytolytic synapse between tumor and T cells, which is followed by a release 
of pore-forming and pro-apoptotic components of cytotoxic T cell granules, mediating cancer 
cell death.5,7 The activation of T cells occurs only in the presence of a target cell.8 To date, 4 BiTE 
antibody constructs, blinatumomab, BAY2010112/AMG 212, MT111/AMG 211, and MT110/AMG 110, 
are or have been tested in clinical trials. Blinatumomab has been approved by the U.S. Food and 
Drug Administration to treat patients with Philadelphia chromosome–negative precursor B-cell 
acute lymphoblastic leukemia.
 Epithelial cell adhesion molecule (EpCAM) is expressed on many epithelial tumors 
and cancer stem cells9 and is therefore an attractive target for BiTE antibody constructs. 
An EpCAM-targeting BiTE called solitomab (AMG 110, formerly known as MT110) has been 
developed.10 AMG 110 mediates lysis of cancer cells by the activation of T cells in vitro and showed 
pharmacologic activity at doses administered of at least 24 µg/d in the clinic.11 
 To support clinical development of AMG 110 and other BiTE antibody constructs, molecular 
imaging can be used as a powerful noninvasive tool to obtain valuable information on tumor 
uptake, biodistribution, and pharmacokinetics. In a clinical setting, this information can 
potentially be used to support patient-tailored drug dosing. Because of its long radioactivity 
decay half-life of 3.27 d, 89Zr is well suited for capturing the in vivo pharmacokinetics of large 
molecules, such as antibodies.12 In addition, labeling antibodies with the near-infrared (NIR) 
fluorescent dye 800CW can be used to study their intratumoral tumor distribution with NIR 
fluorescence imaging and to enable molecular characterization of tumor and tissue sections ex 
vivo.13 We therefore labeled AMG 110 with 89Zr or IRDye 800CW to study its tumor targeting and 
tissue distribution via noninvasive small-animal PET and fluorescence imaging.
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MATERIALS AND METHODS
BiTE antibody constructs and cell lines
AMG 110 is a BiTE antibody construct targeting human EpCAM and human CD3ɛ. The 
nonspecific control BiTE Mec14 shares the same anti-CD3ɛ single-chain antibody arm but targets 
a haptene (mecoprop) with the second arm. Both BiTE antibody constructs, 55 kDa or more 
in size, were provided by Amgen. Two human EpCAM-positive tumor cell lines, the colorectal 
adenocarcinoma HT-29 cell line and the head and neck squamous cell cancer FaDu cell line, and 
a human EpCAM-negative promyelocytic leukemia HL-60 cell line were used. We used HT-29 
xenografts to study dose- and time-dependent tumor uptake of 89Zr-AMG110 because this cell 
line highly expresses EpCAM.14 We additionally used this cell line to compare EpCAM-dependent 
tumor uptake of 89Zr-AMG110 with 89Zr-Mec14. All cell lines were obtained from American Type 
Culture Collection and screened for microbial contamination and tested negative. Cell lines were 
authenticated by Baseclear using short tandem repeat profiling. This was repeated once a cell 
line had been passaged for more than 6 mo after previous short tandem repeat profiling. HT-29 
and HL-60 were routinely cultured in RPMI-1640 medium (Invitrogen) containing 10% fetal calf 
serum (Bodinco BV). FaDu cells were cultured in Dulbecco modified Eagle medium (Invitrogen) 
supplemented with 10% fetal calf serum and 2 mM L-glutamine (Invitrogen). All cells were 
cultured under humidified conditions (37°C, 5% CO2).
Animal experiments
All animal experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Groningen and conducted in male nude BALB/c mice (BALB/cOlaHsd-Foxn1nu; 
Harlan). After 1 wk of acclimatization, 6- to 8-wk old mice were subcutaneously injected with 
10 x 106 HT-29 cells in 0.1 mL of phosphate-buffered saline, with 5 x 106 FaDu cells in 0.1 mL 
of phosphate-buffered saline, or with 2 x 106 HL-60 cells in 0.1 mL of phosphate-buffered 
saline. Tumor growth was monitored by caliper measurements. Penile vein tracer injection was 
performed 3 wk after inoculation of HT-29 cells, 4 wk after inoculation of FaDu cells, and 5 
wk after inoculation for HL-60 cells. All scans and invasive proceedings were performed with 
isoflurane/medical air inhalation anesthesia (5% induction, 2.5% maintenance) for a maximum 
of 90 min.
PET acquisition
Two mice were placed above each other in a Focus 220 rodent scanner (CTI Siemens), with the 
tumor in the field of view. Mice were kept warm on heating mats. Acquisition times differed 
between 10 min (0.5-h time point) and 75 min (144-h time point). A transmission scan of 515 s 
was obtained using a 57Co point source to correct for tissue attenuation.
In vivo PET imaging and ex vivo biodistribution
For determining the time point for optimal tumor visualization, small-animal PET images were 
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obtained 0.5, 3, 6, 24, 48, and 72 h after injection of 20 µg of 89Zr-AMG 110 (5 MBq). Data up to 24 
h were obtained from 6 mice, and data at 48 and 72 h were obtained from 2 mice.
 For ex vivo biodistribution, animals were sacrificed at designated time points. Subsequently, 
organs and tissues were excised and weighed. Samples and prime standards were counted 
for radioactivity in a calibrated well-type γ-counter. Ex vivo tissue activity was expressed as 
percentage injected dose per gram of tissue (%ID/g).
 A dose escalation biodistribution study was performed with 20 (n = 5), 40 (n = 4), and 500 µg 
(n = 3) of 89Zr-AMG 110 (1 MBq) at 24 h after injection. Tumor weights did not differ significantly 
between the dose groups (0.23 ± 0.09, 0.33 ± 0.27, and 0.47 ± 0.62 g, respectively) (Supplemental 
Fig. 1A). Doses higher than 20 µg were supplemented with nonradiolabeled AMG 110. For the 
40 µg protein dose, 89Zr-AMG 110 (1 MBq) time-dependent tumor uptake was also determined. 
Biodistribution studies were performed at 6 (n = 3), 24 (n = 4), 72 (n = 4), and 144 (n = 5) h after 
tracer injection. Tumor weights did not differ significantly between different groups (0.20 ± 0.01, 
0.33 ± 0.27, 0.33 ± 0.10, and 0.35 ± 0.15 g, respectively) (Supplemental Fig. 1B).
 To determine nonspecific tumor uptake, 40 µg (1 MBq) of 89Zr-Mec14 (n= 6) or 89Zr-AMG 
110 (n = 4) were administered intravenously to mice harboring HT-29 tumors. Tumor weights 
did not differ significantly between the 2 groups (0.32 ± 0.11 and 0.33 ± 0.27 g, respectively) 
(Supplemental Fig. 1C). Small-animal PET scans and ex vivo biodistribution were performed 
24 h after tracer injection, at the time when tumor uptake of 89Zr-AMG 110 would be high and 
blood levels relatively low. The biologic half-life of 89Zr-AMG 110 in whole blood and tumor was 
calculated using either %ID per cubic centimeter (%ID/cm3) (20 µg tracer dose, as used for 
determining optimal time point) based on small-animal PET scans or %ID/g (40 µg protein 
dose) by nonlinear regression (1-phase exponential decay) using GraphPad Prism (GraphPad 
Software).
 EpCAM-specific uptake in relation to EpCAM expression was assessed with small-animal 
PET imaging 24 h after injection of 40 µg of 89Zr-AMG 110 in xenografted mice (n = 4–6 per 
group) bearing HT-29, FaDu, or HL-60 tumors. Thereafter, mice were sacrificed for ex vivo 
biodistribution analysis. Tumor weights did not differ significantly between the tumor models 
(0.33 ± 0.27, 0.20 ± 0.13, and 0.34 ± 0.10 g, respectively) (Supplemental Fig. 1D).
PET reconstruction
PET data were reconstructed using a 2-dimensional ordered-subset expectation maximization 
reconstruction algorithm with Fourier rebinning, 4 iterations, and 16 subsets. After reconstruction, 
images were quantified using AMIDE Medical Image Data Examiner software (version 1.0.4; 
Stanford University). Regions of interest were drawn for tumor and blood (heart). The level of 
89Zr-AMG 110 or 89Zr-Mec14 was calculated as %ID/cm3.
Ex vivo fluorescent imaging
For NIR fluorescence imaging, mice bearing HT-29 xenografts (n = 4) were coinjected with 40 
μg of 800CW-AMG 110 and 40 μg of 680RD-Mec14. At 24 h after injection mice, were sacrificed 
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and tumor tissue was excised, formalin-fixed, and paraffin-embedded. Tumor slices were stained 
immunohistochemically for EpCAM (D9S3P; Cell Signaling) and with hematoxylin and eosin. 
Overview images of intratumoral 680RD-Mec14 and 800CW-AMG 110 distribution were obtained 
with the Odyssey infrared imaging system (LI-COR Biosci-ences). For fluorescence microscopy, 
an inverted Leica DMI600B fluorescence microscope equipped with a Lumen Dynamics X-Cite 
200DC light source was used. Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich).
Statistical analysis
Data are presented as mean ± SD. Statistical analysis between 2 groups was performed using the 
Mann–Whitney U test (GraphPad Prism 5). To test whether differences between multiple groups 
were significant, we used a Kruskal–Wallis test (GraphPad Prism 5). A Bonferroni-corrected 
Mann–Whitney U test was subsequently used to compare differences between 2 groups. P values 
of 0.05 or less were considered significant.
RESULTS
In vivo evaluation of 89Zr-AMG 110 and 800CW-AMG 110
Small-animal PET images of the 20 µg 89Zr-AMG 110 dose showed time-dependent tumor 
accumulation, with a maximum of 3.25 ± 0.24 %ID/cm3 at 6 h after injection (Fig. 1A, B) and 
decreasing subsequently. Following the same pattern, kidneys showed the highest tissue uptake 
across time points, reaching a maximum of 60.26 ± 4.01 %ID/cm3 at 6 h, indicating renal 
clearance. Blood levels of 89Zr-AMG 110 dropped rapidly (biologic half-life, 1.51 h; Supplemental 
Fig. 4A). The washout of the tumor was relatively slow (biologic half-life, 99.9 h; Supplemental 
Fig. 4B), starting at 6 h after injection. This resulted in increasing tumor-to-blood ratios over 
time, reaching 1.13 ± 0.29, 3.67 ± 0.29, 4.10 ± 0.42, and 3.53 ± 1.03, respectively, at 6, 24, 48, and 
72 h.
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Figure 1. Biodistribution of 89Zr-AMG 110 at 20-μg dose level. (A) Representative serial small-animal PET imaging at 0.5, 3, 6, 
24, 48, and 72 h after injection in 1 HT-29-bearing mouse. Yellow arrows indicate tumor. (B) In vivo quantification of tumor 
and blood levels of 89Zr-AMG 110 in time as presented in %ID/cm3. Data up to 24 h were obtained from 6 mice, and data at 
48 and 72 h were obtained from 2 mice. Data are mean ± SD.
 A 40- and 500-µg protein dose resulted in a higher (not statistically significant) and more 
reproducible tumor uptake of 89Zr-AMG 110 than 20 µg (5.30 ± 0.21 and 4.9 ± 0.21 vs. 3.6 ± 1.2 
%ID/g; P = 0.57 and 0.75, respectively, Fig. 2A). No statistically significant differences were 
found in tumor-to-blood or tumor-to-muscle ratios among the different protein doses tested 
(Supplemental Figs. 5A and 5B). All organs showed similar 89Zr-AMG 110 levels at all protein 
doses. Highest 89Zr-AMG 110 levels were found in the kidneys, followed by liver and tumor. 
Because of a more reproducible tumor uptake, the remainder of the study was performed with a 
40- instead of a 20-µg dose level.
B
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Figure 2. Dose-dependent 89Zr-AMG 110 biodistribution in HT-29– tumor bearing mice at 24 h after tracer injection. Mice 
were injected with 20- (n = 5), 40- (n = 4), or 500-μg (n = 3) protein doses. No significant differences were observed in organ 
and tumor uptake between dose groups. Data are mean ± SD.
 The duration and level of 89Zr-AMG 110 tumor exposure was protein-dose-dependent and 
differed from blood. Biodistribution of 40 µg of 89Zr-AMG 110 in time resulted in a maximum 
tumor uptake at 6 and 24 h after injection of 5.4 ± 0.2 and 5.3 ± 0.3 %ID/g, respectively (Fig. 
3A), declining subsequently. In contrast, tumor uptake after injection of 20 µg of 89Zr-AMG 110 
already peaked at 6 h and declined steadily thereafter (Fig. 1B). The biologic half-life of 89Zr-AMG 
110 after injection of a protein dose of 40 µg in blood was 4.1 h compared with 1.5 h for the 20 
µg protein dose (Supplemental Fig. 4C). Washout of signal from the tumor was relatively slow 
compared with blood (half-life, 40.2 h; Supplemental Fig. 4D). The prolonged tumor retention 
of 40 µg of 89Zr-AMG 110 resulted in increasing tumor-to-blood ratios over time, reaching 65.1 ± 
15.5 at 144 h (Fig. 3B). The maximal tumor-to-muscle ratio was reached at 24 h (18.6 ± 3.6).
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Figure 3. Time-dependent 89Zr-AMG 110 (40 μg) biodistribution in HT-29–bearing mice. (A) Ex vivo biodistribution of 
89Zr-AMG 110 was performed at 6 (n = 3), 24 (n = 4), 72 (n = 4), and 144 h (n = 5) after injection. (B) Corresponding 
tumor-to-blood ratios increased significantly. Data are mean ± SD. Significance has been calculated for differences in tumor 
uptake and tumor-to-blood ratios. *P ≤ 0.05.
 HT-29 xenografts specifically retained 89Zr-AMG 110 but not the non-EpCAM binding 
89Zr-Mec14 BiTE. Biodistribution of 89Zr-Mec14 showed low tumor uptake of 0.7 ± 0.1 %ID/g 
compared with 5.3 ± 0.3 %ID/g for 89Zr-AMG 110 at 24 h (Fig. 4A; P < 0.01). Accumulation of 
89Zr-Mec14 in blood and all organs except the kidneys was lower (≤ 2.4 %ID/g) than 89Zr-AMG 110 
(≤ 5.6 %ID/g). 89Zr-Mec14 tumor uptake was comparable to non-specific uptake in other organs. 
As a result, a higher tumor-to-blood (33.4 ± 3.1 vs. 7.3 ± 1.2; P <, 0.01; Fig. 4B) and a higher 
tumor-to-muscle ratio (18.6 ± 3.6 vs. 6.7 ± 0.8; P < 0.01) were observed for 89Zr-AMG 110. In line 
with these results, small-animal PET images showed lower tumor uptake of 89Zr-Mec14 than 
89Zr-AMG 110 (Fig. 4C).
A
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Figure 4. (A) Ex vivo biodistribution 24 h after injection of 89Zr-AMG 110 (40 μg, n = 4) or 89Zr-Mec14 (40 μg, n = 6) in 
HT-29–tumor bearing mice. (B) Corresponding tumor-to-blood ratios were significantly higher for 89Zr-AMG 110 than for 
89Zr-Mec14. (C) Representative coronal small-animal PET images of 89Zr-AMG 110 and 89Zr-Mec14 visualize difference in 
tumor uptake. Yellow arrow indicates tumor. Data are mean ± SD. *P ≤ 0.05. **P ≤ 0.01.
 Tumor uptake of 89Zr-AMG 110 was correlated with the level of cell surface EpCAM expression 
(Fig. 5). It was highest in HT-29 tumors (5.3 ± 0.3 %ID/g) followed by FaDu (2.7 ± 0.6 %ID/g) 
and HL-60 (0.8 ± 0.2 %ID/g), whereas no differences were observed in uptake of normal organs 
in mice bearing the different tumor xenografts (Fig. 5A). Difference in tumor uptake could be 
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Figure 5. Correlation between 89Zr-AMG 110 tumor uptake and EpCAM expression on tumor cells. (A) Ex vivo biodistribution 
of 89Zr-AMG 110 (40 μg) 24 h after tracer injection in mice bearing HT-29 (n = 4; high EpCAM), FaDu (n = 5; intermediate 
EpCAM), or HL-60 (n = 6; EpCAM-negative) cells. (B) Representative coronal small-animal PET images. Yellow arrows 
indicate tumor. (C) Differences in EpCAM expression on HT-29 (n = 5), FaDu (n = 5), and HL-60 (n = 4) cells correlated with 
tumor uptake of 89Zr-AMG 110. Data are mean ± SD. *P ≤ 0.05.
 In vivo and ex vivo fluorescence imaging confirmed AMG 110–specific cell surface binding 
of HT-29 xenografts. Similar to 89Zr-AMG 110, in vivo imaging showed HT-29 retention of 
800CW-AMG 110 but not 680RD-Mec14 (Supplemental Fig. 6A). In accordance with low tumor 
levels found for 89Zr-Mec14 at biodistribution 24 h after tracer injection, 680RD-Mec14 was 
cleared rapidly, with a level detectable only ex vivo by 24 h (Supplemental Fig. 6B). Ex vivo 
macroscopic fluorescence imaging of HT-29 tumor slices showed 800CW-AMG 110 colocalizing 
with viable EpCAM-expressing tumor tissue, as shown by hematoxylin and eosin and EpCAM 
staining (Fig. 6A, B). Fluorescence microscopy also showed presence of 800CW-AMG 110 on the 
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Figure 6. Intratumoral distribution of coinjected 800CW-AMG 110 (40 μg) and 680RD-Mec14 (40 μg) in HT-29 tumors. 
(A) EpCAM was predominantly expressed on healthy tumor tissue as visualized with hematoxylin and eosin (H&E) and 
EpCAM immunohistochemical staining. (B) Corresponding macroscopic fluorescent imaging of 800CW-AMG 110 (green) 
and 680RD-Mec14 (red) distribution, with minor overlapping signal (yellow). (C) Fluorescence microscopy images (630x), 
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DISCUSSION
We present the first, to our knowledge, noninvasive preclinical imaging study in which a 
bispecific T cell–engaging antibody construct targeting EpCAM is labeled with a radionuclide, 
or a fluorophore, to visualize and quantify tumor uptake, tissue accumulation, and clearance 
kinetics in vivo. In this study, 89Zr-AMG 110 showed consistent tumor uptake in xenografts that is 
correlated with EpCAM expression. It also showed prolonged tumor retention that is unusual for 
a reversible extracellular binder exhibiting rapid renal clearance.
 Remarkably, HT-29 tumor uptake of 89Zr-AMG 110 remained visible up to 72 h after injection, 
despite minimal cellular internalization. Both tumor uptake and organ uptake of 89Zr-AMG 110 
was higher than those of 89Zr-Mec14, likely the result of faster clearance of 89Zr-Mec14, because 
blood levels of 89Zr-Mec14 were also lower. NIR fluorescent imaging with 800CW-AMG 110 
confirmed AMG 110 localization at the tumor cell membrane in viable HT-29 tumor tissue. 
Minor accumulation of 680RD-Mec14 was observed in necrotic tumor tissue, which is likely 
due to nonspecific binding. Together, these findings clearly demonstrate the advantage of using 
immune-PET to determine the dose level of BiTE antibody constructs necessary for tumor 
targeting, to assess the presence of target, and to study in vivo tissue exposure in real time.
 AMG 110 showed favorable tumor uptake and retention compared with a similar EpCAM 
binding agent. The EpCAM-targeting radiopharmaceutical 68Ga-scFv42
9
 also comprises 2 scFv 
fragments and has a molecular weight (51.2 kDa) similar to 89Zr-AMG 110.15 Furthermore, it 
exhibits monospecific bivalent binding and higher EpCAM affinity than AMG 110 (dissociation 
constant = 0.24 vs. 170–230 nM, respectively, as determined by plasmon resonance analysis).10 
Despite bivalent binding and higher affinity, the highest tumor uptake (in %ID/g) of 68Ga-scFv42
9
 
in HT-29 tumors was 2.8-fold lower than 89Zr-AMG 110.16 Maximum tumor uptake of 68Ga-scFv42
9
 
was reached at 1 h, whereas maximum tumor uptake of 89Zr-AMG 110 was reached at 6 h after 
injection. At these time points, the observed tumor-to-blood ratios were comparable (~1 and 1.1 
± 0.30, respectively). The higher tumor uptake of 89Zr-AMG 110 is most likely due to its longer 
circulating half-life (1.4–4.1 h) than that of 68Ga-scFv42
9
 (0.97 h).
 In addition to differences in tumor uptake kinetics and circulating half-life, preclinical 
imaging studies also showed that different tracers also vary in the ability to saturate tumor 
uptake. In contrast to membrane tumor targets c-MET and human epidermal growth factor 
receptor 3, saturation of EpCAM binding on HT-29 was not observed even when the 89Zr-AMG 
110 total protein dose was increased to 500 µg.17,18 Thurber et al. also observed no saturation of 
EpCAM binding in HT-29 xenografts after injection of an EpCAM antibody labeled with a NIR 
dye (VivoTag 680) at a total protein dose of 180 µg.14 One possible explanation might be related 
to the abundance of cell surface EpCAM on HT-29 cells (2.3 x 106 receptors/cell).14 Another 
example supporting this hypothesis was illustrated by the lack of tumor saturation observed 
for 89Zr-trastuzumab, up to 500 µg in SKOV3-xenografted mice.19 Similar to the high level of 
EpCAM expression on HT-29 cells, expression of the human epidermal growth factor receptor 2 
on SKOV3 cells is also high (6.6 x 106 receptors/cell).20 The inability to saturate human epidermal 
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growth factor receptor 2 and EpCAM suggest that it may be difficult to saturate receptors when 
their cell surface expression exceeds approximately 2 x 106 receptors/cell at the dose levels 
evaluated. Alternatively, saturation of tumor targets may also depend on other in vivo properties 
of the antibodies including binding on/off kinetics, degree of tumor penetration, and access 
to targets at different protein dose levels. Additional radioactive- and optical-labeled antibody 
imaging studies, particularly those in the clinical setting, will help further elucidate mechanisms 
for driving uptake in tumors and tissues of interest.
 Although the current preclinical study examined only the tumor antigen binding 
component of AMG 110, preclinical and clinical imaging studies showed that it is feasible to 
image tumor uptake of tumor-targeting CD3-bispecific antibodies in the presence of circulating 
T cells. A T cell–mediated increase in tumor uptake has been observed with a tetravalent 
bispecific tandem antibody (TandAb), directed at mouse CD3ɛ and fibronectin extra domain 
B, in immunocompetent mice.21 125I-labeled TandAb with CD3ɛ affinity similar to that of AMG 
110 showed that potential T cell binding outside of the tumor did not block tumor uptake or 
change its biodistribution.21 The mice in our study were immunodeficient, so tumor uptake of 
89Zr-AMG 110 was not affected by T cells. Because AMG 110 does not bind mouse CD3ɛ, the effect 
of T cell binding on 89Zr-AMG 110 distribution and tumor uptake could not be studied in immune 
competent mice. In a clinical setting, the presence of T cells might influence biodistribution and 
lead to a higher tumor uptake. Furthermore, 123I-OC/TR F(ab´)2, targeting folate receptor and 
CD3, has been used successfully to image malignant tumor lesions in ovarian cancer patients.22
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CONCLUSION
Given its overexpression by many tumor types, EpCAM is an interesting drug target. Different 
EpCAM-targeted drugs have been developed, including monoclonal antibodies, antibody 
fragments, bispecific antibodies, and antibody-drug conjugates. Similar to these other 
experimental drugs, EpCAM expression on tumor cells is a prerequisite for effective treatment 
with AMG 110. Because EpCAM-dependent 89Zr-AMG 110 tumor uptake has been demonstrated 
preclinically, this tracer, applied clinically, can potentially facilitate patient selection for AMG 
110 treatment by providing information on drug access across all lesions. Moreover, 89Zr-AMG 
110 or other radiolabeled BiTE antibody constructs could potentially support clinical BiTE 
development, because they could give additional information about tissue pharmacokinetics 
and uptake in tumors to support optimal dosing and about uptake in critical organs to anticipate 
toxicity.
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MATERIALS AND METHODS 
Conjugation and labeling of AMG 110 and Mec14.
AMG 110 and Mec14 were first purified with water for injections using a Vivaspin-2 10 kDa filter 
(GE Healthcare). Conjugation was performed by allowing BiTE antibody constructs to react 
with a 6.7-fold molar excess of N-succinyldesferrioxamine-B-tetrafluorphenol (N-sucDf-TFP, 
ABX), as described earlier.1 Conjugated BiTE was radiolabeled on the same day with 89Zr-oxalate 
(PerkinElmer). Free 89Zr was removed by using a Vivaspin-2 10 kDa filter.
 For labeling with respectively IRDye 800CW and 680RD, purified AMG 110 and Mec14 
reacted with a 3-fold molar excess of IRDye as described earlier.2 Unreacted dye was removed 
using PD10 desalting columns (Fisher Scientific).
Quality control of 89Zr-AMG 110 and 89Zr-Mec14. 
Aggregation, fragmentation and concentration of 89Zr-AMG 110, 800CW-AMG 110, 89Zr-Mec14 
and 680RD-Mec14 were assessed using size exclusion high performance liquid chromatography 
(SE-HPLC). The Waters SE-HPLC system was equipped with a dual wavelength absorbance 
detector, an in line radioactivity detector and a size exclusion column (Superdex 75 10/300 GL 
column; GE Healthcare). PBS was used as mobile phase at a flow of 0.7 ml/min Radiochemical 
purity (RCP) of 89Zr-AMG 110 and 89Zr-Mec14 was determined using trichloroacetic acid 
precipitation.3
 The in vitro binding characteristics (immunoreactive fraction; IRF) of the radiolabeled BiTE® 
antibody constructs were determined in a cell binding assay as described by Lindmo et al.4 In 
short, two series of HT-29 cell dilutions were incubated in duplicate with 15 ng/mL 89Zr-AMG 110 
for 2 h at 4°C while shaking. To one of the cell series a 1000 fold excess of cold AMG 110 was added 
to block EpCAM specific binding and set the reference used to correct for non-specific binding. 
After 2 h incubation, cells were washed twice with PBS containing 1% human serum albumin 
(HSA). Radioactivity of standards and cell pellets were measured with a calibrated well-type 
γ-counter (LKB 1282; CompuGamma). The IRF was determined for each separate experiment 
by extrapolating to conditions representing infinite antigen excess, corrected for non-specific 
binding.
In vitro evaluation of 89Zr-AMG 110. 
Internalization of 89Zr-AMG 110 was determined by incubating 106 HT-29 cells with 50 ng 
89Zr-AMG 110 for 1 h at 4°C. Subsequently, unbound 89Zr-AMG 110 was removed by rinsing with 
PBS containing 1% HSA. Remaining activity, defined as initial cell associated radioactivity, was 
measured in a calibrated well-type γ-counter and set to 100%. Next cells were resuspended in 
culture medium (RPMI + 10% FCS, including T = 0) and incubated 1, 2 or 4 h at 4°C or 37°C. 
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Thereafter, medium was removed and cell pellet activity, defined as membrane bound + 
internalized, was measured in a calibrated well-type γ-counter. Finally, cells were stripped using 
urea buffer (4 M urea, 2 M glycine, pH 2.0)5 and washed twice with urea buffer. Radioactivity 
in the stripped pellet, representing the internalized radioactivity, was measured in a calibrated 
well-type γ-counter. Internalization was determined by the following formula: (internalized 
radioactivity/initial cell associated radioactivity) x 100%.
Flow cytometry. 
To determine EpCAM expression by the cell lines, flow cytometry was performed with a BD 
Accuri™ C6 flow cytometer (BD Biosciences). HT-29, FaDu or HL-60 cells were incubated for 
1 h at 4 °C, with 20 µg/mL mouse anti-human EpCAM antibody (Abcam, ab20160) and washed 
twice using phosphate buffered saline (PBS; 140 mmol/L NaCl, 9 mmol/L Na2HPO4, 1.3 mmol/L 
NaH2PO4; pH = 7.4, UMCG) containing 0.5% FCS and 2 mM ethylenediaminetetraacetic acid. 
Subsequently, cells were incubated for 1 h at 4°C with (0.01 mg/mL) goat anti-mouse phycoerythrin 
secondary antibody (Southern Biotech). Cells were finally washed twice and EpCAM expression 
was assessed. Membrane expression was calculated as mean fluorescent intensity and expressed 
as percentage of HT-29 signal. 
In vivo fluorescent imaging 
For NIR fluorescence imaging, mice bearing HT-29 xenografts (n = 4) were co-injected with 
40 μg 800CW-AMG 110 and 40 μg 680RD-Mec14. Mice undergoing fluorescent imaging were 
kept on an alfalfa-free diet to minimize autofluorescence. Imaging was performed at 0.5, 1, 3, 6 
and 24 h after tracer injection, using the IVIS Spectrum (Caliper Life Sciences) imaging system. 
Excitation wavelengths were set at 640 nm for 680RD-Mec14 and 745 nm for 800CW-AMG 110. 
Data were analyzed using Living Image 3.2 software (Caliper Life Sciences). Tumor signal was 
determined by drawing regions of interest around tumor boundaries for both 680RD-Mec14 and 
800CW-AMG 110.
RESULTS
Labeling and quality control of 89Zr-AMG 110 and 89Zr-Mec14. 
AMG 110 and Mec14 were successfully conjugated with N-sucDf-TFP (ratio 1:3) and labeled with 
89Zr. The retention time for AMG 110 and Mec14 was approximately 17 min. 89Zr-N-sucDf-TFP, 
low-molecular-weight impurities and buffer additives eluted around 25 min on the SE-HPLC 
(Supplemental Fig. 2A). Upon N-sucDf-TFP conjugation and 89Zr labeling of AMG 110 and Mec14, 
SE-HPLC did not show aggregation or fragmentation and radiochemical purity was confirmed 
using trichloroacetic acid precipitation tests (respectively 96.8 ± 1.1% and 96.2%; n = 10 and n = 1). 
 Conjugation of N-sucDf-TFP to AMG 110 and subsequent labeling with 89Zr resulted in 
a mean IRF of 0.60 ± 0.03 for EpCAM (Supplemental Figs. 2B and 2C; n = 6). Subsequent to 
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EpCAM binding, 89Zr-AMG 110 showed minimal internalization by HT-29 cells at 37°C in vitro 
(Supplemental Fig. 3).
Supplemental figure 1. Differences in ex vivo tumor weights between the experiments, as measured after mice were 
sacrificed. (A) Difference in tumor weights after resection from mice injected with 89Zr-AMG 110 at 20 µg (n = 5), 40 µg (n 
= 4) or 500 µg (n = 3) dose levels. (B) Difference in tumor weights at 6 (n = 3), 24 (n = 4), 72 (n = 4) and 144 h (n = 5) after 
injection of 40 µg 89Zr-AMG 110. (C) Difference in tumor weights at 24 h after injection of 40 µg 89Zr-AMG 110 (n = 4) or 40 
µg 89Zr-Mec 14 (n = 6). (D) Difference in tumor weights between HT-29 (n = 4), FaDu (n = 5) and HL-60 (n = 6) tumors at 24 
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Supplemental figure 2. Quality control of 89Zr-AMG 110 and 89Zr-Mec 14. (A) A typical SE-HPLC chromatogram of 
89Zr-AMG 110 (upper panel) or 89Zr-Mec 14 (lower panel), which is an overlay of 280 nm and radiochemical signal. (B) Binding 
of 89Zr-AMG 110 to an increasing number of HT-29 cells. Its reciprocal plot to infinite antigen excess was used to determine 
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Supplemental figure 3. Membrane binding and internalization of 89Zr-AMG 110 after binding EpCAM on HT-29 cells. 
Membrane bound and internalized fraction is expressed as percentage of initial cell associated radioactivity. Data is 
presented as mean ± SD. At several time points in the graphs of membrane bound 89Zr-AMG 110, SD is not visible due its 
small size. 
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Supplemental figure 4. Biological half-life of 89Zr-AMG 110 in blood and tumor. Biological half-life of 20 µg 89Zr-AMG 110 
in blood (A) and tumor (B), based on %ID/cm3. Biological half-life of 40 µg 89Zr-AMG 110 in blood (C) and tumor (D), based 
on %ID/g. Data is presented as mean ± SD.
Supplemental figure 5. Dose dependent tumor-to-blood (A) and tumor-to-muscle ratios (B). Mice were injected with 20 
µg (n = 5), 40 µg (n = 4) or 500 µg (n = 3) protein doses. No significant differences were observed in blood or tissue levels 
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Supplemental figure 6. (A) Representative sagittal two-dimensional in vivo fluorescence images at indicated time points, 
after coinjection of 40 μg 800CW-AMG 110 and 40 μg 680RD-Mec14. White arrow indicates location of the tumor. (B) 
Fluorescent tracer uptake in HT-29 tumors over time, normalized to absolute fluorescence levels at 30 min after tracer 
injection. Data is presented as mean ± SD.
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TRANSLATIONAL RELEVANCE
Recent approval of the CD19 and CD3 targeting bispecific T-cell engager (BiTE®) antibody construct, Blincyto, for treating 
B-cell precursor acute lymphoblastic leukemia patients clearly demonstrated that tumor targeted immunity is an 
effective therapeutic approach. BiTE® antibody constructs induced tumor cell killing independent of antigen specificity or 
costimulatory factors by connecting cancer cells to cytotoxic T cells. While this approach has offered significant clinical 
benefits in hematologic malignancy, recent exploration have also been focused on solid tumors. 
This study provides noninvasive molecular imaging insight in solid tumor targeting and biodistribution of the 
carcinoembryonic antigen (CEA) and CD3 targeting BiTE® antibody construct AMG 211 in preclinical mouse xenograft 
models, 89ZrAMG211 PET-imaging showed dosedependent accumulation in CEA-expressing tumors. Although 89Zr-AMG211 
circulating blood half-life was ~1, hour, the signal persisted in the tumors for up to 24 hours. Good Manufacturing Practice 
compliant 89Zr-AMG211 was produced and evaluated in a recently completed clinical trial (NCT02760199).
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ABSTRACT
Background: AMG 211, a bispecific T-cell engager (BiTE®) antibody construct, targets 
carcinoembryonic antigen (CEA) and the CD3 epsilon subunit of the human Tcell receptor 
complex. AMG 211 was labeled with zirconium-89 (89Zr) or fluorescent dye to study drug behavior. 
The goal of this study is to evaluate the tumor targeting properties of 89Zr-AMG211.
Experimental Design: 89Zr-AMG211 was administered to mice bearing CEApositive LS174T 
human colorectal adenocarcinoma and BT474 breast cancer as well as CEAnegative HL60 
promyelocytic leukemia xenografts. Dose-escalating biodistribution with 210 µg 89Zr-AMG211 
supplemented with unlabeled AMG 211 up to 500 µg total protein dose was performed. Non-CEA 
binding BiTE®, 89ZrMec14, served as negative control. 89Zr-AMG211 integrity was determined 
in tumor lysates ex vivo. Intratumoral distribution was studied with IRDye800CW-AMG211. 
Moreover, 89Zr-AMG211 was manufactured according to Good Manufacturing Practice (GMP) 
guidelines for clinical trial NCT02760199.
Results: 89Zr-AMG211 demonstrated dose-dependent tumor uptake at 6 hours. Highest tumor 
uptake was observed with 2 μg and lowest with 500 μg total protein dose. After 24 hours, 10 μg 
89Zr-AMG211 resulted in higher uptake in CEA-positive than CEA-negative xenografts. Although 
blood halflife of 89Zr-AMG211 was ~1 hour, tumor retention persisted for at least 24 hours. 
89Zr-Mec14 did not accumulate beyond background level in CEA-positive tumors. Ex vivo 
autoradiography revealed time-dependent disintegration of 89Zr-AMG211. 800CW-AMG211 was 
specifically localized in CEAexpressing viable tumor tissue. GMP-manufactured 89Zr-AMG211 
fulfilled release specifications. 
Conclusions: 89Zr-AMG211 showed dosedependent CEA-specific tumor targeting and localization 
in viable tumor tissue. Our data support its use as surrogate to evaluate AMG 211 in vivo behavior 
in the clinical setting.  
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INTRODUCTION
Recent advances in immuno-oncology and approval of several immune-enhancing cancer 
therapies have led to great enthusiasm and exploration of various approaches to target cytotoxic 
T cells specifically to tumor for killing. Novel therapeutic approaches such as bispecific T-cell 
engager (BiTE®) antibody constructs are engineered by combining two single-chain variable 
fragment (scFv) domains of two different antibodies.1 One scFv domain is directed against the 
epsilon chain of CD3 (CD3ε), a part of the T-cell receptor complex, and the other domain is 
directed against a tumor-associated antigen. Simultaneous binding of both domains to their 
targets forms a bridge between a tumor cell and a T cell eventually resulting in the formation of 
a cytolytic synapse, followed by killing of the tumor cell via perforin and granzyme B mediated 
lysis.2
 The first BiTE® antibody construct approved is the CD19-targeting molecule blinatumomab. 
It is used to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell 
precursor acute lymphoblastic leukemia. Other BiTE® antibody constructs that have been 
explored in phase I trials include AMG 110 (MT110; solitomab), AMG 211 (MEDI565; MT111), 
and BAY2010112 for targeting of epithelial cell adhesion molecule (EpCAM), carcinoembryonic 
antigen (CEA), and prostate-specific membrane antigen (PSMA) expressing solid tumors, 
respectively.3,4 
 For CEA overexpressing solid tumors, AMG 211 is a potential interesting new BiTE® antibody 
construct. In vitro, AMG 211 lyses explants of metastatic colorectal cancer cells of patients who 
progressed on chemotherapy.5 In addition, immune checkpoint inhibition combined with AMG 211 
resulted in a more potent cytotoxicity towards CEA-positive tumor cells in vitro.6 Although T-cell 
inhibition could not be fully reversed in T cells previously exposed to AMG 211, prior treatment 
with checkpoint inhibition is a potential combination strategy. AMG 211 mediated cytotoxicity 
is independent of the presence of soluble CEA, CEA splice variants, CEA singlenucleotide 
polymorphisms or commonly found oncogenic mutations in colorectal adenocarcinomas.79 
A first-in-human study with an intermittent administration regimen of 3-hour continuous 
intravenous infusion once a day, on days 1 through 5, in 28-day cycles with AMG 211, showed 
a maximum tolerated dose of 5 mg with linear and dose-proportional pharmacokinetics.4 Best 
tumor response was stable disease in 28% of the patients. For BiTE® antibody constructs to be 
effective in solid tumors, the molecule should significantly penetrate tumors, be present in 
sufficient amount to maintain exposure and the tumor should have sufficient T-cell infiltration. 
To establish prolonged steady state exposure, continuous intravenous administration over 7 to 28 
days is currently tested in an ongoing AMG 211 phase I trial (NCT02291614). 
 Strikingly, little is known concerning whole body distribution and tumor targeting of 
BiTE® antibody constructs in cancer patients. Therefore, to enable clinical exploration of BiTE® 
antibody constructs’ in vivo properties, we developed 89Zr-AMG211 for testing in preclinical 
mouse models. With molecular imaging, information on wholebody drug distribution, tumor 
targeting and tissue pharmacokinetics can be obtained non-invasively. In this study, 89Zr-AMG211 
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microPET imaging was also complemented with ex vivo biodistribution and tracer integrity 
analysis. In addition, AMG 211 was labeled with the near-infrared fluorescent dye 800CW to 
study intratumoral distribution. Finally, we manufactured 89Zr-AMG211 according to Good 
Manufacturing Practice (GMP) guidelines in preparation for clinical evaluation.
MATERIALS AND METHODS 
BiTE® antibody constructs and cell lines
The BiTE® antibody constructs AMG 211 (binds human CD3ε and human CEA; formulated 
in 30 mM sodium citrate, 75 mM L-lysine hydrochloride, 6.5% mM trehalose dihydrate, and 
0.02% (w/v) plant derived polysorbate 80; pH 6.0), and Mec14 (binds human CD3ε and the 
herbicide mecoprop; formulated in 10 mM citrate, 75 mM L-lysine hydrochloride, 4% (w/v) 
trehalose dihydrate, and 0.03% (w/v) polysorbate 80, pH 7.0), were provided by Amgen. AMG 211 
equilibrium dissociation constants are estimated at 5.5 ± 2.2 nM and 310 ± 67 nM for human CEA 
and CD3ε, respectively.7 Molecular weights of the BiTE® antibody constructs are approximately 
55 kDa. The human colorectal cancer cell line LS174T (CEA+), human breast cancer cell line 
BT474 (CEA+), and promyelocytic leukemia cell line HL60 (CEA) were used. All cell lines were 
obtained from American Type Culture Collection, screened for microbial contamination and 
tested negative. Cell lines were authenticated by BaseClear using short tandem repeat profiling. 
This was repeated once a cell line has been passaged for more than 6 months after previous short 
tandem profiling. BT474 and HL-60 were routinely cultured in RPMI-1640 medium (Invitrogen) 
containing 10% fetal calf serum (Bodinco BV). LS174T cells were cultured in Dulbecco’s Modified 
Eagle’s Medium with high glucose (Invitrogen) supplemented with 10% fetal calf serum. All cells 
were cultured under humidified conditions at 37°C with 5% CO2. 
Flow cytometry
CEA expression by LS174T, BT474, and HL-60 cells was measured using a BD Accuri™ C6 flow 
cytometer (BD Biosciences) as described earlier.10 In short, cells were incubated for 1 hour at 
4 °C with either 20 µg/mL mouse antihuman CEACAM5 antibody (Santa Cruz; sc-23928) or 
mouse IgG1 (Dako). After washing, cells were incubated for 1 hour at 4 °C with goat antimouse 
phycoerythrin secondary antibody (Southern Biotech). After final washing, expression was 
assessed and calculated as mean fluorescent intensity expressed as percentage of LS174T signal. 
Conjugation and labeling of AMG 211 and Mec14
BiTE® antibody constructs AMG 211 and Mec14 were purified against NaCl 0.9% (Braun) using 
a Vivaspin-2 10 kDa polyethersulfone filter (Sartorius). Next, N-succinyldesferrioxamine-B-ter-
trafluorphenol (N-sucDf-TFP; ABX) was conjugated to BiTE® antibody constructs in a 4-fold 
molar excess, as described earlier.11 After PD-10 desalting column (GE Healthcare) purification, 
conjugated BiTE® antibody constructs were stored at -80 °C. On the day of labeling with 
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89Zr-oxalate (PerkinElmer), N-sucDf conjugated BiTE® antibody constructs were thawed and 
labeled with a maximum specific activity of 500 MBq/mg. For conjugating IRDye 800CW to 
AMG 211 and 680RD to Mec14 (LICOR Biosciences), purified BiTE® antibody constructs were 
reacted with a 3-fold molar excess of IRDye N-hydroxysuccinimide ester as described earlier.12 
Quality control of 89Zr-AMG211 and 89Zr-Mec14
Size exclusion high performance liquid chromatography (SE-HPLC) was used to assess aggregation 
and fragmentation of radiolabeled or fluorescently labeled AMG 211 and Mec14, as described 
previously.10 Protein concentration was determined by ultraviolet-visible spectrophotometry 
(Cary 60; Agilent). 
 Immunoreactivity of 89Zr-AMG211 towards CEA was tested in a competition assay with 
unlabeled AMG 211. Recombinant human CEACAM5 (11077-H08H; Sino Biologicals Inc.) was used 
as target antigen. CEACAM5 protein was diluted in 0.05 M Na2CO3 (pH 9.6) to a concentration 
of 0.5 µg/mL and 100 µL was coated to Nunc-Immuno BreakApart ELISA plates (NUNC) at 
4°C overnight. Next day, wells were blocked using 1% milk powder in 0.05% polysorbate 20 
(Sigma-Aldrich)/PBS (140 mM NaCl, 9 mM Na2HPO4, 1.3 mM NaH2PO4, pH = 7.4, UMCG). After 
blocking, wells were washed three times with 0.05% polysorbate 20/PBS. 89Zr-AMG211 and AMG 
211 were mixed and diluted in PBS to result in a fixed concentration of 185 nM 89Zr-AMG211 and 
varying concentrations of unlabeled AMG 211, ranging from 93 pM to 32 µM. These samples were 
added to the wells and incubated for 2 hours. Samples were washed with 0.05% polysorbate 
20 in PBS and 89Zr-AMG211 bound to the CEA–coated wells were measured for radioactivity. 
CEA binding was expressed as percentage radioactivity bound to CEA–coated wells corrected 
for non-specific binding to uncoated wells. The average amount of CEA bound 89Zr-AMG211 at 
the lowest competing dose of non-radiolabeled AMG 211 was set at 100%. The percentages were 
plotted against the logvalues of AMG 211 concentration using Prism software (GraphPad, Prism 
5). The concentration that resulted in 50% inhibition of the maximum binding was calculated. 
Immunoreactivity was calculated by dividing the half maximal inhibitory concentration (IC
50
) by 
added concentration of 89Zr-AMG211 (185 nM).
Internalization of 89Zr-AMG211
Internalization of 89Zr-AMG211 was assessed as described earlier.10 In short, 106 LS174T cells were 
incubated with 50 ng 89Zr-AMG211 for 1 hour at 4 °C, followed by incubation for 1, 2 or 4 hours at 4 
°C or 37 °C in culture medium. Cells were subsequently stripped using a stripping buffer (0.05 M 
glycine, 0.1 M NaCl, pH 2.8). Radioactivity of the stripped cell pellet was measured in a calibrated 
well-type γ-counter (LKB instruments) and expressed as percentage of cell associated activity. 
Animal experiments
All animal experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Groningen. Six to 8 weeks old male nude BALB/c mice (BALB/cOlaHsd-Foxn1nu, 
Harlan) were allowed to acclimate for 1 week. For xenograft development, 2 x 106 LS174T cells in 0.1 
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mL PBS were subcutaneously injected, for BT474 and HL-60 xenografts, respectively 5 x 106 and 
2 x 106 cells in 1:1 ratio of medium and Matrigel™ (BD Biosciences; 0.3 mL) were subcutaneously 
injected. BT474 inoculated mice received 1 day prior to tumor inoculation a 17-ßestradiol pellet 
(0.18 mg, 90day release; Innovative Research of America). Tumor growth was assessed by 
caliper measurements. Penile vein tracer injection was performed when tumors reached a size 
of 200 mm3. This was reached for LS174T in 11 days, for HL-60 in 2 weeks, and for BT474 in 4 
weeks. Anesthesia was performed with isoflurane/medical air inhalation (5% induction, 2.5% 
maintenance).
In vivo microPET imaging and ex vivo biodistribution
In consecutive experiments, we studied dose and time dependency of biodistribution and tumor 
uptake, specificity of tumor uptake, and variation in uptake in different CEA-expressing tumor 
models. Tumor uptake of 89Zr-AMG211 and 89Zr-Mec14 (isotype control) was analyzed over time. 
MicroPET scanning was performed at 0.5, 3, 6, and 24 hours after injection with 5 MBq (10 µg) of 
tracer. Mice were sacrificed 24 hours after tracer injection and thereafter ex vivo biodistribution 
was performed. 
 To study dose dependent tumor uptake of 89Zr-AMG211, LS174T xenograft bearing mice were 
injected with a protein dose of 2 (n = 6), 10 (n = 6), 50 (n = 6), 100 (n = 6), and 500 µg (n = 3) of 
89Zr-AMG211 (1 MBq), followed by ex vivo biodistribution at 6 hours after injection. Doses higher 
than 10 µg were supplemented with nonradiolabeled AMG 211. 
 Non-specific uptake was studied in two groups of mice bearing LS174T xenografts. Either 10 
µg 89Zr-AMG211 (n = 6; 5 MBq) or 10 µg 89Zr-Mec14 (n = 6; 5 MBq) was administered followed by 
microPET scanning and ex vivo biodistribution at 24 hours after injection. 
To study CEA-dependent uptake, 89Zr-AMG211 was tested in 3 groups of mice bearing differentially 
CEA-expressing tumor models. Mice bearing LS174T, BT474 or HL-60 xenografts were injected 
with 10 µg of 89Zr-AMG211 (n = 6 per group; 5 MBq). Twentyfour hours after tracer injection, mice 
were sacrificed for ex vivo biodistribution. 
 Half of the harvested tumors were paraffin embedded and the other half were used to make 
tumor lysates. Tumor lysates were obtained by homogenization with a Diax600 (Heidolph) in 
RIPA buffer (Thermo Scientific) for 2-5 min. Blood was collected in BD Vacutainer® PST Lithium 
Heparin Tubes (BD Biosciences) and centrifuged to collect plasma. 
 For all ex vivo biodistribution studies, tumor, whole blood, and organs of interest were 
collected and weighed. Samples together with tracer standards were counted in a calibrated 
well-type γ-counter (LKB Instruments). Uptake is expressed as % injected dose per gram of tissue 
(%ID/g). 
 The acquisition and reconstruction of microPET scans were performed as previously 
described.10 After reconstruction, images were interpolated using trilinear interpolation and 
filtered using Gaussian smoothing using AMIDE Medical Image Data Examiner software (version 
1.0.4, Stanford University). Coronal microPET images were used for display. Volumes of interest 
(VOI) of the whole tumor were drawn based on biodistribution tumor weight. For the VOI of 
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the heart an ellipsoid of 3x4.5x4 mm in the coronal plane was drawn. VOIs were subsequently 
quantified. Data are expressed as the mean standardized uptake value (SUVmean). 
SDS-PAGE autoradiography
MiniPROTEAN®TGX™ Precast Gels (Bio-Rad) were loaded with 40 µg protein of tumor lysates 
or mouse plasma from 3 mice, tracer alone as positive control, and free 89Zr-oxalate. Gels were 
exposed overnight to phosphor imaging screens (Perkin Elmer) in Xray cassettes. The screens 
were read using a Cyclone Storage Phosphor System (Perkin Elmer) and Optiquant™ software to 
quantify the intensity of radioactivity. Lanes were split into regions containing intact 89Zr-AMG211, 
high (> 80 kDa) or low molecular weight (< 40 kDa) protein associated radioactivity. Molecular 
weight was verified using ProSieve™ color protein maker (Lonza). 
Ex vivo fluorescent imaging
For nearinfrared fluorescence imaging LS174T xenograft bearing mice were coinjected with 50, 
100 or 250 µg of both 800CW-AMG211 and 680RD-Mec14. At 24 hours after injection, mice were 
sacrificed, tumor tissue was harvested, formalinfixed and paraffin embedded. Four µm sections 
were incubated for 2 min in xylene followed by scanning 800CW-AMG211 and 680RD-Mec14 
with Odyssey infrared imaging system (LICOR Biosciences) for intratumoral distribution. After 
Odyssey scanning, the same tumor sections were stained with hematoxylin and eosin (H&E). 
In addition, subsequent tumor slices were stained with immunohistochemistry using 1 µg/mL 
rabbit monoclonal CEA antibody (11077-R327; Sino Biologicals Inc.). For fluorescent microscopy, 
an inverted Leica DMI600B fluorescence microscope equipped with a Luman Dynamics X-Cite 
200DC light source was used. Nuclei were stained with Hoechst 33342 (Life Technologies).
CD3 binding
Binding of N-sucDf-AMG211 to T cells was assessed using a flow cytometry approach. CD3+ T 
cells were isolated from peripheral blood mononuclear cells, derived from buffy coats of healthy 
volunteers after informed consent (Sanquin) using Pan T-cell Isolation Kit (Miltenyi Biotec). CD3+ 
T cells (100,000) were plated with AMG 211 or N-sucDf-AMG211 (5 µg/mL) for 40 min at 4°C. After 
washing, cells were incubated with biotin labeled His-antibody (20 µg/mL; Dianova) for 30 min 
at 4°C. After another washing procedure, CD3+ cells were incubated with streptavidin-APC (2 µg/
mL; BD Biosciences) for 20 min at 4°C, followed by propidium iodide staining (1 µg/mL; Thermo 
Fisher Scientific) to select live CD3+ cells. Mean fluorescence intensity of N-sucDf-AMG211 and 
AMG 211 bound to CD3+ cells was assessed by Accuri™ C6 flow cytometer (BD Biosciences) and 
expressed as percentage of AMG 211 binding. The assay was used as release test in manufacturing 
of the clinical batch of N-sucDf-AMG211.
GMP manufacturing
Manufacturing was performed according to GMP guidelines. 89Zr-AMG211 was manufactured 
in a 2-step process with first the conjugation resulting after purification in the intermediate 
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N-sucDf-AMG211, followed by the 89Zr labeling, purification, dilution, and sterile filtration 
(Supplemental Fig. 1). Specifications such as conjugation ratio, purity, concentration, endotoxins, 
sterility, residual solvents, radiochemical purity, and immunoreactivity to both CD3 and CEA 
have been assessed. Stability of N-sucDf-AMG211 stored at -80°C was studied up to 6 months.
Statistical analysis
Data are presented as mean ± standard deviation (SD). Mann-Whitney U-test was performed to 
test differences between two groups (GraphPad, Prism 5). A Bonferroni corrected Mann-Whitney 
U-test was performed to compare more than two groups. To test for a dose-dependent relation, 
Cuzick’s test for trend was used. Blood half-life was calculated using one phase decay (GraphPad, 
Prism 5). P values ≤ 0.05 were considered significant. 
RESULTS
AMG 211 is successfully conjugated with NsucDf and labeled with 89Zr
The efficiency of AMG 211 conjugation was 51%. Labeling of N-sucDf-AMG211 resulted in a 
maximum specific activity of 500 MBq/mg with a radiochemical purity of more than 95%, with 
less than 5% aggregates (Supplemental Fig. 2). To prove that labeling AMG 211 did not alter the 
immunoreactivity towards CEA, unlabeled AMG 211 was tested in competition with 89Zr-AMG211 
batches with different chelator to AMG 211 ratios. The 2:1 conjugation ratio showed the best 
preserved immunoreactivity (70.7 ± 7.5% of unlabeled AMG 211) and an average IC
50
 of 131 ± 
14 nM for the competition of CEA binding with 185 nM 89Zr-AMG211 (Supplemental Fig. 3A). 
As immunoreactivity decreased upon higher conjugation ratios (Supplemental Fig. 3B), a 2:1 
conjugation ratio was chosen for further experiments. 
89Zr-AMG211 is internalized in CEA+ LS174T cells
In vitro, 89Zr-AMG211 was internalized in LS174T cells up to 12 ± 3% of initial cell associated 
radioactivity at 4 hours after incubation, allowing over time tumor accumulation due to 
residualizing capacity of 89Zr (Supplemental Fig. 4). 
89Zr-AMG211 shows dose-dependent tumor uptake
In general, tracer uptake was highest in the kidney, indicating renal elimination, followed by 
tumor and liver (Fig. 1). 89Zr-AMG211 showed an inverse protein dose-dependent tumor uptake 
(Fig. 1; Ptrend < 0.001) that was highest at 2 µg (7.5 ± 1.5%ID/g) and lowest at 500 µg (3.9 ± 0.13%ID/g). 
Kidneys showed a similar trend with uptake ranging from 283 ± 34%ID/g at the lowest and 141 ± 
33%ID/g at the highest protein dose. Blood levels were 1%ID/g at 6 hours after injection for all 
dose groups. Based on sufficient tumor uptake and a maximum specific activity of 500 MBq/mg, 
10 µg (5 MBq) was selected for subsequent 89Zr-AMG211 microPET imaging studies. 
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Figure 1. Dose dependent 89Zr-AMG211 biodistribution in LS174T-tumor bearing mice at 6 hours post injection. Mice were 
injected with 2 (n = 6), 10 (n = 6), 50 (n = 6), 100 (n = 6) or 500 µg (n = 3) protein doses. Data are mean ± SD. * P ≤ 0.05; *** 
P ≤ 0.001. 
89Zr-AMG211 demonstrates specific tumor uptake in LS174T xenografts
MicroPET images revealed tumor uptake of 89Zr-AMG211 up to 24 hours after injection, whereas 
non-tumor targeting BiTE antibody construct 89Zr-Mec14 did not show imageable accumulation 
in LS174T xenografts (Fig. 2A). Tumor uptake of 89Zr-AMG211 increased up to 6 hours after 
injection (SUVmean 0.64 ± 0.10) with prolonged retention up to at least 24 hours (SUVmean 0.61 ± 
0.06). In contrast, tumor uptake of 89Zr-Mec14 decreased rapidly after tracer injection (Fig. 2B), 
although blood levels of both tracers showed similar elimination from blood with a circulating 
half-life of 0.72 hours (95% confidence interval 0.51-1.27) for 89Zr-Mec14 and 0.96 hours (95% 
confidence interval 0.76 – 1.36) for 89Zr-AMG211 (Fig. 2B). Specific tumor uptake was confirmed by 
ex vivo biodistribution analysis (Fig. 2C). Twenty-four hours after injection, 89Zr-AMG211 tumor 
uptake was 6.0 ± 1.3%ID/g compared to 0.5 ± 0.2%ID/g for 89Zr-Mec14 (P < 0.01). SDS-PAGE 
autoradiography showed intact 89Zr-AMG211, while 89Zr-Mec14 in LS174T xenografts lysates was 
absent (Fig. 2D), although both 89Zr-AMG211 and 89Zr-Mec14 were present intact in the plasma. 
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Figure 2. Specific tumor uptake of 89Zr-AMG211 in LS174T tumor bearing mice. (A) Representative coronal small-animal 
PET images up to 24 h after injection of 10 µg 89Zr-AMG211 (n = 6) or 89Zr-Mec14 (n = 6). Li = liver; K = kidney; T = tumor. 
(B) Image quantification of LS174T tumors (upper panel) and blood pool (lower panel). Ex vivo (C) biodistribution and (D) 
SDS-PAGE autoradiography 89Zr-AMG211 and 89Zr-Mec14 24 hours after injection. + : 89Zr-tracer prior to injection;  : free 89Zr 
only; tumor: lysates of 3 different LS174T xenografts; plasma: plasma samples from corresponding mice. Data are mean ± 
SD. * P ≤ 0.05; ** P ≤ 0.01. 
Tumor uptake of 89Zr-AMG211 is CEA dependent
89Zr-AMG211 was additionally studied in two other xenograft models. BT474 xenografts were used 
as second CEA-positive tumor model, whereas HL-60 represents CEA-negative tumor model 
(Supplemental Fig. 5). CEA-positive xenografts were clearly visualized with microPET up to 24 
hours after injection while HL-60 tumors were not visible (Fig. 3A). Quantification of tumor 
uptake derived from PET images showed SUVmean values between 0.5 and 0.6 for CEA-positive 
xenografts and below 0.2 for the CEA-negative xenografts (Fig. 3B). Ex vivo biodistribution 
confirmed image derived ranking of tumor uptake at 24 hours after injection, with highest uptake 
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uptake in HL-60 xenografts (0.45 ± 0.05%ID/g; Fig. 3C). 89Zr-AMG211 tumor uptake appeared 
to reflect CEA expression (R2 = 0.81). SDS-PAGE autoradiography demonstrated presence of 
intact 89Zr-AMG211 in CEA-positive tumor lysates, whereas it was absent in CEA-negative tumor 
lysate (Fig. 3D), suggesting that intact 89Zr-AMG211 might only be retained in the presence of cell 
surface tumor target. 
 
Figure 3. Uptake of 89Zr-AMG211 in LS174T (n = 6), BT474 (n = 6) or HL-60 (n = 6) tumor bearing mice. (A) Representative 
coronal small-animal PET images up to 24 hours after injection of 10 µg 89Zr-AMG211. Li = liver; K = kidney; T = tumor. 
(B) Quantification of tumors (upper panel) and blood pool (lower panel). Ex vivo (C) biodistribution and (D) SDS-PAGE 
autoradiography 89Zr-AMG211 24 hours after injection. + : 89Zr-AMG211 prior to injection;  : free 89Zr only; tumor: lysates of 3 
different tumor bearing mice; plasma: plasma samples from corresponding mice. Data are mean ± SD. * P ≤ 0.05; ** P ≤ 0.01. 
Intratumoral 89Zr-AMG211 disintegration over time
While total tumor 89Zr signal remained similar at 6 and 24 hours following tracer injection, ex 
vivo tumor lysates indicated time dependent disintegration of 89Zr-AMG211 in LS174T xenografts. 
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47.6 ± 3.0% at 24 hours after tracer injection (Fig. 4A). In contrast, mostly intact 89Zr-AMG211 
was detected in the plasma samples, indicating stability of the molecule in circulation (Fig. 4B).
Figure 4. Change in integrity of 89Zr-AMG211 in tumor over time. (A) Absolute uptake of 89Zr-AMG211 in LS174T xenografts 
(left panel) and integrity of 89Zr-AMG211 in LS174T lysates (right panel) at 6 and 24 hours after injection. (B) Uptake of 
89Zr-AMG211 in blood (left panel) and integrity of 89Zr-AMG211 in plasma (right panel) at 6 and 24 hours after injection. MW 
= molecular weight. Data are mean ± SD.
800CW-AMG211 localizes predominantly to viable CEA-positive tumor
Intratumoral distribution was studied using fluorescently labeled AMG 211 and Mec14. A dose- 
escalation study was performed by co-injecting 50, 100, and 250 µg of both 800CW-AMG211 and 
680RD-Mec14. Ex vivo analysis at 24 hours after injection showed clear uptake of 800CW-AMG211 
in viable CEA-positive tumor areas and minor uptake in necrotic tumor tissue (Fig. 5A). No large 
differences in the accumulation pattern were observed between the different protein dose groups. 
680RD-Mec14 was predominantly located in necrotic tumor tissue, indicating non-specific 
uptake. In addition, non-specific signal was found in areas with tissue folding. Fluorescent 
microscopy revealed that 800CW-AMG211 is mainly located at the cellular membrane and/or in 
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Figure 5. Intratumoral distribution of escalating doses of coinjected 800CW-AMG211 and 680RD-Mec14 (50, 100 or 250 μg) 
in LS174T tumors. (A) Macroscopic fluorescent imaging of 800CW-AMG211 (green) and 680RD-Mec14 (red) distribution, 
with overlapping signal (yellow) in necrotic tissue as visualized by hematoxylin and eosin (H&E). 800CW-AMG211 mainly 
localizes to viable tissue according to H&E with concordant CEA immunohistochemical staining. (B) Fluorescence 
microscopy images (630×), visualizing membrane and/or cytoplasmic localization of 800CW-AMG211 (green) and Hoechst 
stained nuclei (blue). 
89Zr-AMG211 is manufactured according to GMP guidelines
All 3 conjugation and labeling batches complied with release specifications (Supplemental 
Table I), demonstrating robust manufacturing process of 89Zr-AMG211. Shelf-life of intermediate 
N-sucDf-AMG211 has been set at 6 months at -80°C, and will, if within specifications, be extended 
at future time points.
 The Investigational Medicinal Product Dossier (IMPD) was written, summaries of 
information related to the quality, manufacture and control of the Investigation Medical Product 
A
B
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89Zr-AMG211 are included. The validation results of the three GMP batches and its stability data 
are also part of the IMPD. The IMPD has been approved by the competent authorities to allow 
clinical studies. 
DISCUSSION 
89Zr-labeled bispecific T-cell engager AMG 211 demonstrates CEA-specific tumor uptake and 
prolonged tumor retention up to 24 hours despite rapid elimination from the circulation. 
Furthermore, intact 89Zr-AMG211 was found in circulation as demonstrated by SDS-PAGE 
autoradiography of blood samples collected from treated mice. In tumors, 800CW-AMG211 
localizes to the CEA-expressing viable portion and can be found on the cell surface. Our findings 
indicated that 89Zr-AMG211 binds specifically to CEA and stays intact in circulation in vivo, clinic 
ready 89Zr-AMG211 has been produced, GMP compliant manufacturing was performed and 
consistent through three validation runs. 
 The tumor retention of 89Zr-AMG211 is remarkable. Despite low internalization of 
89Zr-AMG211 in LS174T cells and rapid decreasing blood levels in vivo, 89Zr-AMG211 leads to 
imageable tumors for at least 24 hours after injection. For AMG 211 to induce cytotoxic T-cell 
mediated tumor cell killing, membrane bound intact AMG 211 is necessary, and our data confirmed 
that is the case. Interestingly, even though intratumoral 89Zr-AMG211 was much longer retained, 
part of the signal was likely contributed by disintegrated 89Zr-species. Data on intratumoral 
drug integrity for other bispecific antibodies are currently not available, although essential for 
biological activity. This study demonstrates a new technique to study the intratumoral integrity 
of T-cell directed antibodies and derivatives. In patients treated with blinatumomab targeting 
CD19-positive hematological malignancies, the serum elimination half-life of blinatumomab 
is ~ 2 hours.13,14 In this setting, using continuous infusion, sustainable, predictable, and dose 
linear drug levels in serum are achieved.13,14 Efficacy of such an approach has been shown in 
non-Hodgkin and diffuse large B-cell lymphoma, indicating functional drug exposure in visceral 
tumor lesions.14,15 As shown in our previous studies evaluating 89Zr-AMG110 (targets CD3 and 
EpCAM) in mouse cancer models, prolonged tumor retention for at least 72 hours after a single 
intravenous injection was achieved despite a short circulating halflife similar to 89Zr-AMG211.10 
Together with the current study, our data demonstrates that 89Zr-BiTE® antibody constructs are 
able to accumulate in solid tumors rapidly after intravenous administration and can be found on 
target expressing tumor cell surface beyond blood elimination. Our findings also suggest that a 
constant intravenous supply of AMG 211 should improve functional drug exposure in the tumors 
and perhaps lead to greater anti-tumor effects. 
 AMG 211 localization in CEA-expressing tumor tissue was further demonstrated using the 
800CW imaging tag. Similar observation was also made for a full length bispecific antibody 
targeting CEA and CD3.16 In that study, CEA-expressing tumor cells (LS174T) and human peripheral 
blood mononuclear cells were co-cultured in vitro or co-grafted into immunocompromised mice. 
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Fluorescence reflectance imaging and intravital 2-photon microscopy were employed to analyze 
in vivo tumor targeting of the labeled full length bispecific antibody, while in vitro confocal 
and intravital time-lapse imaging served to assess the mode of action of the molecule. Authors 
suggest that specific tumor localization was mainly through CEA targeting with only minor 
contributions from CD3 binding. This may be similar for AMG 211 since both therapeutics have 
similar equilibrium dissociation constants in the submicromolar range for CD3 and nanomolar 
range for CEA. 
 In tumors with difference in CEA expression, 89Zr-AMG211 showed uptake in both CEA- 
positive LS174T (high) and BT474 (low) xenografts, but not in CEA-negative HL-60 xenograft. 
Despite lower expression of CEA in BT474, microPET images reveal only slightly lower uptake of 
89Zr-AMG211 at 24 hours. Besides target expression, many aspects may play a role in drug uptake 
and efficacy such as perfusion, presence of stroma, tumor interstitial pressure, and anatomical 
location. More interestingly, in vitro potency of redirected lysis is similar between LS174T and 
BT474, despite difference in receptor expression.7 This suggests that although CEA expression is 
required for drug efficacy, the amount of CEA expression may not be the only factor determining 
anti-tumor cytotoxicity. 
 The field of CD3-targeting bispecific antibodies is rapidly expanding and several different 
formats, including BiTE constructs, dual-affinity re-targeting molecules (DART), Tandem 
Diabodies, and others17 are extensively studied in the preclinical setting. While many studies 
have been focused on efficacy, a few of them also addressed the interaction between drug and 
T cells. A bispecific antibody targeting CD3 and CEA increased T-cell infiltration in a human 
LS174T xenograft in a mouse model containing human peripheral blood mononuclear cells.18 
 Different tumor targeting CD3 bispecific molecules may exhibit different in vivo properties. 
In a small SPECT study in five ovarian cancer patients, flow cytometry analysis indicated the 
binding of the bispecific F(abʹ)2 targeting CD3 and the folate receptor to peripheral blood T 
cells.19 However, it is currently unknown whether bispecific antibody constructs like AMG 211 
are first bound to circulating T cells and subsequently recruit them to the tumors, or whether 
the drug travels as a free agent to penetrate tumors and then induces local T-cell activation and 
proliferation, or both. In the current study, the impact of host effector cells could not be taken 
into account, since AMG 211 is not cross-reactive with mouse CD3. Progress has been made in this 
regard, however, modeling the human immune system in a mouse system is still far from perfect.20 
Recently, a clinical study has been completed with 89Zr-AMG211 (NCT02760199). Serial blood 
sampling and peripheral blood mononuclear cell isolation, together with PET scanning could 
aid in analyzing the influence of T cells on 89Zr-AMG211 distribution and assist interpretation of 
in vivo mechanisms underlying tissue accumulation kinetics of the molecule. 
 In conclusion, this study illustrated the feasibility for using 89Zr-AMG211 to assess 
dose-dependent CEA specific tumor uptake and tissue distribution using PET imaging. 
Furthermore, 89Zr-AMG211 can be manufactured according to GMP guidelines. Therefore, our 
data support translating this approach to assess 89Zr-AMG211 in clinical trials to support further 
drug development. 
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SUPPLEMENTARY INFORMATION 
Supplemental figure. 1. Flow chart of the drug substance (N-sucDf-AMG211) manufacturing process and drug product 
(89Zr-AMG211) formulation and filling process.
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Supplemental figure. 2. Quality control of 89Zr-AMG211. Representative SE-HPLC chromatogram of 89Zr-AMG211 with 280 
nm signal (top panel), radiochemical signal (middle panel) and the overlay (lower panel). 
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Supplemental figure. 3. Immunoreactivity of 89ZrAMG-211. (A) Representative competition assay using an effective 
N-sucDf-AMG 211 ratio of 2:1. Curve fit with 95% confidence interval is visualized. (B) Immunoreactivity towards CEA of 
different ratios N-sucDf-AMG 211. Data are mean ± SD.
Supplemental figure. 4. Membrane binding and internalization of 89Zr-AMG211 after CEA binding on LS174T cells (n = 3). 
Membrane bound and internalized 89Zr-AMG211 are expressed as percentage of initial cell associated activity. Data are mean 
± SD.
A B
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Supplemental figure. 5. Expression of CEA on LS174T, BT474 and HL-60 cell lines (n = 3). Membrane expression is 
expressed as percentage of LS174T signal. Data are mean ± SD. 
Supplemental table I. GMP manufacturing of N-sucDf-AMG211 and 89Zr-AMG211. Release criteria are fulfilled for batch 1, 
2, and 3. In addition stability are shown for Ns-ucDf-AMG211 stored at -80°C for 6 months, all quality criteria are still met.
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Positron emission tomography (PET) imaging and drug development  
The development of targeted anticancer drugs is a slow and expensive process. Generally 
targeted drugs are effective in a subpopulation of the patients that are included in clinical trails. 
Therefore, there is a growing interest in the selection of patients that most likely benefit from 
targeted drugs. As PET imaging gives insight into whole body distribution and tumor uptake 
of radiolabeled drugs, it might facilitate the selection of the patients that most likely respond. 
Such an enrichment of the study population may reduce the number of patients required in the 
later phase of clinical development. Furthermore, PET imaging may support the optimization of 
drug dosing and dose scheduling.1,2 This approach is increasingly used during drug development. 
To optimize implementation of PET imaging in clinical trials, it is critical to take into account 
the need for standardized scanning methods and the costs of PET imaging.3,4 Moreover a good 
collaboration between academia and industry will expand the incorporation of molecular 
imaging in general and PET-imaging in particular, in clinical trials. 
Optical imaging of tumors  
Optical imaging with fluorescent tracers that bind tumor associated antigens might facilitate 
real-time tumor visualization in an intra-operative setting and visualization of tumor-margins in 
excised tissue. Optical imaging can additionally be used to study drug distribution on a cellular 
level in excised or biopsied tumor tissue. In chapter 3 we fluorescently labeled anti-human 
epidermal growth factor receptor (HER)2 nanobodies with a near infrared fluorescent dye: IRDye 
800CW. The fluorescently labeled nanobody 800CW-11A4 enabled tumor visualization of HER2 
overexpressing tumors in mice as soon as 4 hours after injection. Fast tumor visualization might 
enable administration and tumor visualization/resection on the same day. Given the slower 
pharmacokinetics of antibodies, same day resection is less likely possible for fluorescently labeled 
anti-HER2 antibodies. Nanobodies have a high stability and can be produced straightforward 
production.5 Clinical trials with 800CW-11A4 are therefore of potential interest and comparison 
with 800CW-trastuzumab would give an answer what the best approach is in which setting.
 Penetration of near infrared light is limited due to strong scattering of light in tissue.6 
Therefore the use of real-time optical imaging might be restricted to the visualization of 
tumor lesions during surgery and endoscopic examination. Optoacoustic imaging may support 
visualization of deeper positioned tumors. This modality allows the use of specific dyes that 
absorb light and generate ultrasonic waves, detectable at multiple positions. The penetration 
depth can therefore be enlarged up to multiple centimeters.7 The drawback of optoacoustic 
imaging however, is its small field of view. Real-time visualization of tumors with molecular 
imaging might therefore require the combination of optoacoustic with fluorescent imaging. 
Half-life extension of therapeutic proteins 
Anticancer drugs that are smaller than the renal cut-off value of 60-70kDa are prone to fast 
renal excretion, resulting in relative low tumor exposure. In order to increase tumor exposure, 
these drug need to be administered frequently. For example, blanitumumab is given as a 4-week 
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continuous infusion. Alternatively, the circulation half-life of these anticancer drugs can be 
extended by introducing albumin affinity, as has been realized for MSB0010853 (chapter 4). 
Other used methods include the conjugation of drugs to polyethylene glycol (PEG), fragment 
crystallizable (Fc)-domains of IgG antibodies or to albumin.8 However, conjugation to Fc-domains 
of IgG antibodies or to albumin does not necessarily result in half-lives similar to respectively 
IgG antibodies or albumin. Although half-life of IgG
1, 2 and 4
 antibodies in humans is ~21 days and 
that of albumin in humans is ~19 days, half-lives of protein constructs that are conjugated to 
Fc-domains of IgG antibodies or albumin generally do not exceed 5 days in humans.8 Clinical 
studies have to demonstrate to what extent the half-life of MSB0010853 is increased in cancer 
patients. Incorporation of PET imaging in clinical studies with 89-Zirconium (89Zr) labeled 
MSB0010853 could reveal whole body distribution and tissue pharmacokinetics of a nanobody 
construct that is able to bind serum albumin in cancer patients.    
Cancer immunotherapy and bispecific T-cell engagers (BiTEs)
Immunotherapy is gaining much attention as a novel treatment of cancer patients. With 
immunotherapy the immune system of cancer patients is stimulated to kill cancer cells more 
effectively. Currently, researchers mainly focus on new strategies, effective combinations and 
biomarkers to assess the effectiveness of new therapeutic options. 
 As a novel class of immunotherapy drugs, BiTEs can potentially be used to stimulate the host 
immune system to attack tumor cells. To date, the U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have approved one BiTE antibody (blinatumomab) for the 
treatment of Philadelphia chromosome-negative relapsed and refractory acute lymphoblastic 
leukemia. In contrast to blinatumomab that targets CD 19, the BiTEs AMG 110 and AMG 211, 
studied in chapters 5 & 6, target respectively epithelial cell adhesion molecule (EpCAM) and 
carcinoembryonic antigen (CEA) positive tumor cells in solid tumors. Solid tumors present 
additional challenges as given heterogeneous antigen expression, accessibility and a complex 
microenvironment that could suppress immune responses.9 A clinical study with AMG 110 
(NCT00635596) did demonstrate signs of biological activity, namely decreased tumor markers, 
anti-tumor activity in biopsied tumors and decreased circulating tumor cells.10 Clinical evaluation 
of AMG 211 is currently ongoing (NCT02291614 and NCT01284231). Incorporating clinical PET 
imaging with 89Zr labeled BiTEs in early phase clinical trials may provide information about 
tumor uptake and distribution in cancer patients. This information could potentially be used 
to facilitate the search for the optimal dosing regimen for BiTEs and help to identify patients 
that may benefit from BiTE treatment. For that reason the biodistribution and tumor uptake of 
89Zr-AMG211 is currently studied in a phase one clinical study (NCT02760199). 
 Preclinical data suggest that it might be of interest to combine BiTEs with other anti-cancer 
therapies. One such strategy to maximize T-cell mediated cancer cell death is combining BiTE 
treatment with the inhibition of immune checkpoints.11 To date the FDA and EMA already 
approved several immune checkpoints inhibitors (e.g. ipilimumab, nivolumab, pembrolizumab 
and atezolizumab). In addition, there is a rational to evaluate immunotherapy combined 
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with other anticancer treatments.12 Unfortunately, the population of cancer patients in which 
combinations can be tested is limited and determining effectiveness by overall survival is 
time-consuming and costly. Furthermore, the response patterns of immunotherapy can be 
completely different from response patterns seen with conventional chemotherapy. For example, 
response to immunotherapy may be preceded by apparent disease progression.13 Therefore 
there is a strong need for consistent biomarkers that can be used to accurately select patient 
that most likely benefit from cancer immunotherapy. Important predictive biomarkers might 
be target expression, the presence of immune cells (e.g. T-cells) in tumors and the ability of the 
drug to penetrate and accumulate in tumors. Molecular imaging with imaging probes, including 
radiolabeled drugs, might enable whole body quantification of these biomarkers. Therefore 
there is a real opportunity for the clinical use of molecular imaging in order to monitor treatment 
response. 
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Being a major cause of death worldwide, cancer remains one of the key disease areas with the 
greatest unmet medical needs. Chemotherapy, the cornerstone of systemic treatment, damages 
all dividing cells. Currently, drugs are being developed that target tumors more selectively. 
Much experience has been obtained with targeted antibodies, which are successfully used in 
daily clinical practice for the treatment of cancer. Among other mechanisms, antibodies can 
bind and subsequent inactivate pro-oncogenic proteins. Their successful use has spurred 
interest in the development of antibody derivatives, including the variable domains of heavy 
chain only antibodies (VHHs or nanobodies). Nanobodies are small with a molecular weight of 
15 kDa, highly stable and straightforward to produce. Therefore these proteins are ideal building 
blocks to create a large variety of tumor targeting constructs. These tumor targeting nanobody 
constructs potentially have therapeutic properties as they can block pro-oncogenic receptors and 
target cytotoxic payloads. Due to their specific binding to tumor-associated antigens, nanobody 
constructs may also serve as imaging agents. 
 In addition, antibodies and antibody derivatives can be produced so that they simultaneously 
target both tumor and host immune cells. By linking both cell types these proteins can stimulate 
the targeted host immune cells to kill the targeted tumor cells. The use of drugs that stimulate 
host immune cells to destroy cancer cells is known as cancer immunotherapy. Due to the 
successes in the field of cancer immunotherapy, it is gaining much attention as an innovative 
treatment to fight cancer. As a novel and relatively new type of anticancer drug Bispecific T-cell 
Engagers (BiTEs) can stimulate the host immune system to kill cancer cells. By linking cytotoxic 
T lymphocytes (CTLs) to tumor cells BiTEs stimulate CTLs to kill adjacent tumor cells. BiTEs 
bind the epsilon chain of cluster of differentiation 3 (CD3ε), a part of the T-cell receptor complex 
on CTLs and a tumor-associated antigen. As many tumor cells highly express epithelial cell 
adhesion molecule (EpCAM) or carcinoembryonic antigen (CEA), BiTE antibodies that connect 
EpCAM or CEA-positive tumor cells with CTLs have the potential to treat a large variety of solid 
cancers. 
 Many anti-cancer drugs are currently in development, including the nanobodies and BITE 
antibody constructs described in this thesis. However, only a minority will eventually be approved 
for clinical use. Two of the biggest challenges are the identification of the best drug candidates 
in early phase clinical studies and the search for an optimal design of late phase clinical studies. 
Early insight in tumor uptake, biodistribution and (organ) pharmacokinetics of drugs might help 
to address these challenges. These characteristics can be visualized and quantified non-invasively 
with positron emission tomography (PET) imaging. When incorporated in early phase clinical 
studies PET imaging can potentially support decision making with regard to clinical development 
of these drugs.
This thesis aimed to obtain insight in the biodistribution and tumor uptake of antibody 
derivatives using molecular imaging, in order to support their drug development.
Chapter 1 provides a concise background and introduction to this thesis. In chapter 2 we 
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reviewed the literature on how protein modification can affect the biodistribution and tumor 
uptake of protein drugs. Newly developed protein drugs that target tumor-associated antigens 
are often modified to increase their therapeutic effect, tumor exposure and safety profile. During 
the development of protein drugs, molecular imaging is increasingly used to obtain additional 
information about their in vivo behavior. Although molecular imaging is increasingly being used 
in the process of protein drug development, much still remains unclear about how to interpret 
molecular imaging data correctly. Consequently, there is a need for gaining more insight in the 
correct way of interpreting (pre)clinical imaging data. Therefore, an overview has been presented 
of which protein properties and protein modifications can affect biodistribution and tumor 
uptake of protein drugs. Protein modifications discussed are: radiolabeling, drug conjugation, 
glycosylation, humanization, albumin binding and polyethylene glycol (PEG)ylation. Protein 
modifications often alter protein levels in blood, liver, spleen, kidneys and tumor. However, 
the impact of protein modification on the in vivo behavior of proteins is depending on the 
type of protein and should therefore be determined for each type of protein drug separately. 
Furthermore, the model in which the in vivo behavior is tested could affect the outcome. The 
overview of specific protein properties and modifications that affect biodistribution and tumor 
uptake of protein drugs, as presented in this chapter, may facilitate a correct interpretation of 
(pre)clinical imaging data with protein based radiopharmaceuticals and fluorescently labeled 
proteins. 
 Fluorescent imaging can potentially facilitate the visualization of tumors overexpressing 
specific tumor-associated antigens. Due to the fact that nanobodies show fast tumor 
accumulation, fluorescent nanobodies might enable tumor visualization shortly after injection. 
Chapter 3 describes the selection and evaluation of high affinity anti-human epidermal growth 
factor receptor (HER)2 nanobodies, which were labeled with the near-infrared fluorophore 
(IRDye 800CW). By studying their biodistribution and tumor uptake we aimed to facilitate the 
development of a potential imaging drug that enables visualization of HER2 overexpressing 
tumors. Site-specific conjugation of IRDye 800CW to three anti-HER2 VHHs preserved high 
affinity binding with the following dissociation constants: 11A4 1.9 ± 0.03, 18C3 14.3 ± 1.8 and 
22G12 3.2 ± 0.5 nM. Based upon different criteria such as binding, production yield and tumor 
accumulation, 11A4 was selected for further studies. Comparison of 11A4-IR with trastuzumab-IR 
showed ∼20 times faster tumor accumulation of the anti-HER2 VHH, with a much higher 
contrast between tumor and background tissue (11A4-IR 2.5 ± 0.3, trastuzumab-IR 1.4 ± 0.4, 4 h 
post-injection). 11A4-IR demonstrated to be a potentially useful tool in image-guided surgery.
 HER3, unlike other members of the HER family, has reduced kinase activity. However, 
HER3 activation and subsequent dimerization with other members of the HER family can 
initiate pro-oncogenic signaling. Blocking HER3 signaling can therefore potentially inhibit 
cancer progression. A recent study showed that blocking two HER3 epitopes with two anti-HER3 
antibodies inhibited tumor cell growth more effectively than each antibody alone. Blocking two 
HER3 epitopes with MSB0010853, a biparatopic nanobody construct, is therefore an interesting 
option. Chapter 4 describes the development and preclinical evaluation of an 89-zirconium 
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(89Zr) labeled MSB0010853. In addition to HER3, MSB0010853 binds albumin to extend its 
circulation time, potentially enhancing tumor uptake. MSB0010853 binds HER3 at domain 
1 and at a second unknown domain. All three Nanobodies target human and mouse antigen. 
Radiolabeling of MSB0010853 with 89Zr was performed with a radiochemical purity of >95%. Ex 
vivo biodistribution showed protein dose- and time-dependent distribution of 89Zr-MSB0010853 
in all organs. Uptake of 89Zr-MSB0010853 in H441 non-small cell lung cancer tumors was only 
time-dependent. Tumor could be visualized up to at least 96 h after injection. Highest mean 
standard uptake value of 0.6 ± 0.2 was observed at 24 h after injection of 25 µg 89Zr-MSB0010853. 
89Zr-MSB0010853 organ distribution and tumor uptake in mice were time-dependent.  Tumor 
uptake correlated with HER3 expression. In contrast to tumor uptake except for kidney uptake, 
organ distribution of 89Zr-MSB0010853 was protein dose-dependent for the tested protein doses 
(5, 10, 25, 100 and 1000 µg). 89Zr-MSB0010853 PET imaging gives insight in in vivo behavior of 
MSB0010853. 
 The first bispecific antibody that activates cytotoxic T-cells to destroy tumor cells 
(blinatumomab) has just recently been approved for the treatment of cancer. Blinatumomab is 
a member of the novel class of BiTE antibodies that facilitate the linkage between tumor cells 
and cytotoxic T-cells. After connecting CD3ε on T-cells with tumor-associated antigens on tumor 
cells, BiTE antibodies activate T-cells to destroy adjacent tumor cells. We used molecular imaging 
as a non-invasive tool to study the biodistribution and tumor uptake of BiTEs, in order to gain 
insight in their in vivo behavior. In chapter 5 we labeled an EpCAM recognizing BiTE antibody 
(AMG 110) with 89Zr or IRDye 800CW. EpCAM is expressed on many epithelial tumors and cancer 
stem cells, it therefore is an interesting target for BiTEs. Specific binding to EpCAM positive 
HT-29 human colorectal adenocarcinoma cells was maintained after 89Zr labeling of AMG 110. In 
mice, HT-29 tumors could clearly be visualized as soon as 3 h after 89Zr-AMG 110 injection and up 
to at least 72 h. Increasing the protein dose from 20 µg to 500 µg did not affect biodistribution 
of 89Zr-AMG 110. Maximum tumor uptake of 89Zr-AMG 110 was obtained 6 h after tracer injection 
(5.35 ± 0.22 %ID/g). Non-specific distribution was determined using 89Zr labeled Mec14, a 
non-specific control BiTE targeting a hapten named mecoprop and human CD3ε. At 24 h after 
injection, tumor uptake of 89Zr-Mec14 was significantly lower than 89Zr-AMG 110, respectively 0.7 
± 0.1 %ID/g and 5.3 ± 0.3 %ID/g. Tumor uptake of 89Zr-AMG 110 depended on and correlated with 
EpCAM expression on tumor cells. Intratumoral distribution of 800CW-AMG 110 demonstrated 
that AMG 110 accumulated in vital EpCAM expressing tumor tissue, as determined ex vivo. In 
contrast, IRDye 680RD labeled Mec14 accumulated in necrotic areas of the tumor, confirming 
EpCAM specific tumor uptake of 800CW-AMG 110. The data in chapter 5 support using 89Zr and 
IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody 
constructs in preclinical and clinical settings. 
 Chapter 5 proved that molecular imaging with BiTEs was feasible. In chapter 6 a second 
BiTE (AMG 211), currently studied in a phase one clinical study (NCT02291614), was radiolabeled 
with 89Zr. Tumor and tissue uptake kinetics and in vivo integrity of 89Zr-AGM211 was preclinically 
evaluated in mouse models in order determine the feasibility to study 89Zr-AGM211 in vivo 
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behavior in the clinical setting. AMG 211 is a BiTE antibody that targets carcinoembryonic antigen 
(CEA) on tumor cells and CD3ε on T cells. For solid tumors of especially the gastrointestinal 
tract, AMG 211 is an interesting new BiTE antibody construct. Chapter 6 provides insight in 
tumor targeting and biodistribution of AMG 211 in preclinical models by non-invasive molecular 
imaging. 89Zr-AMG211 tumor uptake is dose dependent as determined at 6 h after injection. 
Highest relative tumor uptake was observed with 2 μg (7.5 ± 1.5 %ID/g) and lowest tumor uptake 
with 500 μg (3.9 ± 0.1%ID/g). Ten μg 89Zr-AMG211 resulted in a higher uptake in CEA-positive 
xenografts than CEA-negative xenografts. Although blood half-life of 89Zr-AMG211 was 1 hour, 
tumor retention occurred up to 24 h. Ex vivo autoradiography showed intact 89Zr-AMG211 only in 
CEA-positive xenograft lysates. Ex vivo autoradiography revealed a time-dependent disintegration 
of 89Zr-AMG211. 89Zr-Mec14 did not accumulate in CEA-positive tumors. 800CW-AMG211 was 
specifically localized in CEA-expressing vital tumor tissue. GMP-produced 89Zr-AMG211 fulfilled 
production specifications. The results in chapter 6 already allowed to perform PET imaging with 
89Zr-AMG211 in a currently ongoing clinical trial (NCT02760199).
 The results of the studies performed in this thesis are discussed in chapter 7, along with 
the future prospectives regarding the imaging modalities used in this thesis, half-life extention 
of therapeutic proteins and the clinical use of BiTEs. Both nuclear and optical imaging hold 
great promise to support drug development. Intensifying the collaboration between academia 
and industry and standardization of imaging protocols would help to spur the implementation 
of molecular imaging in clinical trials. The biodistribution and tumor uptake of 89Zr-AMG211 is 
currently studied in a phase one clinical study.
In conclusion, this thesis described the development en preclinical evaluation of a fluorescent 
and/or radioactive labeled BiTEs and VHHs/nanobodies to assess biodistribution, tumor uptake 
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Nederlandse samenvatting
Wereldwijd is kanker één van de belangrijkste doodsoorzaken en daarom een ziekte met een 
grote vraag naar nieuwe geneesmiddelen. Chemotherapie, de hoeksteen van de systemische 
behandeling van kankerpatiënten, vernietigt alle delende cellen. Momenteel worden veel 
geneesmiddelen ontwikkeld die selectiever tumorcellen kunnen aanvallen. Er is veel ervaring 
opgedaan met antilichamen, eiwitten met een hoge affiniteit voor specifieke stoffen (antigenen) 
die een afweer reactie kunnen opwekken tegen deze antigenen. Antilichamen herkennen 
ongewenste indringers in het lichaam, zoals virussen en bacteriën, en helpen bij het vernietigen 
van deze indringers. In sommige gevallen kunnen ze ook kankercellen herkennen en helpen 
bij het vernietigen van de herkende kankercellen. Hiernaast kunnen antilichamen binden 
aan pro-oncogene eiwitten op tumorcellen en deze vervolgens inactiveren. Het blokkeren van 
deze eiwitten kan de tumorgroei remmen. Momenteel zijn er verschillen antilichamen op de 
markt die gebruikt worden in de behandeling van kankerpatiënten. Het succesvolle gebruik 
van dergelijke antilichamen heeft ervoor gezorgd dat onderzoekers ook zijn gaan zoeken naar 
andere vergelijkbare eiwitten met potentiële anti-kankereigenschappen, bijvoorbeeld eiwitten 
die zijn afgeleid van antilichamen. Zo zijn er antigen bindende domeinen van lama antilichamen 
(nanobodies) geïsoleerd. Deze nanobodies zijn klein (molecuulgewicht van 15 kDa), stabiel en 
relatief eenvoudig te produceren. Ze kunnen binden aan pro-oncogene eiwitten op tumorcellen 
en net zoals antilichamen de pro-oncogene eiwitten inactiveren. Ook kunnen er toxische 
verbindingen aan worden gekoppeld, zodat die verbindingen met name door tumorcellen 
worden opgenomen. Daarnaast kunnen fluorescent gelabelde nanobodies, gericht tegen eiwitten 
die in hoge mate aanwezig zijn op tumorcellen, potentieel worden gebruikt om tumorweefsel 
zichtbaar te maken in een intra-operatieve of endoscopische setting. 
 Antilichamen en afgeleiden daarvan kunnen zo worden geproduceerd dat ze tegelijkertijd 
binden aan zowel tumorcellen al immuuncellen. Door beide celtypen aan elkaar te koppelen, 
kunnen immuuncellen worden gestimuleerd om aangrenzende tumorcellen aan te vallen. 
Momenteel zijn er verschillende geneesmiddelen op de markt die het immuunsysteem van 
kankerpatiënten activeert om kankercellen op te ruimen. Een dergelijke therapie wordt 
immuuntherapie wordt genoemd. Eén van de nieuwere geneesmiddelen in deze categorie zijn 
de bispecific T-cell engagers (BiTEs). BiTE antilichamen verbinden ‘het differentiatie cluster 3 
epsilon’ (CD3ε), een eiwit op cytotoxische T-lymfocyten (immuuncellen), met specifieke eiwitten 
op tumorcellen. Hierdoor worden cytotoxische T-lymfocyten geactiveerd om aangrenzende 
tumorcellen te vernietigen. Epitheliaal cel adhesiemolecuul (EpCAM) en carcino-embryonaal 
antigeen (CEA) zijn eiwitten die in hoge mate aanwezig zijn op verschillende type kankercellen. 
Door BiTEs te ontwikkelen tegen deze eiwitten, kunnen cytotoxische T-lymfocyten worden 
aangezet tot het vernietigen van EpCAM/CEA positieve tumorcellen.
 Om de ontwikkeling van geneesmiddelen zoals verschillende BiTEs en nanobodies te 
ondersteunen, kan er gebruik gemaakt worden van moleculaire beeldvorming. Dergelijke 
ondersteuning is nodig, omdat slechts een deel van de geneesmiddelen, die zich in klinische 
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ontwikkeling bevinden, uiteindelijk zullen worden toegelaten tot de markt. Hierbij is belangrijk 
om de meest potente geneesmiddelen te selecteren en zo snel mogelijk te begrijpen hoe de 
klinische studies met deze middelen het best uitgevoerd kunnen worden. Door deze middelen 
radioactief te labelen, kan met behulp afbeeldende diagnostiek met positron emissie tomografie 
(PET) informatie worden verkregen over de farmacokinetiek, biodistributie en tumoropname. 
Wanneer vroegtijdig toegepast in klinische studies, kan deze informatie mogelijk bijdragen aan 
het optimaliseren en versnellen van klinisch onderzoek. 
Het doel van dit proefschrift is om met behulp van beeldvormende technieken inzicht te 
verkrijgen in de biodistributie en tumoropname van eiwitten die zijn afgeleid van antilichamen, 
om daarmee geneesmiddelonderzoek van deze eiwitten te ondersteunen.
Hoofdstuk 1 geeft een beknopte achtergrond en een introductie voor dit proefschrift. 
Hoofdstuk 2 betreft een literatuuronderzoek naar hoe modificaties aan eiwitgeneesmiddelen 
de biodistributie en tumoropname van deze middelen kan beïnvloeden. Hierbij is voornamelijk 
gefocust op antilichamen, eiwitten die zijn afgeleid van antilichamen en “protein scaffolds”. 
Modificaties worden meestal toegepast om de effectiviteit en veiligheid te verbeteren. Gedurende 
de ontwikkeling van oncologische geneesmiddelen wordt steeds vaker gebruik gemaakt van 
moleculaire beeldvorming om informatie te verkrijgen over farmacokinetiek, biodistributie en 
tumoropname. Echter modificaties kunnen de farmacokinetiek, biodistributie en tumoropname 
beïnvloeden, waardoor het lastig is om de data, die wordt verkregen met moleculaire beeldvorming, 
goed te interpreteren. Het is daarom belangrijk om te weten waarom en hoe deze modificaties 
de farmacokinetiek, biodistributie en tumoropname kunnen beïnvloeden. Om die reden is 
samengevat welke chemische eigenschappen van eiwitten het in vivo gedrag kunnen beïnvloeden. 
Verder is beschreven hoe radioactief labelen, fluorescent labelen, binding aan cytotoxische 
geneesmiddelen, glycosylering, humanisatie, albumine binding en polyethyleen glycol (PEG)
ylatie, de biodistributie en tumoropname van eiwitten kunnen beïnvloeden. Bovengenoemde 
modificaties blijken voornamelijk de systemische klaring van eiwitten te beïnvloeden alsmede de 
accumulatie van eiwitten in de lever, milt, nieren en tumor. Echter, de impact van modificaties 
op het in vivo gedrag van eiwitgeneesmiddelen is afhankelijk van meerdere factoren. De 
belangrijkste zijn: het type eiwit en het organisme waarin het gedrag onderzocht wordt. Dit 
hoofdstuk geeft een overzicht hoe de chemische eigenschappen van eiwitten en eiwitmodificaties 
de biodistributie en tumoropname van eiwitgeneesmiddelen kan beïnvloeden. In dit hoofdstuk 
is een overzichtelijk gemaakt hoe verschillende chemische eigenschappen en modificaties van 
eiwitten de biodistributie en tumoropname kunnen beïnvloeden, waardoor het mogelijk kan 
bijdragen aan het juist interpreteren van de data die wordt verkregen met radioactief dan wel 
fluorescent gelabelde eiwitten. 
 Fluorescente beeldvorming kan mogelijk gebruikt worden om tumorweefsel in 
kankerpatiënten te detecteren. Nanobodies gericht tegen eiwitten op de celmembraan van 
tumorcellen, kunnen zich snel na injectie ophopen in tumorweefsel. Fluorescent gelabelde 
Nederlandse samenvatting | 183
 
182 | Chapter 9
nanobodies kunnen daardoor in potentie gebruikt worden om tumorweefsel eenvoudiger zichtbaar 
te maken in een intra-operatieve setting. Een eiwit dat, in een subpopulatie van kankerpatiënten, 
sterk verhoogd aanwezig is op tumorcellen, is de pro-oncogene receptor: humaan epidermale 
groeifactor receptor (HER)2. Dit eiwit kan daarom goed worden gebruikt om als doeleiwit te 
fungeren voor fluorescent gelabelde nanobodies. In hoofdstuk 3 is beschreven hoe nanobodies 
gericht tegen HER2 zijn geselecteerd, gelabeld met een fluorfoor (IRDye 800CW) en preklinisch 
zijn geëvalueerd. Doordat IRDye 800CW licht uitzendt in het nabij infrarode gebied van het 
lichtspectrum, penetreert het uitgezonden licht relatief diep door weefsel. Vervolgens hebben 
we de biodistributie en tumoropname van deze fluorescent gelabelde nanobodies bestudeerd, 
met als doel een probe te ontwikkelen die HER2 positieve tumoren zichtbaar zou kunnen maken 
in een intra-operatieve setting. Het conjugeren van IRDye 800CW aan C-terminale cysteines van 
drie anti-HER2 nanobodies (11A4, 18C3 en 22G12) resulteerde in fluorescent gelabelde nanobodies 
die hun hoge affiniteit voor HER2 op SKBR3 borstkankercellen behielden. De gemeten 
dissociatie constanten voor 800CW-11A4, 800CW-18C3 en 800CW-22G12 waren respectievelijk 
1,9 ± 0,03, 14,3 ± 1,8 en 3,2 ± 0,5 nM. Op basis van verschillende eigenschappen waaronder binding, 
opbrengst tijdens productie en tumor accumulatie, werd 11A4 geselecteerd voor verdere studies. 
Vergeleken met 800CW-trastuzumab bleek 800CW-11A4 veel sneller in HER2 positieve SKBR3 
tumoren te accumuleren. Vier uur na injectie gaf 800CW-11A4 een sterker contrast te tussen 
tumor en achtergrond weefsel dan 800CW-trastuzumab, met tumor tot achtergrond ratio’s van 
respectievelijk 2,5 ± 0,3 en 1,4 ± 0,4. Dit hoofdstuk liet zien dat 800CW-11A4 mogelijk ingezet kan 
worden bij het vergoten van de zichtbaarheid van HER2 positieve tumoren tijdens chirurgie. 
 Net zoals HER2 is HER3 ook een pro-oncogene receptor uit de HER familie. Echter, in 
tegenstelling tot de andere receptoren binnen deze receptor familie heeft HER3 een sterk 
verminderde kinase activiteit en is daardoor zelf niet erg actief. HER3 kan wel de overige 
receptoren van de HER familie activeren door aan deze receptoren te binden (dimerisatie). Deze 
activatie kan zo tumorgroei stimuleren. Het blokkeren van de binding tussen deze receptoren 
kan tumorgroei mogelijk remmen. Een recente studie liet zien dat twee antilichamen, die twee 
verschillende plekken (domeinen) van HER3 binden, de groei van tumorcellen effectiever 
kon remmen dan de afzonderlijke antilichamen apart. Het blokkeren van HER3 dimerisatie 
met MSB0010853, een anti-HER3 nanobody construct dat twee HER3 domeinen tegelijk bindt 
(domein 1 en een tweede onbekend domein), is daarom een interessante optie. Naast HER3 bindt 
MSB0010853 ook albumine, waardoor het langer in het bloed blijft circuleren en het meer tijd 
heeft om aan HER3 te binden. MSB0010853 is opgebouwd uit drie verschillende nanobodies. 
Twee nanobodies binden HER3 en één nanobodie bindt albumine. De nanobodies binden beide 
targets van zowel humane als muizen oorsprong. Hoofdstuk 4 beschrijft de ontwikkeling en 
preklinische evaluatie van 89Zr-gelabeld MSB0010853. Het labelen van MSB0010853 met 89Zr 
resulteerde in een radiochemisch zuiver product (zuiverheid > 95%). Ex vivo biodistributie liet zien 
dat orgaanopname van 89Zr-MSB0010853 zowel dosis- als tijdsafhankelijk was. De tumoropname 
van 89Zr-MSB0010853 in H441 niet-kleincellig longkankertumoren was tijdsafhankelijk en tot 96 
uur na injectie nog zichtbaar op PET scans. De hoogste tumoropname werd gemeten 24 uur na 
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injectie van 25 µg 89Zr-MSB0010853 (‘mean standard uptake value’ = 0,6 ± 0,2). Tumoropname 
van 89Zr-MSB0010853 correleerde met het aantal HER3 receptoren op de tumorcel. Dit hoofdstuk 
liet zien dat met 89Zr-MSB0010853 PET imaging de in vivo eigenschappen van MSB0010853 kan 
worden onderzocht.
 Vanwege het succesvolle gebruik van en de recente ontwikkelingen binnen de 
immuuntherapie, is er een sterke focus op de ontwikkeling van geneesmiddelen die het 
immuunsysteem stimuleren om kankercellen te vernietigen. Dat kan mogelijk worden 
bewerkstelligd door het gebruik van bispecifieke (antilichaam) constructen, die immuuncellen 
koppelen aan tumorcellen. Ondanks het feit dat er veel van dergelijke bispecifieke antilichamen 
in ontwikkeling zijn, is het eerste bispecifieke antilichaam construct (Blinatumomab) pas 
recent goedgekeurd voor de behandeling van kankerpatiënten. Blinatumomab is een BiTE 
antilichaam dat cytotoxische T-lymfocyten stimuleert om kankercellen, die het CD-19 eiwit op 
de celmembraan vertonen, te vernietigen. In dit proefschrift is gebruik gemaakt van moleculaire 
beeldvorming als een niet-invasieve techniek om de biodistributie en tumoropname van 
BiTEs te bestuderen. In hoofdstuk 5 is AMG 110, een BiTE antilichaam gericht tegen EpCAM, 
gelabeld met 89Zr en IRDye 800CW. EpCAM komt veelvuldig voor op verschillende epitheliale 
kankercellen en kanker stamcellen, waardoor het een interessant target antigen is voor BiTEs. 
Na het radioactief labelen van AMG 110 met 89Zr, bleef de specifieke binding van AMG 110 aan 
EpCAM op humane colorectale adenocarcinoom (HT-29) kankercellen behouden. In muizen 
kon de tumoropname van 89Zr-AMG 110 al vanaf 3 uur en tot en met 72 uur na injectie duidelijk 
zichtbaar worden gemaakt met PET imaging. Het stapsgewijs verhogen van de eiwitdosering van 
20 µg naar 500 µg had geen invloed op de biodistributie van 89Zr-AMG 110. Zes uur na injectie was 
de tumoropname van 89Zr-AMG 110 maximaal, namelijk 5,35 ± 0,22 % van de geïnjecteerde dosis 
per gram weefsel (%ID/g). Niet-specifieke distributie werd onderzocht met 89Zr gelabeld Mec14, 
een controle BiTE antilichaam dat zich wel bindt aan humaan CD3ε, maar niet aan EpCAM. In 
plaats daarvan bindt het aan een hapteen (mecoprop). De opname van 89Zr-Mec14 in HT-29 
tumoren was 24 uur na injectie significant lager (0,7 ± 0,1 %ID/g) dan dat van 89Zr-AMG 110 
(5,3 ± 0,3 %ID/g). Tumoropname bleek afhankelijk van en correleerde met EpCAM expressie op 
tumorcellen. EpCAM specifieke tumoropname werd ook aangetoond met 800CW-AMG 110, dat 
zich voornamelijk lokaliseerde in vitaal EpCAM positief tumorweefsel. Daarentegen lokaliseerde 
IRDye 680RD gelabeld Mec14 zich voornamelijk in necrotisch tumorweefsel. Dit hoofdstuk liet 
zien dat het labelen van BiTE antilichamen met 89Zr en IRDye 800CW gebruikt kan worden om 
de tumor- en weefselopname van BiTE antilichamen te bestuderen.
 In hoofdstuk 6 is het in vivo gedrag van een tweede BiTE (AMG 211), momenteel in 
fase 1 onderzoek (NCT02291614), bestudeerd door het radioactief te labelen met 89Zr. De 
tumoropname, weefselopname alsook de in vivo integriteit van 89Zr-AMG211 zijn onderzocht in 
muismodellen. Het uiteindelijke doel hiervan is om de haalbaarheid te toetsen of het vivo gedrag 
van 89Zr-AMG211 te onderzoeken is in de klinische setting. AMG 211 is een BiTE antilichaam 
gericht tegen humaan CEA op tumorcellen en humaan CD3ε op T-lymfocyten. De tumoropname 
van 89Zr-AMG211 was dosis-afhankelijk 6 uur na injectie. Een eiwitdosering van 2 μg resulteerde 
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in de hoogst gemeten tumoropname (7,5 ± 1,5 %ID/g) en een eiwitdosering van 500 μg in de laagst 
gemeten tumoropname (3,9 ± 0,1%ID/g). Tumoropname van 89Zr-AMG211 (10 μg) was hoger in 
CEA-positieve tumoren dan in CEA-negatieve tumoren. Ondanks een halfwaardetijd in het 
bloed van 1 uur, was tumoropname van 89Zr-AMG211 tot 24 uur na injectie zichtbaar op PET scans. 
Echter lieten ex vivo integriteitstesten zien dat 89Zr-AMG211 wordt afgebroken in de tumor. Waar 
89Zr-AMG211 accumuleerde in CEA-positieve tumoren, deed 89Zr gelabeld controle BiTE (Mec14) 
dat niet. Met behulp van fluorescente beeldvorming werd aangetoond dat 800CW-AMG211 
zich vooral lokaliseert in vitaal tumor weefsel dat CEA tot expressie brengt. 89Zr-AMG211 kon 
worden geproduceerd volgens de wereldwijd erkende richtlijnen die de goede manieren van 
produceren (GMP) van geneesmiddelen beschrijven. De resultaten van hoofdstuk 6 hebben het 
mogelijk gemaakt om de distributie en tumoropname van 89Zr-AMG211 te bestuderen in klinisch 
onderzoek (NCT02760199).
 De resultaten van de studies beschreven in dit proefschrift zijn bediscussieerd in hoofdstuk 
7, tezamen met de toekomstperspectieven gericht op de beeldvormende technieken beschreven 
in dit proefschrift, halfwaardetijd verlenging van geneesmiddelen en het klinische gebruik 
van BiTEs. Zowel nucleaire als optische beeldvorming zijn veel belovende technieken die 
geneesmiddelonderzoek kunnen ondersteunen. Een intensievere samenwerking tussen de 
academie en de industrie als het standaardiseren van protocollen in de moleculaire beeldvorming 
zou de implementatie van deze beeldvorming in klinische studies doen versnellen.     
Samenvattend beschrijft dit proefschrift de ontwikkeling en preklinische evaluatie van fluorescent 
en/of radioactief gelabelde BiTEs en nanobodies om de weefseldistributie, tumoropname en in 
vivo stabiliteit van deze kandidaat-geneesmiddelen te bestuderen. 






Promoveren doe je grotendeels alleen, wat echter niet wegneemt dat ik erg fijn heb samengewerkt. 
Zonder deze samenwerking was dit proefschrift er niet geweest. Daarnaast zijn er natuurlijk 
mensen om mij heen die me altijd hebben gesteund en die altijd in mij hebben geloofd. Mede 
door hen was ik in staat dit proefschrift af te ronden. 
Hierbij wil ik iedereen bedanken die heeft bijgedragen aan dit proefschrift, waarbij ik een aantal 
mensen in het bijzonder wil bedanken. 
Allereerst wil ik mijn promotoren Prof. dr. J.G.W. Kosterink, Prof. dr. E.G.E. de Vries en 
co-promotor dr. M.N. Lub-de Hooge bedanken. 
Prof. dr. Kosterink, Jos, bedankt voor de plek die je mij hebt gegeven in de ziekenhuisapotheek 
van het Universitair Medisch Centrum Groningen (UMCG) en de mogelijkheid om vanuit daar 
mijn promotie vorm te geven. Zonder deze plek was dit boekje nooit tot stand gekomen. De 
goede samenwerking tussen de ziekenhuisapotheek, oncologie en nucleaire geneeskunde is echt 
uniek. De grote lijnen van mijn promotie zijn bij jou altijd veilig geweest. Daarnaast heeft jouw 
positieve blik bijgedragen aan de voortgang van mijn promotie. 
Prof. dr. De Vries, Liesbeth, de vele uren die je in mij gestoken hebt, hebben zijn vruchten 
afgeworpen. Zowel tijdens mijn promotie als daarvoor heeft de toewijding die jij liet zien mij 
altijd gemotiveerd om door te gaan. Op zondag mailen betekende vaak nog diezelfde dag een 
antwoord. Of het antwoord nu gegeven werd vanuit Nederland, of van daarbuiten, was daarbij 
ook geen probleem! Veel respect heb ik dan ook voor jouw onuitputtelijke inzet. Je was voor mij 
een inspirator, zowel wetenschappelijk inhoudelijk, als op andere aan onderzoek aangrenzende 
gebieden. 
Dr. Lub-de Hooge, Marjolijn, naast je reguliere werkzaamheden in de ziekenhuisapotheek had je 
ook vaak tijd voor mij om de voortgang te bespreken. De vele suggesties tijdens onze overleggen 
waren altijd erg welkom. Met vragen wist je me altijd uit te dagen om verder te denken. Hierbij 
bracht jouw klinische ervaring mij verder.  
Verder wil ik ook de leden van de leescommissie bedanken voor het beoordelen van het 
manuscript: Prof. dr. N.H. Hendrikse, Prof. dr. P.H. Elsinga en Prof. dr. J.A. Gietema.
Dank gaat tevens uit naar alle co-auteurs en andere personen die nauw betrokken zijn geweest bij 
het tot stand komen van de artikelen. In het bijzonder wil ik bedanken:
Dr. Terwisscha van Scheltinga, Anton, ik kon altijd langskomen met vragen en met mijn verhaal 
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over de dagelijkse gang van zaken in het onderzoek. Jouw ervaring en interesse  in hetzelfde 
onderzoeksgebied zorgde ervoor dat ik constructief met je kon sparren.
Drs. Waaijer, Stijn, het was fijn om jou te begeleiden tijdens je stage in het UMCG. Zeer gedreven, 
geïnteresseerd en meedenkend. Daarnaast ben jij ook een belangrijke kracht geweest voor twee 
hoofdstukken in dit proefschrift. Bedankt voor een fijne en goede  samenwerking en succes met 
jouw eigen promotietraject! 
Dr. Pool, Martin, met jouw inzet en meedenken hebben we hoofdstuk 5 iets extra’s kunnen geven. 
Waarschijnlijk komen we elkaar als toekomstige collega’s ziekenhuisapotheker weer tegen.   
Prof. dr. Van Dam, Go, jouw Nature Medicine publicatie m.b.t. het visualiseren van tumoren met 
fluorescente beeldvorming is een inspiratiebron voor velen, waaronder ikzelf. Bedankt  voor het 
beschikbaar stellen van jouw kennis en de faciliteiten op jullie afdeling.
Dr. Kijanka, Marta, despite the distance Groningen-Utrecht it was great working together with 
you. Our study with luminous mice is grafted in my memory.  
Dr. De Vries, Erik, dank voor alle hulp die je mij hebt geven op m.n. het chemische vlak van 
tracerontwikkeling. De verschillende projecten op de afdeling van de nucleaire geneeskunde en 
medische beeldvorming hebben mijn kennis rondom radiochemie en productie van radiofarmaca 
zeker vergroot. Helaas heeft onze samenwerking niet geresulteerd in het aantal publicaties waar 
wij samen op hoopten. 
Dr. Cheung, Kam, thank you for all the constructive conversations we had and the confidence 
you have in me.
Zonder het werk van mijn voorgangers had ik de onderzoeken in dit proefschrift niet kunnen 
uitvoeren. Veelal kon ik de door mijn voorgangers verkregen informatie goed gebruiken om 
mijn onderzoek efficiënt en correct uit te voeren. Dank daarvoor. Wouter Nagengast, onder 
jouw leiding en mede door jouw enthousiasme is mijn interesse in de moleculaire beeldvorming 
binnen de oncologie aangewakkerd. Dank!  
Hetty Timmer-Bosscha en Coby Meijer, wat vond ik het fijn om met jullie samen te werken. 
Hetty jouw praktische ervaring heeft bijgedragen aan het juist kunnen uitvoeren van mijn 
experimenten. Coby, niet alleen kon ik bij jou terecht voor bestellingen, maar tevens voor goed 
(wetenschappelijk) advies. 
Esther van Straten en Anouk Funke, dank voor alle hulp bij het verkrijgen van subsidies, het 




Ondersteuning heb ik ook gekregen van het secretariaat van de Klinische Farmacie en 
Farmacologie en de Medische Oncologie. Annemiek van Dijk, Jessica Tuinstra, Wianda Goense, 
en Gretha Beuker, Bianca Smit en Anja Bos, dank voor jullie administratieve hulp de afgelopen 
jaren. 
In een grote moderne organisatie is het altijd goed om ondersteuning te krijgen op gebied van 
ICT. Hierbij wil ik dan ook de ICT-medewerkers bedanken van de afdeling Klinische Farmacie en 
Farmacologie. Dick Frieswijk, 27 maart proost ik nu ook op jouw verjaardag. 
Wat is het fijn dat ik gewerkt heb samen met meedenkende analisten! Silke Bonsing-Vedelaar 
en Linda Pot-de Jong. Niet alleen was het een feest om met jullie samen te werken, jullie konden 
ons als promovendi altijd helpen met praktische en bruikbare tips. Dank daarvoor! Om dezelfde 
reden wil ik ook alle medewerkers van het medisch oncologisch laboratorium bedanken. 
Het samenwerken met verschillende disciplines, zoals binnen het “imaging team” van het UMCG, 
heb ik altijd erg leerzaam gevonden. Bruikbare aanvullingen en kritische vragen resulteerden 
vaak in beter onderzoek. Ik wil dan ook alle leden van het imaging team bedanken waarmee ik 
samengewerkt heb! 
Moleculaire beeldvorming loopt als rode draad door dit proefschrift. Een goede samenwerking 
met de afdeling Nucleaire Geneeskunde en Moleculaire Beeldvorming (NGMB) van het UMCG 
was dan ook van groot belang. Iedereen binnen deze afdeling stond altijd paraat om mee te 
denken om zowel praktische als theoretische vragen te beantwoorden. Graag wil ik een aantal 
personen in het bijzonder bedanken: Andrea Parente, Aniek Visser, Bram Maas, David Vallez 
Garcia, Inês Farinha Antunes, Jürgen Sijbesma, Johan de Jong en Philip Elsinga. Bedankt voor 
een fijne samenwerking. 
Wie zie je tijdens het werk als promovendus vaker dan je kamergenoten? Wat ben ik dan ook blij 
met de kamergenoten die ik in het UMCG heb gehad! Arianna Pranger, Eva ter Weele, Kim van 
der Elst en Marjolijn van Wanrooy, wat vond ik het fijn om jullie als kamergenoot te hebben. Veel 
kon er onderling met elkaar gedeeld worden, zowel een lach als een traan. Eva, jouw gelukstekens 
hebben uiteindelijk toch geholpen! ;-) Eva en Kim, met jullie heb ik de laatste periode in het 
UMCG een kamer gedeeld. Die bijzondere periode zal ik niet snel vergeten.
Ook wil ik mijn nieuwe collega’s bedanken van Ziekenhuisgroep Twente, dank voor het 
meedenken in de afrondende fase van mijn proefschrift! Wat is het fijn om de opleiding  tot 
ziekenhuisapotheker te mogen starten met zulke collega’s! Dank! Hiernaast wil ik de Raad van 
Bestuur van Ziekenhuisgroep Twente bedanken voor de financiële bijdrage aan het proefschrift. 
Naast het werk mag een goed sociaal leven niet worden onderschat. Ondanks het feit dat ik 
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voetballen al bijna ben verleerd geniet ik nog steeds van de weekenden weg en ongezouten 
meningen van de leden van niet het beste maar wel het gezelligste voetbalelftal dat ik ken, ofwel 
HALEN 2. Jullie kunnen als geen ander ervoor zorgen dat de beide benen gewoon op de grond 
blijven staan.  
Daarnaast ben ik ongelooflijk dankbaar dat ik een actieve vriendengroep om me heen heb 
gehad die mij door de moeilijke perioden heen heeft getrokken. De momenten van klaverjassen, 
bierproeverijen, stedentrips, stapavonden en goede gesprekken zal ik dan ook nooit vergeten. 
Laten we daar dan ook vooral mee doorgaan. Wat ben ik dankbaar om deel uit te maken van 
zo’n geweldige groep vrienden!!  Bedankt: Bert Geerts, Christian Scheper, Ewoud Meijer, Gertjan 
Tijms, Hans Roosjen, Koen van de Ven, Sander Dijk, Sander Koenen en Sander van der Kolk. 
Heren, dank voor al die fantastische momenten!!
Een laatste groep die niet mag worden vergeten is mijn familie!  Ooms, tantes, neven, nichten 
wat is het toch fijn om zo’n leuke, gezellige en grote familie te hebben!
Pa, ma en Jeroen, wat ben ik dankbaar dat ik in dit gezin groot ben gebracht! Zonder jullie hulp 
was deze reis als promovendus een heel stuk lastiger geweest. Jullie hebben mij altijd gesteund, 
zowel voor, als tijdens mijn promotietraject. Niks was voor jullie te gek. Bezoek uitstellen vanwege 
mijn werkzaamheden rondom mijn promotie hoeft niet meer. Hierbij wil ik ook Ellen, Femke, 
René, Nienke en Joost bedanken. Vaak hebben jullie mijn verhalen moeten aanhoren. En als ik 
weer eens op Terschelling was, hadden René, Nienke en Joost niet veel aan mij. Ik waardeer het 
enorm dat jullie altijd begrip hebben getoond voor de tijd en aandacht die ik in mijn promotie 
heb gestoken. 
Als laatste wil ik stil staan bij de personen die het dichtst bij mij staan, namelijk Laura, Feline 
en Benthe. Laura, woorden komen tekort als ik wil beschrijven hoeveel jij voor mij betekend 
hebt tijdens mijn promotietraject! Bij deze een diepe buiging. Wat heb ik een kracht gehaald uit 
onze relatie en ons gezin! Hoe jij bent omgegaan met mijn promotietraject en de manier waarop 
jij altijd klaar stond en staat om onze  “uitdagingen” aan te gaan is geweldig. Wat is het dan ook 
enorm fijn om met jou, Feline en Benthe een gezin te vormen!!!! Feline en Benthe, ook al hebben 
jullie het nog niet door, jullie zijn een bron van kracht voor mij. Feline, de manier hoe jij de 
wereld in kijkt, daar kunnen veel mensen (waaronder ikzelf) veel van leren! Benthe, de lach op 
jouw gezicht verzacht véél.
Ondanks dat ik mijn best heb gedaan en veel mensen heb genoemd, heb ik waarschijnlijk nog 
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